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Abstract 
 
ADP-ribosylation controls many cellular processes, including transcription, DNA repair, 
and bacterial toxicity. ADP-ribosyltransferases and poly-ADP-ribose polymerases 
(PARPs) catalyze mono- and poly-ADP-ribosylation, respectively, and depend on a 
highly conserved glutamate residue in the active center for catalysis. However, there is 
an apparent absence of this glutamate for the recently described PARPs 6-16, raising 
questions about how these enzymes function. Therefore the enzymatic properties of 
PARP10, a representative of the novel PARP enzymes, were analyzed in detail. It was 
found that PARP10, in contrast to PARP1, lacks the catalytic glutamate and has mono-
ADP-ribosyltransferase rather than polymerase activity. Despite this fundamental 
difference PARP10 also modifies acidic residues. Molecular modeling shows that an 
acidic residue of the substrate can be placed in a favorable position to stabilize the 
oxocarbenium transition state of the reaction. This function is normally executed by the 
catalytic glutamate in ADP-ribosyltransferases and bona fide PARP enzymes. 
Consequently, a novel catalytic mechanism for PARP10 is proposed, in which the 
acidic target residue of the substrate functionally substitutes for the catalytic glutamate, 
using substrate-assisted catalysis to transfer ADP-ribose. This mechanism explains 
why the novel PARPs are unable to function as polymerases. Accordingly, it is 
suggested to subdivide the PARP family into three classes: one representing bona fide 
PARP enzymes with poly-ADP-ribose polymerase activity like PARP1, a second one 
representing PARP-related mono-ADP-ribosyltransferases like PARP10, and a third 
one without enzymatic activity due to the lack of critical residues in the NAD+ binding 
fold. This discovery will help to illuminate the different biological functions of mono- 
versus poly-ADP-ribosylation in cells. 
The transport across the nuclear envelope through nuclear pore complexes is achieved 
by the interaction of cargo proteins with karyopherins that mediate transport processes 
into and out of the nucleus. These interactions are in general dependent on the 
presence of a nuclear localization signal (NLS) or a nuclear export sequence (NES) in 
the cargo protein. It was shown previously that PARP10 possesses a functional NES 
and accumulates in the nucleus if nuclear export is inhibited. Since PARP10’s 
molecular weight exceeds the diffusion limit of the nuclear pore complexes significantly, 
it has to be imported into the nucleus in an active fashion. In order to locate a potential 
NLS in PARP10 subcellular localization studies and fluorescence bleaching techniques 
were performed to visualize nucleocytoplasmic shuttling. While it was possible to 
confirm the presence of a single classical NES in PARP10, no classical NLS could be 
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detected. In fact the data suggest that three regions within PARP10 have the ability to 
enter the nucleus and thus potentially contribute to the nuclear import of PARP10. 
Surprisingly, the analysis of the subcellular PARP10 localization revealed the 
enrichment in remarkable cytoplasmic foci. Co-localization studies showed no 
conclusive overlap between PARP10 foci and previously described cytoplasmic 
substructures. Using time-lapse microscopy it was possible to show that PARP10 foci 
are highly dynamic, tend to fuse, can disintegrate and form de novo. Importantly, the 
deletion of the N-terminal RNA recognition motif in PARP10 dramatically impaired the 
formation of these foci indicating a potential role for RNA in their development. 
Although PARP10 foci do not overlap with RNA-processing particles, i.e. P bodies or 
stress granules, certain components present in P bodies are found in these foci. This 
co-localization is greatly enhanced in the presence of stress that blocks translation and 
triggers the formation of stress granules. Thus PARP10 enriches in novel cytoplasmic 
foci that might play a role in RNA processing suggesting a role for PARP10 in the 
regulation of cellular stress responses. 
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Zusammenfassung 
 
Viele zelluläre Prozesse werden mittels ADP-ribosylierung gesteuert, unter anderem 
Transkription, DNA-Reparatur und bakterielle Toxizität. ADP-Ribosyl-Transferasen und 
Poly-ADP-Ribose-Polymerasen (PARPs) katalysieren die Mono- beziehungsweise 
Poly-ADP-Ribosylierung von Proteinen in Abhängigkeit von einem hoch konservierten 
Glutamat-Rest in ihrem aktiven Zentrum. Allerdings fehlt dieses Glutamat 
offensichtlicher Weise in den kürzlich beschriebenen PARPs 6-16, was zu der Frage 
führt, wie diese Enzyme katalytische ADP-Ribosylierung bewerkstelligen. Um dieser 
Fragestellung nachzugehen, wurden die katalytischen Eigenschaften von PARP10, 
einem Vertreter dieser neuen PARP-Enzyme, eingehend untersucht. Anhand dieser 
Studien lässt sich schlussfolgern, dass PARP10 im Gegensatz zu PARP1 das 
katalytische Glutamat fehlt and daher als Mono-ADP-Ribosyl-Transferase und nicht als 
Polymerase fungiert. Trotz dieses fundamentalen Unterschiedes modifiziert PARP10 
ebenso wie PARP1 saure Aminosäure-Reste. Anhand eines molekularen Modells der 
katalytischen Domäne von PARP10 konnte gezeigt werden, dass ein saurer Rest des 
Substrates so im aktiven Zentrum positioniert werden kann, dass er in der Lage wäre 
den Übergangszustand der Reaktion, welcher durch ein Carbokation gekennzeichnet 
ist, zu stabilisieren. Diese Stabilisierung erfolgt normalerweise durch das katalytische 
Glutamat. Infolgedessen wird ein neuartiger katalytischer Mechanismus für PARP10 
vorgeschlagen, in dem der saure Aminosäure-Rest des Substrates funktionell das 
katalytische Glutamat ersetzt. Die ADP-Ribosylierung durch PARP10 stellt somit eine 
substrat-assistierte Katalyse dar. Dieser Mechanismus liefert eine Erklärung für die 
nicht vorhandene Polymerase-Aktivität der neuen PARP-Enyzme. Daher wird die 
Unterteilung der PARP-Familie in drei Klassen vorgeschlagen: eine mit  bona fide 
PARP-Enyzmen wie PARP1, die Polymerase-Aktivität besitzen, eine weitere mit 
PARP-ähnlichen Mono-ADP-Ribosyl-Transferasen wie PARP10 und eine dritte mit 
Proteinen, die aufgrund des Verlustes essentieller Reste in der NAD+-Bindungstasche 
enzymatisch inaktiv sind. Die Entdeckung mono-ADP-ribosylierender PARP-Enyzme 
wird hilfreich sein, um die verschiedenen biologischen Funktionen der Mono- 
gegenüber Poly-ADP-Ribosylierung genauer zu untersuchen. 
Der Transport über die Kernmembran durch die Kernporen wird erreicht durch 
Interaktion der zu transportierenden Proteine mit Karyopherinen, welche Import in den 
und Export aus dem Nukleus vermitteln. Diese Interaktionen sind in der Regel 
abhängig von einem Kern-Lokalisations-Signal (NLS) oder einer Kern-Export-Sequenz 
(NES) im zu transportierenden Protein. Es konnte bereits gezeigt werden, dass 
PARP10 ein funktionelles NES besitzt und nach Inhibition des Kern-Exports im 
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Nukleus zu finden ist. Da das Molekulargewicht von PARP10 die Grenze für freie 
Diffusion über die Kernporen bei Weitem überschreitet, muss es aktiv in den Nukleus 
transportiert werden. Um ein potentielles NLS in PARP10 zu identifizieren, wurden 
subzelluläre Lokalisationen untersucht und Fluoreszenz-Bleich-Techniken angewendet, 
um nukleozytplasmatischen Transport sichtbar zu machen. Während es möglich war 
die Gegenwart eines einzelnen funktionellen NES in PARP10 zu bestätigen, konnte ein 
klassisches NLS nicht nachgewiesen werden. Die vorliegenden Daten lassen vielmehr 
vermuten, dass drei Bereiche innerhalb von PARP10 die Fähigkeit haben in den 
Nukleus zu gelangen und daher potentiell zum Kern-Import von PARP10 beitragen. 
Die Untersuchung der subzellulären Lokalisation von PARP10 zeigte überraschender 
Weise eine Anreicherung in auffälligen zytoplasmatischen Foci. Kolokalisations-
Studien zeigten keine schlüssige Überlappung mit zuvor beschriebenen 
zytoplasmatischen Substrukturen. Mittels Zeitraffer-Mikroskopie konnte gezeigt 
werden, dass PARP10-Foci hoch dynamisch sind, dazu neigen zu fusionieren, sich 
auflösen und wieder de novo bilden können. Bedeutsamer Weise beeinträchtigt die 
Deletion des RNA-Erkennungs-Motivs in PARP10 die Entstehung dieser Foci merklich, 
was auf eine Rolle von RNA in deren Bildung hindeuten könnte. Obwohl PARP10-Foci 
keine Überlappung mit RNA-prozessierenden Partikeln, d.h. P bodies und stress 
granules, zeigen, kommen bestimmte Komponenten von P bodies auch in PARP10-
Foci vor. Diese Kolokalisation kann durch die Erzeugung von Stress, welcher die 
Translation blockiert und die Bildung von stress granules fördert, deutlich gesteigert 
werden. Es lässt sich schlussfolgern, dass sich PARP10 in bis dato neuartigen 
zytoplasmatischen Foci anreichert, die eine Rolle bei RNA-Prozessierung spielen 
könnten, was auf eine mögliche Funktion von PARP10 in der zellulären Stress-Antwort 
hindeutet. 
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1. Introduction 
 
1.1 Post-translational modifications: regulators of protein function 
Proteins are subject to a whole array of post-translational modifications (PTMs) that 
fulfill regulatory functions on the modified proteins. A brief survey of reversible protein 
modifications shall illustrate how PTMs regulate protein and thereby cell function by a 
complex network of agonistic and antagonistic enzymes as well as protein domains 
serving as readout system and redirecting the initial event to downstream target 
proteins. 
 
The best-studied example of PTMs is phosphorylation which involves the transfer of 
the ?-phosphate group from ATP to specific amino acids; in eukaryotes, these are 
usually hydroxyl groups of serine, threonine or tyrosine residues. The first protein 
kinase activity was reported in 1954 (Burnett and Kennedy, 1954) for the 
phosphorylation of casein. In the next decades, a rapidly growing body of evidence 
underlined the importance of reversible phosphorylation as a versatile tool to regulate 
protein function. Phosphatases removing the phosphate group from the modified 
residues were discovered and were shown to have specificity towards the individual 
phosphorylated residue (Barford et al., 1998). In addition, a multitude of modular 
protein domains that recognize phosphorylated amino acid residues have been 
analyzed in great detail. To name just two examples, SH2 domains and PTB domains 
recognize phosphotyrosine residues in target proteins achieving binding specificity by 
their different requirements for adjacent residues (Pawson et al., 2001; Yan et al., 
2002). 
 
To date, besides phosphorylation a variety of further PTMs have been identified and 
are studied including methylation, ubiquitination, acetylation and ADP-ribosylation. 
Especially in the field of epigenetics, the careful analysis of chromatin modifications 
has revealed a complex, well coordinated regulation of the chromatin state by PTMs 
occurring on histone tails (Kouzarides, 2007a) (Figure 1). At the beginning of 
deciphering the functional relevance of these modifications, the so-called histone code 
(Strahl and Allis, 2000), it was believed that certain histone marks would be predictive 
of gene activation while others would correlate with gene repression. However, recent 
observations suggest that many histone marks are highly dynamic (Berger, 2007). It 
turns out that many of the histone marks seem to have several, sometimes opposing 
roles. One modification that has drawn broad attention is the trimethylated lysine of 
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histone H3 (H3K4me3), a modification that is associated with and regarded as a 
hallmark of active promoters (Li et al., 2007). Recently, it was shown that the basal 
transcription factor TFIID directly binds to the H3K4me3 mark in promoter regions 
resulting in transcriptional activation (Vermeulen et al., 2007). Interestingly, the 
asymmetric dimethylation of H3R2 (H3R2me2a) inhibits binding to H3K4me3, whereas 
acetylation of H3K9 and H3K14 potentiates TFIID interaction (Vermeulen et al., 2007). 
These findings fit with the observation that H3R2me2a counter-correlates with 
H3K4me3 on human as well as yeast promoters (Guccione et al., 2006; Kirmizis et al., 
2007). Recent studies suggest that the H3R2me2a prevents trimethylation of H3K4 by 
inhibiting the binding of an ASH2/WDR5/MLL-family methyltransferase complex that is 
responsible for establishing the H3K4me3 mark. Reciprocally, H3K4me3 prevents 
H3R2 dimethylation by the arginine methyltransferase PRMT6 (Guccione et al., 2007). 
While the so far discussed roles of H3K4me3 are clearly connected to gene activiation, 
it is surprising that other protein complexes involved in transcriptional repression like 
the Sin3-HDAC1 deacetylation complex or the JMJD2A demethylase can also be 
recruited by the H3K4me3 mark. A possible explanation would be that H3K4me3 
establishes gene activation but afterwards reinstates a repressional state (Berger, 
2007). This example shall illustrate how post-translational modifications are connected 
via crosstalk mechanisms, a regulatory principle that is realized not only for post-
translational modifications of histones but also of other proteins (Hunter, 2007). 
 
 
Figure 1. 
Post-translational modifications of core histones. 
This figure is adapted from a SnapShot on histone-modifying enzymes (Kouzarides, 2007b). 
Depicted are only those post-translational histone modifications, for which the associated 
enzymes were identified. 
Ac: acetylation; Me: methylation; P: phosphorylation; Ub: ubiquitination 
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1.2 ADP-ribosylation: an unusual post-translational modification 
The modification of proteins by ADP-ribosylation is a phylogenetically ancient 
mechanism. It involves the transfer of ADP-ribose from NAD+ to target proteins 
accompanied by the release of nicotinamide. The consumption of NAD+ by ADP-
ribosylating enzymes connects them not only to the energy metabolism but also to 
other NAD+-consuming enzymes including histone deacetylases of the Sirtuin family 
and ADP-ribosyl cyclases (Ying, 2006). NAD+, found in a cytosolic concentration of 
about 500 ?M and possessing a half-life of about 1-2 h (Elliott and Rechsteiner, 1975; 
Rechsteiner et al., 1976; Williams et al., 1985), and its reduced form NADH act as co-
enzymes in numerous redox reactions, playing pivotal roles in many fundamental 
cellular processes, including mitochondrial oxidative phosphorylation as co-factors for 
three rate-limiting enzymes of the TCA cycle. In addition, NAD+ has been implicated in 
affecting cell death, in the regulation of calcium homeostasis and in controlling gene 
expression (Ying, 2006). Thus, the consumption of NAD+ by NAD+-consuming enzymes 
has to be tightly controlled. 
 
The presence of poly-ADP-ribose (pADPr) was first described by P. Chambon and co-
workers in 1963 (Chambon et al., 1963) and subsequently its structure was solved 
(Doly and Mandel, 1967; Reeder et al., 1967; Sugimura et al., 1967). The gene 
encoding the responsible enzyme named poly-ADP-ribose polymerase (PARP) was 
isolated in the late 1980s (Alkhatib et al., 1987; Kurosaki et al., 1987; Uchida et al., 
1987). In the meantime another ADP-ribosylation reaction was discovered during the 
analysis of bacterial toxins (Gill et al., 1969; Honjo et al., 1968). While PARP enzymes 
catalyze the poly-ADP-ribosylation of proteins, the discovered toxins were shown to 
mono-ADP-ribosylate proteins.  Consequently, the presence of mammalian mono-
ADP-ribosyltransferases (mART) was suggested and ecto-enzymes with mART activity 
were discovered, while the molecular identity of postulated intracellular enzymes is less 
clear (Corda and Di Girolamo, 2003; Hassa et al., 2006; Okazaki and Moss, 1996; 
Okazaki and Moss, 1999; Seman et al., 2004). Recent evidence suggests that 
mitochondrial SIRT4 and nuclear SIRT6 possess mono-ADP-ribosyltransferase activity 
(Haigis et al., 2006; Liszt et al., 2005), potentially contributing to the mono-ADP-
ribosylation of intracellular proteins. 
 
1.3 The PARP superfamily of ADP-ribosylating enzymes 
PARP1, the founding and best-studied member of the PARP family, was for a long time 
considered to be the only enzyme in mammalian cells that could generate pADPr 
polymers. However, in recent years additional enzymes have been described and 
Introduction  4 
systematic studies have indicated that 17 different proteins exist that share a catalytic 
PARP domain and thus may contain polymerase activity (Ame et al., 2004; Otto et al., 
2005). Besides the PARP domain a wide spectrum of protein domains are present in 
the different members of the PARP family, suggesting that these proteins are involved 
in a broad spectrum of physiological activities (Figure 2). 
 
Figure 2. 
The PARP superfamily (from (Schreiber et al., 2006)). 
The domain architecture of the 17 members of the poly(ADP-ribose) polymerase (PARP) 
superfamily and of poly(ADP-ribose) glycohydrolase (PARG). 
Protein-protein interaction motifs: BRCT (BRCA1 C-terminus), WWE (domain with conserved 
WWE motif), SAM (sterile ?-motif), ANK (ankyrin), vWA (von Willebrand factor type A), 
MVP-BD (major vault protein binding domain); Nucleic acid binding motifs: Zn finger, DBD 
(DNA binding domain), RRM (RNA recognition motif); ADP-ribose (and derivatives) binding 
motif: macro; Motifs of unknown function: WGR (Trp-Gly-Arg motif), HPS (homopolymeric 
His-Pro-Ser motif), VIT (vault inter-?-trypsin domain). 
Within each putative PARP domain, the region homologous to the PARP signature (residues 
859–908 of PARP-1) is darkened. Please note that several members display splicing variants 
(e.g. PARP-3, PARP-9, PARP-14 and PARP-15), but for simplicity, only one variant is shown. 
MLS, mitochondrial localization signal; NES, nuclear export signal; NoLS, nucleolar 
localization signal; NLS, nuclear localization signal. 
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Indeed, the so far described members of the PARP superfamily display a significant 
diversity in their biological functions. The following paragraph will summarize the 
current state of knowledge about the analyzed PARP proteins. 
 
1.3.1 PARP1 
PARP1 represents the by far most intensively studied PARP enzyme and was 
described to participate in a wide range of cellular activities, including DNA repair, 
apoptosis and chromatin dynamics (D'Amours et al., 1999; Kim et al., 2005; Schreiber 
et al., 2006). Already in the late 1970’s, an intimate relationship between poly-ADP-
ribosylation and a rapid and considerable decrease in cellular NAD+ levels after 
genotoxic stimuli was suggested (Goodwin et al., 1978; Skidmore et al., 1979). Indeed, 
in the presence of DNA strand breaks PARP1 activity and the levels of pADPr can be 
increased up to 500-fold with a concomitant reduction of NAD+ (Alvarez-Gonzalez and 
Althaus, 1989; Singh et al., 1985; Wielckens et al., 1983). The inhibition of PARP 
activity during DNA damage using chemical inhibitors can prevent the depletion of 
NAD+, ATP and deoxynucelotides (Das and Berger, 1986; Sims et al., 1983) 
suggesting a consumption of NAD+ by PARP1 during pADPr synthesis. The catalytic 
activation of PARP1 by DNA was shown to be dependent on the type of DNA, with 
undamaged DNA being ineffective, but with nicked DNA being a potent activator 
(Benjamin and Gill, 1980). This activation depends on a N-terminal DNA-binding 
domain in PARP1 containing two unusual zinc fingers (aa 21-56 and 125-162), with 
finger F1 being mainly responsible for activation by double-strand breaks (DSBs), while 
both fingers are necessary for the stimulation in response to single-strand breaks 
(SSBs) (Ikejima et al., 1990). The PARP1 zinc fingers are structurally and functionally 
unique and represent a DNA-break sensing motif. They coordinate zinc molecules with 
an unusual Cys-Cys-His-Cys motif and recognize altered DNA structures rather than 
particular sequences (Gradwohl et al., 1990). Interestingly, DNA can also serve as 
potent PARP1 activator in the absence of strands breaks. It was observed that PARP1 
can be efficiently activated by binding to DNA hairpins, cruciform DNA and stable DNA 
loop regions (Lonskaya et al., 2005). A similar kind of zinc finger motif is found in the 
DNA repair enzyme DNA ligase III (Caldecott et al., 1996). Consistently, recent 
observations made by database searches suggest that PARP-like zinc fingers are 
evolutionary conserved in the eukaryotic lineage and associated with various enzymes 
implicated in nucleic acid transactions (Petrucco and Percudani, 2008). In addition to 
its zinc fingers, PARP1 contains additional DNA bindings motifs, which do not 
participate in enzymatic activation. Two helix-turn-helix motifs (aa 200-220 and 280-
285) (Saito et al., 1990; Uchida et al., 1987) mediate strong binding of PARP1 to 
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undamaged dsDNA and a fragment comprising these motifs behaves like the full-length 
enzyme in DNA footprinting assays (Buki and Kun, 1988; Sastry et al., 1989; 
Thibodeau et al., 1993). 
 
Considering its DNA binding activities and its dramatic activation by DNA strand 
breaks, it is not surprising that PARP1 plays an important role in DNA repair processes. 
PARP1 is an integral component of the base excision repair pathway (BER), and its 
function can be explained by the ‘shuttling model’ (Figure 3): (1) SSBs are recognized 
by PARP1 resulting in full enzymatic activation; (2) activated PARP1 poly-ADP-
ribosylates itself in an auto-modification reaction as well as histones H1 and H2B and 
possibly other proteins; (3) the poly-ADP-ribosylation of histones and/or of PARP1 itself 
causes relaxation of the chromatin and facilitates access to the site of the DNA lesion; 
(4) components of the BER pathway like XRCC1 and DNA ligase III are recruited by 
recognizing the locally produced pADPr; (5) poly-ADP-ribosylated PARP1 is repulsed 
from the DNA by electrostatic interference between the negatively charged DNA and 
the negatively charged pADPr; (6) the enzymatic activity of PARP1 is shut down to a 
basal level after the disruption of DNA binding; (7) the enzyme poly-ADP-ribose 
glycohydrolase efficiently removes the pADPr from PARP1 preparing it for another 
cycle of DNA damage recognition and initiation of DNA repair (Althaus et al., 1994; 
D'Amours et al., 1999; Schreiber et al., 2006; Zahradka and Ebisuzaki, 1982). 
 
 
Figure 3. 
A model explaining PARP1’s role in DNA SSB repair (modified from(Schreiber et al., 2006)). 
For explaining text, see bottom of next page.  
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Beside its role in the BER pathway, increasing evidence suggests that PARP1 is 
involved in an alternative DSB repair pathway. While DBSs are routinely repaired via 
the non-homologous end-joining (NHEJ) pathway involving the coordinated action of 
the DNA-dependent protein kinase (DNA-PK) and the XRCC4-DNA ligase IV complex, 
the BER components PARP1, XRCC1 and DNA ligase III are also capable to repair 
DSBs providing a backup pathway for the classical NHEJ mechanism (Audebert and 
Calsou, 2007; Audebert et al., 2004; Audebert et al., 2006). Interestingly, some 
components of the NHEJ pathway were shown to posses an pADPr binding motif 
mediating a non-covalent interaction with free pADPr and poly-ADP-ribosylated 
proteins (Althaus et al., 1999). Although PARP1 binds to DSBs and participates in their 
repair via an alternative non-homologous repair pathway, it is not involved in the repair 
of DSBs via homologous recombination (Helleday et al., 2005). However, it is clearly 
important for maintaining genomic stability (D'Amours et al., 1999; Herceg and Wang, 
2001; Kim et al., 2005) and was shown to protect eroded telomeres via an interaction 
with the telomere repeat factor TRF2 (Gomez et al., 2006). Thus, it was proposed that 
the loss of PARP1 activity results in an increase of recombinogenic lesions, rather than 
PARP1 being involved in recombination as such (Helleday et al., 2005). This 
hypothesis is supported by two clinically important studies reporting the effectiveness 
of PARP1 inhibition in hereditary breast cancer (Bryant et al., 2005; Farmer et al., 
2005). This familial form of breast cancer is in some cases caused by an inherited 
defect and subsequent loss of heterozygosity (LOH) in one of the BRCA1 or BRAC2 
alleles, both playing important roles in the repair of DNA DSBs by homologous 
recombination (Venkitaraman, 2002). It was shown that BRCA deficient cells are 
hypersensitive to PARP1 inhibitors leading to massive cell death. Importantly, the 
inhibition of PARP1 in tumorigenic cells not only stopped the growth of the tumor in 
xenograft models, but resulted in a partially and sometimes complete remission (Bryant 
et al., 2005; Farmer et al., 2005). 
 
 
 
 
Legend Fig. 3: 
PARP1 detects DNA lesions such as SSBs (red) resulting in DNA-dependent dimerization and 
subsequent enzymatic activation. The local synthesis of pADPr implements the relaxation of the 
chromatin around the site of the lesion and the attraction of DNA repair enzymes like XRCC1. 
Poly-ADP-ribosylated PARP1 is repulsed from the DNA resulting in disruption of the 
enzymatically functional homodimer and return of the enzymatic activity to basal levels. pADPr 
attached to PARP1 is rapidly degraded by PARG. 
The numbering refers to the text above that explains the ‘shuttling model’. 
The chromatin structure was taken from (Khorasanizadeh, 2004). 
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These observations led to the model (Figure 4) that spontaneously occurring SSBs 
cannot be repaired in the absence of PARP1 activity, in this case achieved by chemical 
inhibition of the enyzme, resulting in the collapse of replication forks. BRCA proficient 
cells are able to repair these profound lesions via homologous recombination, while in 
BRCA deficient cells these lesions are either repaired by error-prone pathways leading 
to further genetic instability or are directly lethal to cells (Helleday et al., 2005). 
Driven by these promising studies, several pharmaceutical companies have initiated 
oncology clinical trials with PARP1 inhibitors, and first promising results show the 
effectiveness of PARP1 inhibition in potentiating the activity of DNA-damaging agents 
(Ratnam and Low, 2007). But two very recent studies dampened the enthusiasm about 
the use of PARP1 inhibitors in cancer therapy, showing that BRCA2 deficient cells can 
evade the cell death mediated by PARP1 inhibitors through the acquisition of 
secondary mutations in the BRCA2 gene, which restore the protein function in 
homologous repair (Edwards et al., 2008; Sakai et al., 2008). Thus, tumor cells might 
get resistant to the chemotherapeutical agents by further mutations favorable to survive 
the cancer therapy, which will lead to recurrence of the tumor (Sakai et al., 2008). 
 
 
Figure 4. 
Mechanism for specific killing of BRCA2 defective cells with inhibitors of PARP (from 
(Helleday et al., 2005)). 
PARP1 is involved in the efficient repair of spontaneous SSBs, lack of repair causes replication 
forks to collapse. Thus the number of collapsed replication forks is increased following 
treatment with PARP inhibitors. BRCA2 proficient cells efficiently repair collapsed replication 
forks with homologous recombination and resume replication without error. Cancer cells that 
lack functional BRCA2 fail to repair collapsed replication forks, these are either repaired by 
error-prone repair or are directly lethal to cells. 
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PARP1’s role in DNA repair is closely linked to its role in the regulation of chromatin 
structure. Chromatin can be relaxed to the typical ‘beads on a string’ structure due to 
poly-ADP-ribosylation of histone H1 by PARP1, whereas the modified H1 remains 
associated with chromatin. Degradation of pADPr by PARG reverts the chromatin to a 
more condensed state (Aubin et al., 1983; de Murcia et al., 1986; Poirier et al., 1982). It 
was also shown that auto-modified PARP1 is able to dissociate chromatin independent 
of direct enzymatic activity via non-covalent interactions with histones which led to the 
proposal of a ‘histone shuttle’ mechanism:  pADPr covalently attached to PARP1 could 
serve as a scaffold for sequestering histones producing a locally relaxed chromatin 
state. Subsequent cleavage of pADPr by PARG would then free the histones and allow 
histone-DNA complexes to rebuild (Althaus, 1992; Althaus et al., 1994; Realini and 
Althaus, 1992). Consistently, a study analyzing polytene chromosomes in Drosophila, 
which possesses only two PARP genes, i.e. a PARP1 and a PARP5 orthologue 
(Adams et al., 2000; Hanai et al., 1998), shows that the chemical inhibition of PARP 
activity as well as the blockage of PARP1 expression inhibits the synthesis of pADPr, 
chromatin decondensation, and the transcription of genes induced by heat shock or 
hormones (Tulin and Spradling, 2003). The same group also published at the first 
glance contradictory results showing that dPARP1 promotes the formation of compact 
chromosome structures in Drosophila (Tulin et al., 2002). Genetic disruption of PARP1 
expression resulted in larval lethality, failure in nucleoli formation and in 
decondensation of heterochromatic, but not euchromatic regions. Interestingly, larval 
lethality could be restored by expression of a PARP1 mutant predicted to lack 
enzymatic activity, suggesting a role for PARP1 in the organization of heterochromatin 
independent of its catalytic activity (Tulin et al., 2002). Three studies from the Kraus lab 
support this idea and provide significant insight into PARP1’s function in 
heterochromatin formation (Kim et al., 2004; Krishnakumar et al., 2008; Wacker et al., 
2007). The first study shows that PARP1 incorporates into chromatin by virtue of 
nucleosome-binding properties resulting in chromatin compaction and transcriptional 
repression, a function reminiscent of the linker histone H1. The binding to nucleosomes 
stimulates the auto-poly-ADP-ribosylation of PARP1 leading to the release of PARP1 
from chromatin and subsequent chromatin relaxation, a finding contrary to the models 
described above which favor either a relaxation of chromatin by the poly-ADP-
ribosylation of histones or a stripping of histones from the DNA caused by their 
interaction with poly-ADP-ribosylated PARP1 (Kim et al., 2004). Recent observations 
support PARP1’s role in chromatin compaction (Wacker et al., 2007). Using atomic 
force microscopy, the authors show that the DBD of PARP1 is necessary and sufficient 
for binding to nucleosomes, but is neither efficient in chromatin compaction nor 
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completely efficient in transcriptional repression. Instead, the catalytic domain of 
PARP1 cooperates with the DBD to promote the compaction of chromatin and 
transcriptional repression independent of its catalytic activity (Wacker et al., 2007). A 
very recent study using a genome-wide ChIP-chip approach suggests that PARP1 and 
histone H1 exhibit a reciprocal binding pattern at many RNA polymerase II-transcribed 
promoters, with PARP1 being enriched around the transcriptional start sites of actively 
transcribed genes (Krishnakumar et al., 2008). In addition, a subset of genes positively 
regulated by PARP1 showed a significant increase in H1 binding after PARP1 
knockdown providing a functional link between PARP1 and H1 at these promoters 
(Krishnakumar et al., 2008). In summary, an important role of PARP1 in general 
chromatin compaction and in the transcriptional regulation of certain promoters seems 
likely, although Parp1-/- mice show no developmental abnormalities (Wang et al., 1995), 
which would be expected from a major regulator of chromatin structure. 
 
Beside PARP1’s role in regulating transcription via the modulation of chromatin 
structure, several studies indicate that it can work as a specific cofactor for certain 
transcription factors (reviewed in (Hassa and Hottiger, 2008; Kim et al., 2005; 
Schreiber et al., 2006)). Expression profiling in Parp1-/- mouse embryonic fibroblasts 
(MEFs) revealed that about 1% of 11,000 analyzed genes were differentially expressed 
in comparison to MEFs derived from wild-type littermates, with Parp1 loss resulting in 
the down-regulation of several genes involved in DNA/RNA repair or synthesis and up-
regulation of many genes encoding extracellular matrix or cytoskeletal proteins 
(Simbulan-Rosenthal et al., 2000). A further study analyzed the expression of 
inflammatory cytokines and NF-?B-dependent genes in LPS-stimulated glia cells of 
Parp1+/+ and Parp1-/- mice observing a great reduction in IL-6, IL-1ß, ICAM-1, and 
vesicular adhesion molecule-1, while the expression of the majority of analyzed genes 
was not changed significantly (Ha et al., 2002). However, Western Blot analysis of 
protein expression after several time points following LPS-stimulation showed a 
broader role of PARP1 in the LPS-induced activation of cytokine expression, with 
catalytic activity being relevant for the expression of only some PARP1-dependent 
genes (Ha et al., 2002). A recent expression profiling in Parp1-/- ES cells and liver cells 
shows that almost 10% of the genes in ES cells show altered expression in the Parp1-/- 
background and 3.3% in the liver cells, with a majority of the genes being down-
regulated in the absence of Parp1 (Ogino et al., 2007). Consistent with these 
expression studies, PARP1 was suggested to act as transcriptional co-factor for NF-
?B, E2F-1, B-MYB, AP-2, PAX6, TEF1 and the viral protein Tax, a function that is not 
necessarily dependent on its ADP-ribosylation capacity (Anderson et al., 2000; Butler 
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and Ordahl, 1999; Cervellera and Sala, 2000; Hassa et al., 2003; Kannan et al., 1999; 
Plaza et al., 1999; Simbulan-Rosenthal et al., 2003). Other studies implicate a role for 
PARP1 in assisting transcriptional repression, e.g. in repressing its own expression 
(Soldatenkov et al., 2002) or as a co-repressor of the nuclear hormone receptor RXR 
(Miyamoto et al., 1999). Again a general dependency on its catalytic activity could not 
be shown for the co-repressor function and seems to depend on the interacting 
transcription factor. 
 
Besides its function as classical co-activator or co-repressor in transcription, some 
studies provide evidence for a role of PARP1 as a co-repressor/co-activator exchange 
factor at certain promoters (Hassa et al., 2005; Ju et al., 2006; Ju et al., 2004; Pavri et 
al., 2005). In the context of NF-?B-dependent gene activation, PARP1 is able to 
physically interact with the co-activator complex Mediator and the histone acetyl 
transferase p300 as well as with the histone deacetylases HDAC1-3 (Hassa et al., 
2005). Acetylation of several lysine residues in PARP1 by p300/CBP results in the 
enhanced interaction with p50 and subsequent activation of NF-?B-dependent gene 
expression by p300 and the Mediator complex in response to inflammatory stimuli, 
suggesting a stimulus-dependent induction of PARP1-dependent NF-?B activation in 
concert with further transcriptional co-activators (Hassa et al., 2005). An interplay 
between PARP1 and Mediator was also observed when studying the essential factors 
for retinoic acid receptor (RAR)-mediated transcription from the RARß2 promoter (Pavri 
et al., 2005). PARP1 occupies RAR-responsive promoters continuously along with the 
Mediator complex and other factors as confirmed by ChIP experiments, but after 
ligand-dependent induction of gene expression it is indispensable for converting 
Mediator from its inactive state (Cdk8+) to its active state (Cdk8-) through the release 
of the repressing Cdk8 module (Pavri et al., 2005). Interestingly, PARP1 directly binds 
Cdk8 via its N-terminal region, and the interaction is weakened after TNF-? stimulation, 
which precedes the acetylation of PARP1 and subsequent NF-?B activation (Hassa et 
al., 2005). A similar situation was observed in neural differentiating stem cells: PARP1 
as component of the groucho/TLE co-repressor complex mediates the release of this 
complex upon PDGF stimulation and, after PDGF-triggered activation of CaMKII?, 
allows for the recruitment of co-activators like CBP and subsequent promoter activation 
(Ju et al., 2004). The catalytic activity is essential for this function and several 
components of the groucho/TLE complex including TLE1, the DNA topoisomerase 
TopoIIß and Nucleolin get ADP-ribosylated by PARP1 (Ju et al., 2004). The authors 
extended their model by a further study providing evidence that the signal-dependent 
activation of transcription requires the transient formation of dsDNA breaks by TopoIIß 
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and concomitant PARP1 activation, the latter inducing a nucleosome-specific exchange 
of histone H1 against the high-mobility group (HMG) B protein and local changes in 
chromatin structure (Ju et al., 2006). 
 
Another physiological role of PARP1 is its closely linked involvement in inflammation 
and apoptosis (Figure 5). As mentioned above, PARP1 triggers the expression of pro-
inflammatory genes after exposure to external stress signals like ischemia or LPS 
resulting in the generation of reactive oxygen species, PARP1 activation, translocation 
of AIF to the nucleus, DNA degradation, subsequent excess PARP1 activation with 
concomitant NAD+ and ATP depletion, and finally caspase-independent, necrotic cell 
death which promotes an inflammatory response in the surrounding tissue (Schreiber 
et al., 2006). An alternative apoptotic route, which is taken in the presence of limited 
DNA damage, is p53-dependent and involves the release of cytochrome c and 
activation of the caspase cascade (Schreiber et al., 2006). 
 
 
 
Figure 5. 
PARP at the crossroad of survival and inflammation (from (Schreiber et al., 2006)). 
For explaining text, see bottom of next page. 
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In agreement with this proposed action of PARP1 are the data obtained from studies 
on knockout mice. In various models of inflammation, including diabetes and septic 
shock, Parp1-/- mice show enhanced resistance (Hassa and Hottiger, 2002; Mabley et 
al., 2001; Oliver et al., 1999). 
 
In summary, PARP1 is involved in a wide variety of physiological processes with its 
catalytic activity being important for some, but not all of its functions. How regulation of 
PARP1’s role in these processes is achieved is poorly understood and has to be 
elucidated in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend for Fig. 5: 
In response to inflammatory stress, NF-?B–PARP1 induce the transcription of pro-
inflammatory genes (e.g. the inducible nitric oxide synthase (iNOS) gene) in macrophages. The 
subsequent production of nitric oxide (NO) and reactive oxygen species (step 1) triggers DNA-
strand breaks (for example, in postmitotic cells) (step 2) that activate PARP1 and PARP2 (step 
3). Poly(ADP-ribose) (PAR) has a short half-life and is rapidly degraded by PARG. This 
reaction produces an as yet unidentified molecular signal, which is possibly free PAR, that is 
transmitted from the nucleus to the mitochondria (step 4), where it induces a reduction of the 
mitochondrial membrane potential (??m) and the release of apoptosis-inducing factor (AIF) 
and possibly endonuclease G (EndoG) (step 5). AIF translocates into the nucleus where it 
induces the degradation of DNA into high-molecular weight fragments (chromatinolysis, step 
6). This overactivates PARP1 and PARP2 in a second wave of strong PAR synthesis (step 7) 
that leads to NAD
+
 and ATP depletion (step 8) and, finally, cell death (step 9). In proliferating 
cells that face a limited amount of DNA damage, PARP inhibition impairs DNA repair and 
promotes cell death via apoptosis, mainly through p53 activation. p53 modifies the expression 
of anti-apoptotic (BCL2) and pro-apoptotic (BAK) factors that regulate the release of 
cytochrome c (cyto c), which subsequently associates with Apaf1 (not shown) and procaspase-
9. This triggers the caspase-activation cascade, the activation of inhibitor of caspase-activated 
DNAse (iCAD)–CAD, which promotes DNA fragmentation, and the cleavage of PARP1 to 
avoid futile DNA repair. 
I?B, inhibitor of NF-?B; IL, interleukin; Pol II, RNA polymerase II; TNF, tumor-necrosis 
factor. 
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1.3.2 PARP2 
PARP2 was discovered in the late 1990s and displays high homology to the C-terminus 
of PARP1 harboring the catalytic domain and also contains a N-terminal DNA-binding 
domain (Ame et al., 1999). As expected, its catalytic properties strongly resemble those 
of PARP1, with the synthesis of long pADPr polymers being dependent on the binding 
to and activation by nicked DNA (Ame et al., 1999). Consequently, it was observed that 
PARP2 shares many functions with PARP1 in DNA repair processes: it interacts with 
the same components of the BER pathway, its enzymatic activity is required for an 
efficient BER of DNA lesions, it is able to hetero-dimerize with PARP1 within the same 
regions being responsible for its homo-dimerization, and PARP1 and PARP2 poly-
ADP-ribosylate each other in a trans-ADP-ribosylation reaction (Schreiber et al., 2002). 
In addition, Parp2-/- mice are hypersensitive to DNA-damaging agents similar to Parp1-/- 
mice, and the double mutant Parp1-/- Parp2-/- mice are embryonically lethal 
demonstrating an essential role in early embryogenesis and underlining their at least 
partial functional redundancy in maintaining genome integrity (Menissier de Murcia et 
al., 2003). Further similarities between PARP2 and PARP1 include their interaction with 
TRF2 and a role in telomere protection (Dantzer et al., 2004; Gomez et al., 2006), the 
cleavage of PARP2 and PARP1 during caspase-dependent apoptosis, mediated by 
caspase-8 or caspase-3, respectively (Benchoua et al., 2002; Kaufmann et al., 1993; 
Tewari et al., 1995), and their localization to centromeres where they interact with and 
poly-ADP-ribosylate centromeric proteins (Saxena et al., 2002). 
 
 
1.3.3 PARP3 
PARP3 can undergo auto-ADP-ribosylation as described for PARP1 and PARP2 and 
was found to be associated with the centrosome where it preferentially interacts with 
the daughter centriole throughout the cell cycle (Augustin et al., 2003). PARP3 
overexpression interferes with the G1/S phase cell cycle progression, and it was 
described to interact with PARP1 at centrosomes (Augustin et al., 2003). A recent 
study disputed the centrosomal localization of PARP3, but suggested a preferentially 
nuclear localization, an association with polycomb group (PcG) bodies and an 
interaction with PcG protein complexes (Rouleau et al., 2007). In addition, PARP3 was 
identified as part of DNA repair protein complexes by a proteomic approach, revealing 
an association e.g. with PARP1 and the DNA ligases III and IV (Rouleau et al., 2007). 
Thus, PARP3 might be involved in the maintenance of transcriptional repression and 
might be linked to the DNA repair machinery. 
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1.3.4 PARP4 
PARP4 (vPARP) was originally identified as a component of mammalian 
ribonucleoprotein complexes called vaults (Kickhoefer et al., 1999). It interacts with and 
ADP-ribosylates the major vault protein, undergoes auto-ADP-ribosylation and portions 
of the cellular PARP4 co-localize with cytoplasmic vault particles, while in mitotic cells 
PARP4 shows co-localization with the mitotic spindle (Kickhoefer et al., 1999). The 
incorporation of PARP4 into vault-like MVP-containing particles depends only on the C-
terminal domain lacking catalytic activity, and the incorporation into vault complexes 
leads to the stabilization of PARP4 and MVP (Zheng et al., 2005). Another study shows 
an interaction of PARP4 with the telomerase-associated protein 1 (TEP1), but the 
analysis of Parp4-/- mice revealed that these mice are viable and fertile without any 
apparent defects in telomer length or function and in the structure of vault particles (Liu 
et al., 2004). Thus, PARP4 is dispensable for the function of vaults as wells as for 
maintaining telomere function. The only phenotype observed so far for Parp4-/- mice is 
an increased susceptibility to carcinogen-induced colon tumorigenesis (Raval-
Fernandes et al., 2005). 
 
1.3.5 PARP5a and PARP5b (Tankyrase1 and 2) 
PARP5a and 5b are two closely related members of the PARP superfamily whose 
functions were mainly connected to telomeres, although additional roles in mitosis and 
vesicular trafficking have been proposed (reviewed in (Hsiao and Smith, 2008)). 
PARP5a (Tankyrase1) was identified in a yeast-two hybrid screen as an interaction 
partner for the telomeric repeat binding factor 1 (TRF1), with binding to TRF1 being 
mediated through the ankyrin repeats of PARP5a (Smith et al., 1998). It is able to 
catalyze auto-poly-ADP-ribosylation, poly-ADP-ribosylates TRF1 and co-localizes with 
TRF1 at telomeric DNA (Smith et al., 1998). A careful analysis of its ADP-ribosylation 
capacity revealed that PARP5a is able to synthesize pADPr with an average chain 
length of 20 units but lacks the ability to form branched polymers as described for 
PARP1 and PARP2 (Rippmann et al., 2002). The ability of PARP5a to ADP-ribosylate 
TRF1 depends on TRF1 binding through the ankyrin repeat cluster (ARC) V (Seimiya 
et al., 2004). PARP5a’s ability to associate with telomeres was shown to be dependent 
on TRF1, and in addition to its telomeric localization it also resides at nuclear pore 
complexes during interphase and localizes to mitotic centrosomes (Smith and de 
Lange, 1999). Consequently, a role for PARP5a in the telomere elongation was 
proposed, suggesting that the ADP-ribosylation of TRF1 by PARP5a releases TRF1 
from telomeres allowing access of telomerase to telomeres (Cook et al., 2002; Smith 
and de Lange, 2000). This release might be regulated by a second TRF1-interacting 
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factor, TIN2 (Ye and de Lange, 2004). In contrast to this model, a mutant PARP5a 
lacking ARC V and unable to ADP-ribosylate TRF1 seems to be sufficient to loosen the 
telomeric heterochromatin and to promote telomere elongation (Muramatsu et al., 
2007b). 
 
Beside its role in telomere function, PARP5a was described to be important for the cell 
to pass through mitosis correctly, a function being strictly dependent on its catalytic 
activity (Chang et al., 2005a; Dynek and Smith, 2004). Specifically, the knockdown of 
PARP5a results in mitotic arrest due to a failure in chromosomal segregation. While 
one study connected this observation to a post-anaphase arrest induced by failure of 
sister chromatid segregation at their telomeres (Dynek and Smith, 2004), the authors of 
another study suggest that PARP5a is required for the assembly of bipolar spindles 
with PARP5a knockdown resulting in a pre-anaphase arrest (Chang et al., 2005a). The 
proposed role in spindle formation is supported by the fact that the essential spindle 
protein NuMA was found to be a substrate for PARP5a-mediated poly-ADP-ribosylation 
in mitosis (Chang et al., 2005a; Chang et al., 2005b). The knockdown of PARP5a 
resulted in the loss of poly-ADP-ribosylated NuMA, but NuMA was still localized 
correctly to the spindle poles. In contrast, knockdown of NuMA completely abolished 
the localization of PARP5a to spindles during mitosis, indicating an essential role for 
NuMA in the recruitment of PARP5a (Chang et al., 2005b). A potential regulation of 
PARP5a in mitosis might be achieved through the phosphorylation by GSK3 (Yeh et 
al., 2006). 
 
While most of the PARP5a molecules are associated with the nuclear envelope during 
interphase (Smith and de Lange, 1999), a cytoplasmic portion was shown to be 
associated with the Golgi (Chi and Lodish, 2000). Closer analysis revealed an 
interaction of PARP5a with the insulin-responsive amino peptidase (IRAP) that likely 
recruits it to GLUT4 storage vesicles in adipocytes (Chi and Lodish, 2000). 
 
An interesting aspect of crosstalk between different members of the PARP superfamily 
was reported for PARP5a and PARP1 (Yeh et al., 2005). While the overexpression of 
PARP5a in MDCK cells resulted in lower steady-state NAD+ levels without affecting 
cellular viability, it rendered the cells more resistant to the cytotoxic effects mediated by 
H2O2 and the DNA-alkylating agent MNNG. This effect was due to the inhibition of 
PARP1 activation and concomitant NAD+ consumption, thus providing evidence for a 
cytoprotective function of PARP5a mediated through crosstalk with PARP1 (Yeh et al., 
2005). 
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The gene encoding PARP5b, at that time designated as the TNKL gene, was cloned in 
2001 and located to chromosome 10q23-24 (Kuimov et al., 2001). Almost 
simultaneously, the PARP5b protein was identified as an interaction partner of the 
adaptor protein Grb14, and both proteins were shown to be enriched in a subcellular 
fraction containing Golgi vesicles and endosomes (Lyons et al., 2001). At the same 
time, an association of PARP5b with TRF1 was reported, and strong overexpression of 
PAPR5b was found to cause cell death dependent on its catalytic activity (Kaminker et 
al., 2001). The findings of both reports remind of the ones obtained for PARP5a (see 
above). Consistently, the poly-ADP-ribosylation of TRF1 by PARP5b and the 
subsequent release of TRF1 from telomeres was described, indicating a potentially 
redundant role for PARP5a and PARP5b in telomere regulation (Cook et al., 2002). 
Considering the high homology of both tankyrases (see Figure 2), these observations 
were not surprising. Indeed, the discovery of a tankyrase-binding motif in several of the 
interaction partners shared between both tankyrases (Sbodio and Chi, 2002) and their 
reciprocal ability to associate and to colocalize (Sbodio et al., 2002) suggest a high 
redundancy in terms of physiological function, a situation resembling the close 
connection between PARP1 and PARP2 (see above). Interestingly, the analysis of 
Parp5b-/- mice revealed a significant decrease in the body weight pronounced in male 
mice, but no differences in telomere length as expected from the proposed role in the 
maintenance of telomere length (Chiang et al., 2006). Studies on transgenic mice 
carrying a Parp5b gene with a deletion of the catalytic domain presented similar 
results, showing no effects on telomere length and telomere capping, but a growth 
retardation phenotype (Hsiao et al., 2006). An explanation for the normal telomeres in 
these mice might be that murine TRF1 does not contain a tankyrase-binding motif as 
its human counterpart and consequently does neither interact with PARP5a nor does it 
get modified by it (Muramatsu et al., 2007a). Due to the high telomerase activity in 
rodents compared to mammals and their long telomeres, these species might have 
evolved to get along without the tankyrase-mediated maintenance of telomere length 
(Muramatsu et al., 2007a). 
 
 
1.3.6 PARP7 (TiPARP) 
Parp7 was identified as a gene upregulated by the treatment of mouse hepatoma cells 
with 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) (Ma et al., 2001), a halogenated 
aromatic by-product of industrial processes causing pleiotropic harmful effects in 
mammalian species because it serves as ligand for the cytoplasmic receptor AhR and 
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induces its translocation to the nucleus where it hetero-dimerizes with its partner 
protein Arnt and binds to enhancer sequences called dioxin-response elements (DREs)  
(Ma, 2001). Parp7 is broadly expressed in murine tissues and likely possesses 
enzymatic ADP-ribosylation capacity, although it was not determined whether it 
undergoes auto-ADP-ribosylation (Ma et al., 2001). Since a partial sequence of the rat 
Rm1 gene is homologous to the 3’ end of Parp7, it was speculated that Parp7 might be 
the murine homologue of the rat protein RM1 that is proposed to play a role in memory 
formation (Matsuo et al., 2000), even though no experimental data exist for this 
hypothesis (Ma et al., 2001). 
 
1.3.7 PARP9, 14, 15 (BAL1, 2, 3 / macroPARPs) 
The gene encoding PARP9 was originally identified as BAL1 (B-aggressive lymphoma 
1) gene in a screen for risk-related genes in diffuse large B cell lymphoma (DLBCL) 
and mapped to chromosome 3q21 (Aguiar et al., 2000). It encodes a nuclear protein of 
88 kDa with a N-terminal duplicated macro domain (Aguiar et al., 2000), a protein motif 
involved in the detection of different forms of ADP-ribose and in transcriptional 
repression (discussed below). The overexpression of PARP9 in B-cell lymphoma cells 
stimulated their migration in transwell assays, indicating a tumor-promoting role for 
PARP9 in malignant B cells (Aguiar et al., 2000). Interestingly, PARP9 interacts with 
the E3 ligase BBAP (Takeyama et al., 2003), and the expression of both genes is 
regulated by an interferon-?-responsive bidirectional promoter (Juszczynski et al., 
2006). BBAP regulates the subcellular localization of PARP9, and PARP9 
overexpression in DLBCL cell lines resulted in an increase in the expression of multiple 
interferon-stimulated genes, suggesting an important role for PARP9 in inflammatory 
processes (Juszczynski et al., 2006). Despite the fact that PARP9 contains a C-
terminal PARP domain, it lacks catalytic activity due to the absence of conserved 
residues essential for catalysis (discussed below), but it is able to repress transcription 
in general via its macro domains as assessed by reporter gene assays (Aguiar et al., 
2005). 
 
A database search identified two genes related to BAL1, which consequently were 
named BAL2 and BAL3 (Aguiar et al., 2005). Both genes were mapped to chromosome 
3q21 arranged in tandem with the previously identified BAL1 (Aguiar et al., 2005). The 
encoded proteins, PARP14 and PARP15, like PARP9 possess N-terminal macro 
domains and a C-terminal PARP domain, but in contrast to PARP9, the C-terminal 
region of both proteins is subject to an auto-ADP-ribosylation indicating an intact 
catalytic activity (Aguiar et al., 2005). PARP15 was reported to have a transcriptionally 
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repressive function, which is not as pronounced as for PARP9 but also mediated by its 
macro domains. Since its PARP domain alone slightly stimulated transcription, it was 
suggested that the intrinsic PARP activity of PARP15 might counteract the repressive 
effect of the macro domains (Aguiar et al., 2005). 
 
PARP14 was identified in a yeast two-hybrid screen as interaction partner of STAT6 
and was named collaborator of STAT6 (CoaSt6) (Goenka and Boothby, 2006). In spite 
of its three macro domains and in contrast to the repressive effect of the related 
proteins PARP9 and PARP15, PARP14 was described to have a potentiating effect on 
the IL-4-induced transcriptional activation by STAT6 mediated mainly by its macro 
domains (Goenka and Boothby, 2006). Importantly, PARP14 seems to be a specific co-
activator for the STAT6-mediated transcription, since it failed to stimulate the 
interferon-?-induced gene expression by STAT1 (Goenka and Boothby, 2006). 
Although the macro domains were described to be sufficient for the co-activator 
function of PARP14 in reporter gene assays as well as for the endogenous IL-4-
induced expression of the STAT6 target CD23 (Goenka and Boothby, 2006), the same 
authors suggest in their more recent study that the intrinsic PARP activity of PARP14 is 
essential for its STAT6 co-activator function (Goenka et al., 2007). They propose a 
model in which PARP14 ADP-ribosylates p100, a STAT6 co-activator enhancing the 
interaction of STAT6 with the basal transcription machinery, thereby mediating a 
stimulatory effect on the STAT6-driven gene expression (Goenka et al., 2007). The 
obvious discrepancy between these two studies from the same group is hard to explain 
at the current state of knowledge and will require further investigations. Referring to the 
physiological role of PARP14, it is interesting to note that in a subset of DLBCLs a high 
expression of components of the IL-4 signaling pathway is observed (Guiter et al., 
2004; Lu et al., 2005), whereas other subsets of DLBCLs exhibit changes in the 
interferon-? signaling pathway (Juszczynski et al., 2006). It is tempting to speculate that 
PARP14 and PARP9 might have antagonistic functions in DLCBLs, with one involved 
in IL-4 and the other involved in interferon-? signaling. 
 
1.3.8 PARP13 (ZAP(L)) 
The rat orthologue of PARP13 was identified by its ability to significantly impair the 
replication of murine leukaemia virus and lacks a PARP domain (Gao et al., 2002). Its 
antiviral property was linked to the specific binding and degradation of viral mRNAs in 
the cytoplasm (Gao et al., 2002), and the binding was shown to be mediated by the 
four CCCH zinc finger motifs in ZAP (Guo et al., 2004). The degradation of viral 
mRNAs involves the recruitment of the RNA processing exosome through an 
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interaction of ZAP and the exosome component hRrp46p (Guo et al., 2007). 
Interestingly, expression of the murine ZAP gene is induced by interferon-? and -ß in a 
PKR-independent fashion, and its protein product inhibits Sindbis virus replication, 
thereby linking the ZAP protein to the interferon-mediated antiviral activities (Zhang et 
al., 2007). Interestingly, the human ZAP gene can be expressed in two alternatively 
spliced isoforms (Kerns et al., 2008). While the short isoform ZAP(S) does not code for 
a PARP domain, the longer isoform ZAP(L) encodes a protein containing a C-terminal 
PARP domain in addition to the CCCH zinc finger motifs, the TiPARP homology 
domain and a WWE domain (Kerns et al., 2008). The longer isoform was also named 
PARP13 (Ame et al., 2004). Both isoforms are expressed in a broad range of tissues, 
with ZAP(S) showing in general significantly higher expression levels (Kerns et al., 
2008). Careful analysis of the rat gene also revealed the presence of a longer ZAP 
isoform containing a PARP domain. Since no ESTs have been reported for this PARP 
domain, it is likely that rat ZAP(L) is expressed at lower levels than ZAP(S) (Kerns et 
al., 2008). Evolutionary analysis provides strong evidence for a positive selection of the 
PARP domain within ZAP(L) throughout primate evolution, and the PARP domain 
increased the antiviral properties of ZAP against both retroviruses and alphaviruses 
(Kerns et al., 2008). Thus, although it is unclear whether the PARP domain in ZAP(L) is 
functional in terms of catalysis, it is likely that its physiological role is connected to 
antiviral effects. 
 
1.3.9 PARP10 
PARP10 exhibits a unique domain composition among the PARP family members, 
combining potential DNA/RNA binding motifs and ubiquitin interacting motifs with the 
catalytic PARP domain (Figure 6). 
 
 
Figure 6. 
The domain architecture of PARP10. 
Indicated are the different domains present in PARP10 as derived from database prediction of 
conserved protein motifs. The numbering refers to the PARP10 amino acids. In the C-terminal 
region the catalytic core domain and the residues involved in binding of c-MYC are marked. 
RRM, RNA recognition motif; Gly, Glycine-rich region; NES, nuclear export sequence; Glu, 
Glutamate-rich region; UIM, ubiquitin interacting motif; PARP, catalytic PARP domain 
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PARP10 was identified as an interaction partner of the prototypical oncoprotein c-MYC 
by affinity purification of a c-MYC protein complex from Jurkat T cells (Yu et al., 2005b). 
The PARP10 protein with an apparent molecular weight of 150 kDa was described as a 
catalytically competent PARP enzyme that ADP-ribosylates itself as well as core 
histones, but neither its interaction partner c-MYC nor the bHLH protein MAX, the 
heterodimerization partner of MYC (Yu et al., 2005b). The binding of PARP10 to c-
MYC is mediated by a C-terminal region encompassing aa 700-907, and c-MYC binds 
PARP10 via its N-terminal region in a Myc box II (MBII)-dependent manner and via its 
C-terminal 176 amino acids (Yu et al., 2005b). Interestingly, both regions have been 
implicated in c-MYC’s ability to transform cells (Henriksson and Luscher, 1996). 
 
The PARP10 gene was mapped by FISH analysis to chromosome 8q24 (Yu et al., 
2005a), a region where also the c-MYC gene is localized (Henriksson and Luscher, 
1996). The analysis of chromosomal translocation in Burkitt’s lympohoma cell lines 
revealed a localization of PARP10 telomeric from c-MYC, which afterwards could be 
specified to 8q24.3 (Yu et al., 2005b). A closer inspection of the chromosomal Parp10 
locus in mouse exhibited an overlap of the most 3’ exons 10 and 11 of Parp10 with the 
non-coding exons -1 and 0a of the plectin1 gene. In addition, a hypothetical plectin1 
promoter localized in intron 9 of Parp10 was suggested (Lesniewicz et al., 2005). This 
head-to-tail arrangement is likely conserved in rat and human and might potentially 
account for intergenic regulation of gene expression (Lesniewicz et al., 2005). 
Orthologues of PARP10 could be identified in rodents and in Fugu, but not in 
invertebrates suggesting that PARP10 has evolved in the vertebrate lineage 
(Lesniewicz et al., 2005). A single 3.8 kb mRNA transcript could be detected in a broad 
range of human tissues suggesting a ubiquitous expression with some preference for 
hematopoietic tissues (Yu et al., 2005b). 
 
PARP10 was reported to be localized preferentially in the cytoplasm and to shuttle 
between the cytoplasm and the nucleus in a Crm1-dependent fashion dependent on its 
functional NES (Yu et al., 2005b). Importantly, PARP10 was able to impair the c-
MYC/Ha-RAS-driven transformation of rat embryo fibroblast in a dose-dependent 
manner which is abrogated in a PARP10 mutant carrying a non-functional NES. 
Additionally, PARP10 inhibited the E1A/Ha-RAS-driven transformation suggesting that 
PARP10 might serve as a potent inhibitor of transformation in general. In both cases its 
catalytic properties seems dispensable for its function (Yu et al., 2005b). The analysis 
of starved 3T3-L1 cells re-entering the cell cycle after stimulation with FCS suggest that 
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overexpression of PARP10 in these cells interferes with progression into S-phase (Yu 
et al., 2005b). 
 
Another study shows that PARP10 gets phosphorylated at Threonine-101 by Cyclin 
E/CDK2, and its phosphorylated form is localized to the nucleolus during interphase 
and to the RNA-Pol I containing nucleolus organizing regions during mitosis (Chou et 
al., 2006). The authors observed an accumulation of HeLa cells in G1-phase after 
knockdown of PARP10 by shRNA accompanied by a decrease in cell number 
suggesting an important role for PARP10 in cell viability (Chou et al., 2006). In addition, 
it was shown that the phosphorylated form of PARP10 is preferentially present in 
proliferating cells, which led the authors to speculate that their antibody recognizing the 
phosphorylated PARP10 might be useful as a biomarker for proliferation (Chou et al., 
2006). 
 
1.4 ADP-ribose binding motifs 
The first indication for an ADP-ribose binding motif was published in the late 1990s: 
three regions within the tumor suppressor protein p53, two in its core DNA binding 
domain and one in its oligomerization domain, were observed to bind pADPr, either 
free or attached onto PARP1, through strong non-covalent interactions (Malanga et al., 
1998). The binding of p53 to pADPr interfered with its DNA-binding properties in gel 
shift assays, suggesting a potential regulation of p53’s functions by pADPr (Malanga et 
al., 1998). Interestingly, p53 was also found to undergo covalent poly-ADP-ribosylation 
by PARP1 which impairs its DNA binding properties (Mendoza-Alvarez and Alvarez-
Gonzalez, 2001) and was suggested to block the Crm1-dependent export of p53, 
thereby resulting in nuclear p53 accumulation in the presence of DNA damage (Kanai 
et al., 2007). Further studies led to the discovery of a pADPr-binding motif composed of 
a cluster rich in basic amino acids and a pattern of hydrophobic amino acids 
interspersed with basic residues (Pleschke et al., 2000). This motif is not only present 
in p53, but also in several DNA repair enzymes like DNA ligase III or XRCC1, in NF-?B, 
iNOS and telomerase (Pleschke et al., 2000). Surprisingly, all of these proteins were 
previously reported either as interaction partner/substrate of PARP1 or to act in the 
same functional pathway as PARP1 (discussed above). Thus, the non-covalent 
recognition of pADPr might add an additional layer of complexity to the PARP1-
dependent regulation of these proteins. 
 
Recently, it was described that the macro domain serves as high-affinity ADP-ribose 
binding module (Karras et al., 2005). Using ITC binding assays, the authors reported 
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specific binding of the macro domain from Af1521, a protein from the thermophilic 
organism Archaeoglobus fulgidus, to ADP-ribose with a KD in the range of 120 nM 
(Karras et al., 2005). The binding to ADP was substantially diminished compared to 
ADP-ribose suggesting an important role for the distal ADP-ribose in recognition by the 
macro domain. This is supported by the crystal structure of Af1521 with bound ADP-
ribose showing that the ADP-ribose is bound in a L-shaped cleft on the protein surface 
with the adenine moiety residing in a deep hydrophobic pocket. Consistent with data 
from the binding assays, the distal ribose is able to form several H-bonds that are not 
present in the ADP-bound structure of Af1521, thus explaining the higher affinity for 
ADP-ribose (Karras et al., 2005). Importantly, the macro domains of additional proteins 
including the histone variant mH2A and PARP9 were also able to bind ADP-ribose. 
Furthermore it was observed that the macro domains of Af1521 and PARP9 are not 
restricted to recognize ADP-ribose, but are capable of binding pADPr (Karras et al., 
2005). This finding was confirmed by analysis of viral macro domains that are able to 
bind ADP-ribose, free pADPr and PARP1-bound pADPr efficiently (Egloff et al., 2006). 
Unexpectedly, the macro domain of mH2A1.1 was not capable of recognizing pADPr, 
instead it binds 2’- or 3’-OAADPR, a metabolite produced during the deactylation 
reaction catalyzed by Sirtuins, with similar affinity as ADP-ribose (Kustatscher et al., 
2005). Analyzing the splice variant mH2A1.2, the authors could show that subtle 
differences between the variants mH2A1.1 and mH2A1.2 in the ligand-binding pocket 
abrogate the binding of mH2A1.2 to OAADPR (Kustatscher et al., 2005). 
 
Interestingly, the macro histone variants mH2A1 and mH2A2 are associated with the 
inactive X chromosome (Chadwick and Willard, 2001; Costanzi and Pehrson, 1998; 
Costanzi and Pehrson, 2001), and mH2A1 is not only concentrated on the inactive X 
chromosome but also depleted on active genes (Changolkar and Pehrson, 2006). This 
suggests a potential role for this histone variant in transcriptional repression. Indeed, 
mH2A1.2 was identified as a strong transcriptional repressor blocking transcription at 
the initiation step (Doyen et al., 2006). The repression is mediated by the non-histone 
region of mH2A1.2, the macro domain, and involves the repression of histone 
acetylation and nucleosome remodeling (Doyen et al., 2006). Since mH2A1.1 exhibits 
a different expression pattern in tissues and development compared to mH2A1.2 
(Pehrson et al., 1997), further experiments are necessary to discriminate between the 
physiological roles of these highly related histone variants. 
 
Two recent reports suggest an inhibitory role of mH2A1 towards the catalytic activity of 
PARP1 (Nusinow et al., 2007; Ouararhni et al., 2006), thereby linking the macro 
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domain as proposed ADP-ribose binding motif to the regulation of an ADP-ribosylating 
enzyme. Nusinow et al. observed an interaction between mH2A1.2 and PARP1’s zinc 
finger region and its catalytic domain, and the catalytic activity of PARP1 could be 
repressed by the macro domains of all mH2A family members (Nusinow et al., 2007). 
Importantly, the knockdown of PARP1 expression resulted in reactivation of a reporter 
gene embedded in the inactive X chromosome, which led to the proposal that mH2A 
might contribute to gene silencing by inhibiting PARP1 activity (Nusinow et al., 2007). 
In the study by Ouararhni et al., a direct interaction between PARP1 and mH2A1.1 was 
demonstrated and PARP1 could be identified as a component of mH2A1.1-
nucleosomes (Ouararhni et al., 2006). Catalytic PARP1 activity of this nucleosomal 
complex was inhibited, while nucleosomes containing a mH2A1.1 mutant deficient in 
ADP-ribose binding showed normal PARP1 activity. Under stringent conditions PARP1 
was released from these nucleosomes containing mutant mH2A1.1 but not from the 
mH2A WT nucleosomes, suggesting that the capacity to bind ADP-ribose mediates the 
recruitment and the catalytic inhibition of PARP1 by mH2A1.1 (Ouararhni et al., 2006). 
Importantly, the promoters of the inducible heat shock genes Hsp70.1 and Hsp70.2 
were enriched in mH2A1.1 and bound PARP1, and heat shock released both proteins 
from the promoter dependent on PARP1’s catalytic activity thereby allowing 
transcriptional activation (Ouararhni et al., 2006). 
 
In summary, the macro domain represents an ADP-ribose binding motif with distinct 
domains possessing slightly different specificities for ADP-ribose-related ligands and 
has been implicated in transcriptional repression. Further experiments need to clarify 
whether the macro domain functions as ADP-ribose binding motif in vivo, e.g. 
recognizing locally produced pADPr. The fact that mH2A1.1 is able to bind the 
metabolite OAADPR produced by enzymatically active Sirtuins, that all mH2A variants 
likely participate in transcriptional silencing and that mH2A1 potentially inhibits PARP1 
activity in vivo suggests a functional interplay of Sirtuins, PARPs and the mH2A histone 
variants in regulating chromatin structure and gene expression. Future work will be 
needed to shed light on these functional network centered around ADP-ribose. 
 
Recently, a third ADP-ribose binding motif termed pADPr-binding zinc finger (PBZ) was 
discovered (Ahel et al., 2008). It was reported that this C2H2 zinc finger is present in 
eukaryotic DNA repair and checkpoint control proteins and binds pADPr (Ahel et al., 
2008). The binding of the PBZ-containing proteins CHFR and APLF to pADPr was 
significantly stronger than for the pADPr-binding protein XRCC1 and was abrogated by 
mutations targeting the PBZ consensus sequence (Ahel et al., 2008). Interestingly, 
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PBZ-containing proteins were targets of PARP1-mediated ADP-ribosylation dependent 
on a functional PBZ motif, and the analyzed PBZ-containing proteins co-localized with 
pADPr in vivo (Ahel et al., 2008). Importantly, a functional PBZ motif is essential for the 
role of CHFR in the antephase checkpoint and treatment with the PARP inhibitor KU-
0058948 overrides this checkpoint in CHFR-proficient cells (Ahel et al., 2008). 
Therefore, the PBZ motif might play a physiological role in DNA repair and cell cycle 
checkpoint processes dependent on its ability to recognize pADPr. 
 
1.5 Insights into the catalytic mechanism of ADP-ribosylation reactions 
The structure of pADPr is well characterized (Figure 7): it is a homopolymer of ADP-
ribose units linked by glycosidic ribose-ribose 2’-1’’ bonds (Chambon et al., 1966; Miwa 
et al., 1977; Reeder et al., 1967; Sugimura et al., 1967) with a heterogeneous chain 
length reaching up to 200-400 units in vitro and in vivo under conditions of stimulated 
DNA damage (Adamietz et al., 1978; Alvarez-Gonzalez and Jacobson, 1987; Juarez-
Salinas et al., 1982). Long polymers synthesized by PARP1 and PARP2 can be 
branched in an irregular manner (Hayashi et al., 1983), and the chemical structure of 
the branching site was defined as O-D-ribofuranosyl-(1’’’-2’’)-O-D-ribofuranosyl-(1’’-2’)-
adenosine-5’,5’’,5’’’-triphosphate (Miwa et al., 1981). Branching can occur with an 
average frequency of about one branching point per 20-50 linear ADP-ribose units 
(Alvarez-Gonzalez and Jacobson, 1987; Hayashi et al., 1983; Kawaichi et al., 1981; 
Miwa et al., 1979). 
 
Figure 7. 
Structure of pADPr (from (Ruf et al., 1998b)). 
Displayed is the chemical structure of branched pADPr attached to a substrate protein via an 
ester linkage between the carboxylate group of an acidic amino acid side chain and the hydroxyl 
group of ribose (discussed above). 
 
The conformation of long pADPr chains likely adapts a helicoidal structure resembling 
nucleic acids (Minaga and Kun, 1983a; Minaga and Kun, 1983b). Indeed, it was 
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observed that antibodies raised against pADPr show cross-reactivity with DNA and 
RNA, and vice versa (Kanai et al., 1978; Sibley et al., 1986; Sibley et al., 1988). 
Considering the complex chemical structure of pADPr, one might wonder about how a 
single enzyme might be able to catalyze all the different steps involved in the transfer 
of pADPr to target proteins. The following paragraph will try to shed light on the 
mechanistic details of the poly-ADP-ribosylation reaction catalyzed by PARP1. If 
necessary, short excursions to the mono-ADP-ribosylating toxins will help to 
understand certain catalytic details. 
 
The process of poly-ADP-ribosylation by PARP1 can be subdivided into three parts: the 
initiation, the elongation and the branching reaction. The initiation is characterized by 
the attachment of a single ADP-ribose moiety from NAD+ to the ?-carboxy group of 
glutamic acid residues or less likely aspartic acid residues resulting in the formation of 
a labile ester bond that is unstable in dilute alkali and neutral hydroxylamine (Burzio et 
al., 1979; Kawaichi et al., 1980; Riquelme et al., 1979). The elongation step involves 
the transfer of further ADP-ribose moieties to an already attached ADP-ribose unit 
through glycosidic linkages (Chambon et al., 1966; Miwa et al., 1977; Ueda et al., 
1979). The third reaction catalyzed by PARP1 is the branching reaction that occurs in 
an irregular manner (Kawaichi et al., 1981; Miwa et al., 1979; Reeder et al., 1967). In 
addition, at nanomolar NAD+ concentrations an abortive NAD+ glycohydrolase activity 
was suggested for PARP1 (Bauer et al., 1986). PARP1 undergoes a strong auto-
modification reaction that targets several acidic residues residing mainly in the central 
auto-modification domain (Kawaichi et al., 1981). Although up to 28 auto-modification 
sites were reported (Desmarais et al., 1991; Kawaichi et al., 1981), analysis of the 
auto-mono-ADP-ribosylation by PARP1 suggests that a maximum of eight residues 
within the 22 kDa auto-modification domain are targeted (Mendoza-Alvarez and 
Alvarez-Gonzalez, 1999). The auto-modification likely exhibits an inhibitory effect on its 
catalytic properties, since an increase in Vmax and a decrease in Km was observed for 
the auto-modified enzyme compared to unmodified PARP1 (Kawaichi et al., 1981; 
Zahradka and Ebisuzaki, 1982). It has been reported that PARP1 itself is the major 
acceptor of pADPr in vitro (Kawaichi et al., 1981) as well as in vivo (Adamietz, 1987; 
Kreimeyer et al., 1984; Ogata et al., 1981). Accordingly, most of the enzymatic studies 
for PARP1 have analyzed the auto-modification reaction. 
 
The Km values of purified PARP1 for NAD
+ was determined to be ca. 20-80 ?M 
(Alvarez-Gonzalez, 1988; Kawaichi et al., 1981; Lagueux et al., 1995; Mendoza-
Alvarez and Alvarez-Gonzalez, 1993) with a Vmax of 0.5-2 pmol/min/mg enzyme and a 
Introduction  27 
turnover rate kcat/Km ? 2.2 x 104 for the auto-poly-ADP-ribosylation reaction (Alvarez-
Gonzalez, 1988; Kawaichi et al., 1981; Mendoza-Alvarez and Alvarez-Gonzalez, 1993). 
Histones were reported to act as allosteric activators of enzymatic PARP1 activity 
stimulating it up to 20-fold (Carter and Berger, 1982; Ito et al., 1979; Okayama et al., 
1977; Petzold et al., 1981). In addition, a stimulation by some transcription factors was 
observed (Griesenbeck et al., 1999; Oei and Shi, 2001), with the mechanistic details 
remaining unsolved. Compared to the polymerization reaction, the initiation reaction 
proceeds around 230 times slower with an apparent Km for NAD
+ of around 12 ?M and 
with a 50-fold lower kcat/Km ? 0.4 x 103 (Mendoza-Alvarez and Alvarez-Gonzalez, 1999). 
Thus, the initiation reaction is the rate-limiting step in the enzymatic reaction catalyzed 
by PARP1. It was suggested that the initial mono-ADP-ribosylation occurs in a 
distributive manner (Mendoza-Alvarez and Alvarez-Gonzalez, 1993), i.e. that potential 
target glutamates are mono-ADP-ribosylated in a random fashion without proceeding 
directly to the elongation reaction. In contrast, the polymerization reaction (elongation 
and branching) was shown to be highly processive (Naegeli et al., 1989), i.e. that once 
the enzyme has started the polymerization reaction at one mono-ADP-ribosylated 
residue, it will proceed until the possible longest and branched pADPr is synthesized 
onto this residue. The processive mode implies a constant pattern of reaction 
intermediates during the time course of the reaction. Indeed, it was observed that the 
relative size distribution of the synthesized pADPr remained constant during the auto-
modification of PARP1, and in addition, the sequential polymerization led to a time-
dependent increase in pADPr-carrying PARP1 molecules (Naegeli et al., 1989). Thus, 
PARP1 uses a processive mode for its polymerization reaction. The elongation reaction 
by PARP1 could theoretically occur via a protein-proximal mechanism or a protein-
distal mechanism. Although results from early studies favored a protein-proximal 
mechanism (Ikejima et al., 1987), it was later shown that PARP1 uses a protein-distal 
mechanism for the elongation, adding ADP-ribose moieties to the AMP terminus of the 
growing pADPr chain (Alvarez-Gonzalez, 1988). 
 
Several lines of evidence indicate that PARP1 acts as a homodimeric enzyme. First, 
using several biochemical approaches Bauer et al. (Bauer et al., 1990) were able to 
show that PARP1 associates in macromolecular complexes. The ability for self-
association is encoded in the N-terminal part of PARP1 comprising the DBD and the 
auto-modification domain (Bauer et al., 1990). Furthermore, maximal catalytic activity 
correlated with the presence of dimeric forms of PARP1, while monomeric PARP1 was 
suggested to act predominantly as NAD+ glycohydrolase (Bauer et al., 1990). In 
support of these results, the central auto-modification domain was proposed to be 
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involved in the homo-/hetero-dimerization of PARP1 (Uchida et al., 1993). Second, it 
was shown that the PARP1 auto-modification reaction occurs intermolecularly, since 
initial rates of auto-poly-ADP-ribosylation and of initial auto-mono-ADP-ribosylation vs. 
the enzyme concentration increased with second order kinetics (Mendoza-Alvarez and 
Alvarez-Gonzalez, 1993; Mendoza-Alvarez and Alvarez-Gonzalez, 1999). Third, it was 
suggested that the binding of PARP1 to nicked dsDNA triggers its dimerization 
dependent on its DBD resulting in its subsequent enzymatic activation, promoting both 
the initiation as well as the elongation and branching reaction (Le Cam et al., 1994; 
Mendoza-Alvarez and Alvarez-Gonzalez, 1999; Panzeter and Althaus, 1994). This is 
supported by the observation that PARP1 protects SSBs in DNA footprinting assays in 
a symmetrical manner indicating that PARP1 binds nicked DNA as a dimer (Gradwohl 
et al., 1990; Menissier-de Murcia et al., 1989). Finally, proteolytic fragments of PARP1 
can be modified in trans by the full-length protein pointing at an intermolecular auto-
modification reaction (Kameshita et al., 1986). In summary, it is undisputed that the 
PARP1 auto-modification reaction needs a catalytic dimer, but it remains obscure if 
both molecules of the dimer function simultaneously as catalyst and acceptor or if one 
catalyzing molecule modifies one acceptor molecule. Regarding the high-molecular 
nature of pADPr and the potential sterical problems that might occur if two poly-ADP-
ribosylated proteins have to be placed in a catalytically competent position to each 
other, it is tempting to speculate that the second mechanism is in place, although 
experimental evidence is still missing. 
 
The basal enzymatic activities including initiation, elongation, branching and NAD+ 
glycohydrolase activity depend on the presence of the C-terminal 54 kDa catalytic 
domain of PARP1 comprising aa 526-1014 (Kameshita et al., 1986; Kameshita et al., 
1984). Although initial reports suggested that the catalytic domain per se is not able to 
undergo auto-ADP-ribosylation and is enzymatically inactive if separated from the rest 
of the protein (Kameshita et al., 1986; Kameshita et al., 1984), Simonin et al. 
unambiguously showed that even a shorter 40 kDa C-terminal fragment of PARP1 
retained in principle all the catalytic activities observed for the full-length protein except 
of the dramatic stimulation by DNA (Simonin et al., 1993a; Simonin et al., 1990). While 
the Km value for NAD
+ was comparable to the one determined for full-length PARP1 
indicating equally efficient NAD+ binding, the specific activity was about 500-fold lower 
for the catalytic 40 kDa fragment similar to the basal activity of PARP1 in the absence 
of nicked DNA (Simonin et al., 1993a). Since the auto-modification domain that 
contains most if not all target glutamates for the auto-ADP-ribosylation by PARP1 is 
absent in the 40 kDa fragment, distinct glutamate residues must be targeted in this 
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auto-modification reaction. This can be interpreted as a rather unspecific targeting of 
surface-exposed glutamate residues by the catalytic domain of PARP1, an assumption 
in accordance with the broad range of substrates identified for PARP1 without any 
obvious consensus sequence. Thus, it is tempting to speculate that the distributive 
initiation reaction occurs rather unspecifically at glutamate residues of target proteins 
that are recruited, most likely by specific interactions with PARP1, in vicinity of the 
catalytic PARP1 domain. A similar mechanism was recently suggested for the histone 
acetyl transferases CBP/p300 which also target a broad range of substrates at lysine 
residues lacking any consensus sequence (Liu et al., 2008). 
 
A first important step to determine the important residues involved in the catalysis by 
PARP1 was made by Marsischky et al. who aligned the catalytic domain of PARP1 to 
the catalytic domains of ADP-ribosylating toxins and mutated the most strikingly 
conserved residues (Marsischky et al., 1995). They suggested a similar active site 
structure between ADP-ribosylating toxins and PARP1 and observed a strong 
conservation of a histidine, a tyrosine and a glutamate residue in the catalytic domain 
of PARP1 from various species (Marsischky et al., 1995). Importantly, the 
corresponding amino acids in Diphtheria toxin were shown to participate in NAD+ 
binding (histidine and tyrosine) and directly in catalysis (glutamate) as extracted from 
the crystallographic structure (Domenighini et al., 1994). Indeed, replacing the 
conserved histidine with an alanine dramatically decreased the specific enzymatic 
activity rendering the enzyme in principle inactive (Marsischky et al., 1995). A 
comparable severe phenotype was observed for the mutation of the conserved Glu-988 
to an alanine. Although the Km for NAD
+ was only little affected by this replacement, the 
Vmax value were dramatically lower than in the WT enzyme resulting in an about 1,100-
fold reduction in specific enzymatic activity (Marsischky et al., 1995). Careful enzymatic 
experiments revealed that the initiation reaction was reduced approximately 30-fold in 
the E-988A mutant, while the capacity to catalyze the elongation reaction was 
abrogated (Marsischky et al., 1995). A conservative replacement of Glu-988 with an 
aspartic acid residue resulted in retention of the elongation capacity, although the 
average chain length was about 2-fold shorter and the initiation reaction was impaired 
as seen for the E-988A mutant (Marsischky et al., 1995). Consistent with these 
observations, the authors proposed that the catalytic glutamate Glu-988 might act as a 
general base catalyst in the initiation reaction by activating the 2’-hydroxyl group of the 
terminal adenosine allowing its nucleophilic attack on the nicotinamide-ribose bond of 
an incoming NAD+ (Marsischky et al., 1995). 
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In support of these results, the crystallographic structure of the catalytic PARP1 domain 
from chicken revealed significant structural similarities between PARP1 and ADP-
ribosylating toxins (Ruf et al., 1996). The NAD+ binding motif of PARP1 differs 
significantly from the Rossman fold found in other NAD+-consuming enzymes (Figure 
8). Its core is composed of five ß-strands arranged in two abutting ß-sheets and is 
complemented by a sixth ß-strand participating in this anti-parallel confirmation. An ?-
helix is interspersed between ß-strands 2 and 3 and a long loop region connects ß-
strands 4 and 5 (Otto et al., 2005; Ruf et al., 1996). By analyzing the PARP1 structure 
with a bound nicotinamide analogue and superimposing the results to the situation in 
bacterial toxins, a putative NAD+ binding site was determined to be between the two 
central ß-sheets with Gly-863, Tyr-907 and Glu-988 involved in binding the 
nicotinamide moiety and participating in catalysis (Ruf et al., 1996). 
 
 
Figure 8. 
Structural comparison of the catalytic cores of PARP1 and Diphtheria toxin reveals a shared 
NAD
+
 binding motif (newly-arranged from (Otto et al., 2005)). 
For explanations, see top of next page. 
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Legend Figure 8: 
Two abutting sheets of anti-parallel ? strands form the upper and lower jaws of a Pacman-like 
NAD-binding crevice in all known structures of ADP-ribosyltransferases (upper panel). The 
structures are depicted from the "front view" with a full view of the ligands bound in the active 
site crevice. The ligands NAD and 3MB are colored cyan and are depicted as stick models. The 
central four ?-strands (from top to bottom: ? 5, ? 2, ? 1, ? 3, colored orange) are conserved in all 
mARTs and PARPs. The ? strands at the edges of the respective sheets (? 4 and ? 6, colored 
pink) show greater structural variation than the central ? strands. The H-Y-E motif residues are 
depicted in red and their side chains are shown as sticks. The glutamic acid residue (E-988 
inPARP1) at the front edge of ? 5 is the critical catalytic residue in both Diphtheria toxin and  
PARP1. Diphtheria toxin (DT) and PARP1 share the following additional structural features: 
the orientation of ? 6, the alpha helix between ? 2 and ? 3 (colored yellow) and the conserved 
histidine (His-862 inPARP1) and tyrosine (Tyr-896 in PARP1) amino acid residues in ? 1 and ? 
3. Note that the loop between ? 4 and ? 5 (colored magenta) differs significantly between both 
enzymes (discussed below). 3MB, 3-Aminobenzamide, an NAD-analogous PARP inhibitor 
 
 
The central role of this catalytic core domain was corroborated by deletion 
experiments. As expected, removal of structurally conserved regions led to complete 
abrogation of the catalytic activity (Cherney et al., 1991; Simonin et al., 1990). 
Photoaffinity labeling identified two potential adenine binding residues, Trp-1014 at the 
extreme C-terminus and Lys-893 (Kim et al., 1997). While non-conservative mutations 
of Lys-893 abrogated enzymatic activity (Kim et al., 1997; Simonin et al., 1993b), Trp-
1014 was dispensable and seems not to play an important role in NAD+ binding (Kim et 
al., 1997; Simonin et al., 1993b). The refined structures of the inhibitor-bound and 
unligated catalytic PARP1 domain and a local structural alignment to the situation in 
bacterial toxins revealed further residues involved in NAD+ binding (Figure 9) (Ruf et 
al., 1998a). 
 
Figure 9. 
Schematic drawing of hydrogen bonds (dotted lines) and hydrophobic contacts (parallel lines) to 
NAD
+
 (from (Ruf et al., 1998a)). 
Dashed-line boxes are used for residues from the N-terminal domain. In the homologous 
complex DT:NAD
+
 the phosphates are hydrogen bonded to water molecules, one of which is 
also present in unligated PARP-CF and depicted here. 
DT, Diphtheria toxin; PARP-CF, PARP1 catalytic fragment 
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It could be shown that the adenine moiety is buried in a deep pocket that leaves some 
space for water molecules and is fixed by several hydrogen bonds and hydrophobic 
interactions (Ruf et al., 1998a). Confirming previous results, the nicotinamide moiety is 
mainly hold in place by Gly-863 and Tyr-907 (Ruf et al., 1998a). Mutagenic studies 
confirmed the catalytic importance of residues located in the NAD+ binding motif 
comprising aa 855-1005 in PARP1 (Rolli et al., 1997). Mutation of many of these 
residues did neither effect the elongation nor the branching reaction, but decreased the 
specific enzymatic activity, which is in line with their potential role in binding the co-
substrate NAD+. Interestingly, some of the catalytically important residues are not 
located in the catalytic core domain, but either in the N-terminal ?-helical domain (aa 
662-784) or in the external face of the catalytic domain (Rolli et al., 1997). Due to the 
occlusion of the adenine binding pocket by helix F and the close vicinity of some 
residues to the active site, the N-terminal helical domain was suggested to relay the 
DNA binding signal to the catalytic domain resulting in a rearrangement more 
favourable for catalysis (Ruf et al., 1996). Indeed, the gain-of-function mutant L713F 
residing in helix D exhibits a 9-fold higher activity, while the Km for NAD
+ is unchanged 
(Miranda et al., 1995). Leu-713 is positioned near aa 881-888 which possess low 
mobility and are equivalent to the “active site loop” in bacterial toxins (Ruf et al., 
1998a). In contrast to the situation in PARP1, this loop becomes labile upon NAD+ 
binding in the toxins (Bell and Eisenberg, 1996; Li et al., 1996). It was suggested that 
the helix D participates in mobilization of this region upon DNA-binding by PARP1, 
thereby increasing the access to the substrate (Rolli et al., 1997). Besides these 
findings, the random mutagenesis of residues in the catalytic domain of PARP1 
revealed that especially Tyr-986 close to the catalytic glutamate Glu-988 participates in 
the elongation reaction (Rolli et al., 1997). While the conservative Y986S mutant was 
only slightly affected in the elongation reaction, the non-conservative substitution 
Y986H showed in addition an about 15-fold increase in branching frequency (Rolli et 
al., 1997). The production of short and highly branched pADPr by PARP1 Y986H 
indicates that branching is not per se restricted to longer ADP-ribose chains. Instead, it 
was suggested that the intrinsic helical nature of longer pADPr presents a more 
favorable conformation for branching than the shorter linear forms, and that the mutant 
Y986H would introduce a distortion of the polymer terminus positioning the terminal 
ribose in a convenient manner (Rolli et al., 1997). 
 
As outlined above the bacterial mono-ADP-ribosyltransferases and PARP enzymes 
share a similar NAD+ binding fold and a catalytic glutamate residue at a conserved 
position in the vicinity of the nicotinamide ribose (Domenighini et al., 1994; Domenighini 
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and Rappuoli, 1996; Okazaki and Moss, 1994; Ruf et al., 1998a). An essential role for 
the conserved glutamate has repeatedly been demonstrated for both the toxins 
(Aktories et al., 1995; Bohmer et al., 1996; Douglas and Collier, 1990; Lukac and 
Collier, 1988; Pizza et al., 1988) and PARP1 (Marsischky et al., 1995). The catalytic 
glutamate was proposed to act as a general base catalyst to remove a hydrogen from 
the incoming nucleophilic ribose (Marsischky et al., 1995), but studies from bacterial 
toxins showed that it acts by stabilizing the transition state of the reaction: the charged 
nicotinamide of NAD+ is bound in a hydrophobic pocket and isolated from solvent, 
which promotes the transition state by ground state destabilization (Berti et al., 1997).  
The C1’ carbon faces out of the active site, poised for attack by the incoming 
nucleophile, which can be a diphthamide moiety, arginine, cysteine, or glutamic acid, 
depending on the identity of the ADP-ribosyltransferase. Reaction of the nucleophile 
with C1’ leads to an inverted configuration in the ADP-ribosylated product 
(Oppenheimer, 1978; Oppenheimer and Bodley, 1981; Scheuring and Schramm, 
1995). For the toxins, kinetic isotope effects of the enzyme-catalyzed hydrolysis of 
NAD+ as well as ADP-ribosylation reactions indicate that the transition state bond 
orders are small for both the nicotinamide leaving group and the incoming nucleophile, 
and that the transition state has a high degree of oxocarbenium ion character (Berti et 
al., 1997; Parikh and Schramm, 2004; Rising and Schramm, 1997; Scheuring et al., 
1998; Scheuring and Schramm, 1997). In other words, when the nucleophile has 
begun to form a bond with the anomeric carbon (C1’), the bond to the leaving group 
has almost been broken. Thus, for diphtheria toxin, the NAD+ hydrolytic reaction has 
been termed “dissociative Sn2” (Berti et al., 1997). The catalytic glutamate does not 
appear to be important for binding of NAD+, since its mutation in PARP1 (Marsischky et 
al., 1995) as well as bacterial toxins (Bohmer et al., 1996; Douglas and Collier, 1990) 
does not affect the dissociation constant for NAD+. Instead, the catalytic glutamate 
functions to stabilize the oxocarbenium ion transition state that develops during the 
reaction. The intimate contact between the nicotinamide ribose and the conserved 
glutamic acid has been demonstrated by photoaffinity labeling studies (Aktories et al., 
1995; Barbieri et al., 1989; Carroll and Collier, 1984; Carroll and Collier, 1987), which 
have shown that the gamma carbon of the glutamate side chain becomes covalently 
linked to C6 of the nicotinamide ring (Carroll et al., 1985). On this basis, the carboxyl 
group of the catalytic glutamate must be very close to the C1’-N1 bond, and therefore 
well-positioned to stabilize the oxocarbenium ion transition state through a charge 
interaction. The oxocarbenium of the transition state forces the four ribose atoms C2’, 
C1’, O4’ and C4’ of the nicotinamide ribose into a planar conformation. Since the 3’-
endo conformation of the nicotinamide ribose is close to this transitional conformation 
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and the 2’-endo conformation shields the C1’ atom, the bacterial mono-ADP-
ribosyltransferases bind NAD+ in this favorable conformation (Bell and Eisenberg, 
1996; Li et al., 1996). The same was assumed to hold true for PARP1 (Ruf et al., 
1998a). A recent study analyzed the role of Glu-988 in the PARP1-mediated hydrolysis 
of NAD+ by means of a combined quantum mechanical/molecular mechanical 
(QM/MM) study. As demonstrated for the bacterial toxins, it could be shown that the 
reaction indeed proceeds through a SN2 dissociative mechanism and involves an 
oxocarbenium ion transition state (Bellocchi et al., 2006). The catalytic Glu-988 
stabilizes the Michaelis complex of the reaction and the transition state via electrostatic 
interaction, thereby lowering the activation energy by 13.4 kcal mol-1 (Bellocchi et al., 
2006). Thus, the essential importance of the highly conserved catalytic glutamate for 
the enzyme-catalyzed ADP-ribosyltransferase reaction is undisputed. 
 
Based on the previously obtained results and on a crystal structure of PARP-CF with 
the non-hydrolysable carba-NAD+, Ruf et al. suggested the following reaction 
mechanism for the elongation and branching reaction by PARP1 (Figure 10): the 
proposed acceptor site binding the prolongable pADPr forms a unique groove which is 
absent in other ADP-ribosyltransferases (Ruf et al., 1998b). Especially the 
pyrophosphate of the terminal ADP-ribose is bound tightly through several hydrogen 
bonds, and the adenine moiety is hold in place by hydrophobic interactions with Met-
890. Importantly, the mutants K903Q and K903E lost their ability to form pADPr without 
affecting the binding of NAD+ confirming the important role of the acceptor site in 
pADPr formation and underlining that the non-affected initiation reaction requires 
structural conditions distinct from the ones for elongation (Ruf et al., 1998b). The NAD+ 
donor site was described previously from studies on inhibitor-bound PARP1-CF (Ruf et 
al., 1998a) and was confirmed by mutations targeting Gly-863, Tyr-896 and Tyr-907. 
As expected, these mutations diminished the binding of NAD+ without affecting the 
enzyme’s capacity to synthesize pADPr (Ruf et al., 1998b). In the elongation reaction 
the catalytic glutamate acts by increasing the nucleophilicity of the acceptor ribose and 
by stabilizing the oxocarbenium ion transition state in the donor nicotinamide ribose. 
Since in the initation reaction the nucleophile is a carboxylate group of an amino acid 
side-chain that under physiological pH does not require the activation by Glu-988 as 
base catalyst, the role of the catalytic glutamate in the initiation reaction is restricted to 
the stabilization of the transition state (Ruf et al., 1998b). For the branching reaction, a 
rotation of the bound pADPr by 180° was proposed, which might be possible due to the 
fact that the active site in PARP1 is open on both sides. In the reverse orientation, the 
nicotinamide ribose is bound to the acceptor site instead of the adenine ribose allowing 
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the catalysis of branched pADPr (Ruf et al., 1998b). In summary, data from these 
studies explain the role of the conserved His-Tyr-Glu triad in the discussed ADP-
ribosyltransferases, with histidine and tyrosine participating in the binding of NAD+ and 
with the catalytic glutamate acting to stabilize the oxocarbenium transition state and 
promoting the elongation reaction by facilitating the nucleophilic attack of the ribose 
hydroxyl groups. 
 
As outlined above, the enzymatic activity of mARTs and PARPs was described to be 
dependent on a well-conserved catalytic glutamate residue in the active center 
(Bellocchi et al., 2006; Holbourn et al., 2006; Marsischky et al., 1995; Ruf et al., 
1998b). However, in several of the novel postulated PARP enzymes the existence of 
this important glutamate is disputed by sequence comparisons, suggesting that either 
these enzymes are catalytically inactive or that another mechanism is in place (Ame et 
al., 2004; Otto et al., 2005). Thus, these findings indicate that the PARP family may not 
be homogenous regarding their catalytic activity. Instead it is possible that distinct 
subfamilies exist that may differ in their enzymatic activity as well as other features. 
 
Figure 10. 
Proposed reaction mechanism for the elongation and branching reaction by PARP1 (from (Ruf 
et al., 1998b)). 
Left panel: Schematic drawing showing hydrogen bonds as dotted lines and nonpolar 
interactions as parallel bars. The nucleophilic attack is marked by an arrow. 
Right panel: A polymer subunit consists of A (adenine ribose), P (phosphate), N (nicotinamide 
ribose) and ad (adenine). Apart from the adenine, the subunit shows internal symmetry. The 
binding sites for the donor NAD
+
 and for the accepting subunit of pADPr are marked by dotted 
rectangles. At the acceptor site, the adenine is only weakly bound when compared with the 
phosphates, and there is space for polymer extensions over both ends of the site. Consequently, 
the polymer can bind in two orientations related by a 180° rotation (left and right sketch). 
Because of the given donor site position, the two binding orientations at the acceptor site give 
rise to elongation and branching as sketched. 
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1.6 Protein sorting: directing proteins to the desired destinations 
Regarding the fact that several thousand proteins coexist in a single cell, each 
occurring in copies from a few hundreds to several millions, it is obvious that specific 
proteins have to be targeted efficiently to their destinations within the cell. This 
targeting is guided by sorting signals in the transported protein. One can distinguish 
three general classes of sorting signals: signal sequences representing a continuous 
stretch of amino acids that are often removed from the mature protein by a signal 
peptidase, signal patches representing the three-dimensional arrangement of amino 
acids from different regions of the primary protein sequence, and post-translational 
modifications like glycosylation or fatty acylation. Proteins are targeted via these sorting 
signals to different destinations: to cytoplasmic organelles like mitochondria, lysosomes 
or peroxisomes, to the nucleus, and in many cases to the ER and the Golgi where 
especially secreted and membrane proteins pass the secretory pathway. With respect 
to this work, the transport across the nuclear envelope will be described in more detail. 
 
1.7 Transport across the nuclear envelope 
The double lipid bilayer of the nuclear envelope separates the nucleus and the 
cytoplasm and represents a significant barrier for the export of RNAs and proteins into 
the cytoplasm as well as for the nuclear import of proteins. The transport across the 
nuclear envelope occurs via nuclear pore complexes (NPCs) that form channels 
spanning the nuclear envelope. NPCs are complex macromolecular structures of 60-
130 MDa composed of several copies of about 30 different proteins called nucleoporins 
(Allen et al., 2000). The NPC consists of several ring systems and additional 
components, and the majority of NPCs shows a typical eight-fold radial symmetry 
(Figure 11) (Allen et al., 2000). 
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Figure 11. 
Structure of the nuclear pore complex (from (Allen et al., 2000)). 
Shown is a structural representation of the NPC with direct visualization of individual 
components. The presence of a central transporter is disputed due to experimental evidence 
arguing against it (Fahrenkrog and Aebi, 2003). 
 
The functional inner diameter of the nuclear pore is around 30 nm allowing ions, 
metabolites, and proteins smaller than 40-60 kDa to diffuse across the nuclear 
envelope (Allen et al., 2000; Terry et al., 2007). But the majority of the proteins have to 
be transported in an active fashion via interaction with specialized import and export 
proteins called karyopherins, which can be subdivided into importins and exportins 
regarding their function (Pemberton and Paschal, 2005). These interactions are driven 
via signal sequences termed nuclear localization signal (NLS) or nuclear export 
sequence (NES) (Macara, 2001). The classical NLS, which is the predominant signal to 
target proteins to the nucleus, is a monopartite or bipartite stretch of basic amino acids 
and is recognized by importin-? (Lange et al., 2007). Many proteins entering the 
nucleus lack a classical NLS and can be imported e.g. through a direct interaction with 
importin-ß, through a piggyback mechanism along with an interacting NLS-containing 
protein or through a basic surface patch functioning in an NLS-like fashion (Macara, 
2001; Stewart, 2007). The classical NES has a Leu-rich consensus sequence and is 
less clearly defined as the NLS because other hydrophobic sequences can replace the 
conserved leucines and the length of the intervening stretches are partially variable 
Introduction  38 
(Macara, 2001). The NES mediates the interaction of the NES-harboring protein with 
the export protein Crm1 (Pemberton and Paschal, 2005).  
 
Common to all nucleocytoplasmic shuttling processes, regardless of whether import or 
export is in place or if the transport is mediated by classical NLS or NES, is the 
dependency on the small GTPase Ran. Most of the Ran molecules are present in their 
GTP-bound state and are localized in the nucleus, but a small subpopulation of Ran-
GDP is cytoplasmic. The gradient of Ran-GTP between the nucleus and the cytoplasm 
is the driving force of the nuclear import/export processes, and in addition, Ran-GTP is 
responsible for the disassembly of import cargo complexes and the assembly of export 
cargo complexes (Figure 12) (Macara, 2001; Pemberton and Paschal, 2005). 
 
The Ran gradient is maintained through important regulators of Ran, RanGAPs and 
RanGEFs. RanGAPs activate the intrinsic GTPase function of Ran resulting in the 
hydrolysis of GTP to GDP, while RanGEFs act as nucleotide exchange factors 
converting Ran-GDP to Ran-GTP (Quimby and Dasso, 2003). The nuclear RanGEF 
RCC1 is associated with chromatin and efficiently maintains the high nuclear levels of 
Ran-GTP, while RanGAP is localized to the cytoplasmic face of the NPC and activates 
the GTP hydrolysis leading to cytoplasmic Ran-GDP (Quimby and Dasso, 2003). Thus, 
Ran and its respective GEF and GAP play an essential role in transport processes 
across the nuclear envelope. 
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Figure 12. 
Overview about some major nuclear transport pathways (from (Pemberton and Paschal, 2005)). 
A. Nuclear import of Ran-GDP mediated by NTF2. 
B. Nuclear import of nuclear localization sequence (NLS) cargo mediated by the karyopherin-?: 
importin-ß1 heterodimer (abbreviated Imp-? and Imp-ß). Nuclear import of NLS cargo 
mediated by direct binding to importin-ß1 and other karyopherin-ß family members is not 
shown. 
C. Nuclear export pathways that mediate recycling of importin-ß1 and karyopherin-?; the latter 
requires CAS as an export receptor. 
D. Nuclear export of nuclear export sequence (NES) cargo mediated by Crm1. RanGAP is 
anchored to the cytoplasmic side of the NPC and RanGEF is shown bound to chromatin. For 
simplicity, the model depicts only the minimal components necessary to form the 
pretranslocation transport complexes, and post-translocation intermediates and accessory factors 
are not shown. 
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1.8 Aim of this work 
ADP-ribosylation represents an evolutionary ancient post-translational modification and 
serves as a regulator of protein function. The enzymes involved can be divided into 
mono-ADP-ribosylating enzymes including bacterial toxins and into the poly-ADP-
ribosylating enzymes of the PARP family. It was described previously that PARP10 
possesses ADP-ribosyltransferase activity and undergoes auto-modification. Although 
an antibody directed towards poly-ADP-ribose displayed weak reactivity towards ADP-
ribosylated PARP10, the ability of PARP10 to form polymers of ADP-ribose has not 
been shown conclusively. Recent sequence alignments suggested that the PARP 
superfamily that is constituted of seventeen members is heterogenous regarding 
essential residues involved in catalysis. Since the presence of a conserved glutamate 
residue in the active center of PARP10 was disputed, we considered analyzing the 
catalytic activity of PARP10 in-depth. Therefore the first part of this work examines the 
catalytic properties of PARP10 and extends the findings to related enzymes of the 
PARP family. 
 
PARP10 is a mainly cytoplasmic protein that accumulates in the nucleus upon 
treatment with Leptomycin B, a potent inhibitor of Crm1-dependent nuclear export. 
While a functional NES was identified in PARP10, no classical NLS mediating nuclear 
import could be determined. Thus it remained elusive how PARP10 is able to enter the 
nucleus. Since the PARP10-interacting protein c-MYC is an exclusively nuclear protein, 
understanding the nuclear import mechanism would help to gain insights into the 
functional interaction between PARP10 and c-MYC. Therefore the second part of this 
work analyzes the subcellular localization of PARP10 and its nucleocytoplasmic 
shuttling in order to define the regions responsible for nuclear uptake. 
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2. Results and discussion 
 
2.1  The PARP10-mediated ADP-ribosylation reaction 
 
2.1.1 PARP10 functions as mono-ADP-ribosyltransferase 
Our previous studies had shown that the C-terminal half of PARP10 possesses 
catalytic activity (Yu et al., 2005b). To further evaluate the enzymatic properties of 
PARP10, we purified full-length PARP10 and a catalytically inactive mutant (PARP10-
G888W) by Tandem Affinity Purification (TAP) from HEK293 cells (Fig. 13A and data 
not shown). Mass spectrometry analysis and reactivity with PARP10-specific antibodies 
confirmed that these proteins are PARP10 (data not shown). ADP-ribosylation assays 
demonstrated robust C-TAP-PARP10 auto-modification with incorporation being linear 
over at least 20 minutes (Fig. 13B). However, C-TAP-PARP10 did not display a 
mobility shift upon auto-ADP-ribosylation, which is indicative of the pADPr formation 
catalyzed by PARP1, PARP2 and the Tankyrases (PARP5a and b) (Fig. 14) (Ame et 
al., 1999; Naegeli et al., 1989; Rippmann et al., 2002; Smith et al., 1998).  
 
Figure 13. 
A. C-TAP-PARP10 and C-TAP were purified from stably transfected HEK293 cells and 
analyzed by Coomassie blue staining. 
B. Purified C-TAP-PARP10 was incubated with 
32
P-NAD
+
 and 50 ?M NAD+ at 30°C for the 
times indicated. The reactions were stopped by adding SDS-sample buffer and the proteins were 
analyzed by SDS-PAGE and autoradiography. The displayed experiment is representative for 
two independent experiments. 
 
Therefore we compared the activities of PARP10 and PARP1. Purified C-TAP-PARP10 
and N-TAP-PARP10 underwent auto-modification, while C-TAP-PARP10-G888W was 
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inactive (Fig. 14A). Importantly, neither C-TAP-PARP10 nor N-TAP-PARP10 revealed 
any change in mobility, unlike PARP1 that showed a substantial increase in apparent 
molecular weight due to pADPr formation (Fig. 14A). Furthermore and in contrast to 
PARP1, auto-modified PARP10 was not or only poorly stained by mAb 10H that was 
reported to recognize pADPr chains of at least twenty ADP-ribose moieties (Kawamitsu 
et al., 1984) (Figs. 14B and a 20-fold longer exposure in 14C). A weak signal was 
measurable by pAb 96-10-04 that is described to recognize oligomers of six or more 
ADPr moieties (Alexis Biochemicals) (Fig. 14B). In both situations no shift in apparent 
mobility of PARP10 was detected. 
 
 
Figure 14. 
For legend, see top of next page. 
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A. Indicated proteins were incubated in the presence of a constant amount of 
32
P-NAD
+
 and 
increasing concentrations of unlabeled NAD
+
 as indicated. Proteins were separated by SDS-
PAGE, visualized by Coomassie blue staining and incorporated label detected by 
autoradiography. 
B. The reactions were performed as in panel A but without 
32
P-NAD
+
. The reaction products 
were analyzed by Western blotting using polyclonal antibodies (96-10-04) or a mAb (10H) 
specific for pADPr. PARP1 and PARP10 were detected using specific polyclonal antibodies. 
C. The experimental set-up was as in Fig. 2B. The reaction products were analyzed by Western 
blotting using mAb (10H) specific for pADPr. The staining with mAb 10H was 20x longer as 
that in Fig. 14B. 
D. HEK293 cells were transfected with plasmids expressing the indicated HA-tagged proteins. 
These were immunoprecipitated from whole cell lysates and their auto-ADP-ribosylation 
measured using 
32
P-NAD
+
 and the indicated concentrations of unlabeled NAD
+
.  
E. Endogenous PARP10 was immunoprecipitated from U937 promyelocytes using the 
polyclonal serum 891-6 or the corresponding prebleed 891-0 (Yu et al., 2005b) and analyzed for 
auto-ADP-ribosylation as in panel B. 
All experiments were at least performed twice with similar findings. 
 
 
To exclude interference of the residual TAP-tag with catalytic activity, we expressed 
HA-tagged versions of PARP10 and PARP1 transiently in HeLa cells. TAP- and HA-
tags display no sequence homology. Analysis of the HA-tagged proteins supported the 
results obtained for TAP-tagged PARP10 (Fig. 14D). Finally endogenous PARP10 from 
U937 promyelocytes was immunoprecipitated using a polyclonal PARP10 antiserum 
(Yu et al., 2005b). Similarly, this protein auto-modified without any change in mobility 
(Fig. 14E) and was not reactive to mAb 10H (data not shown). Thus full-length PARP10 
is unable to generate long polymers that would alter the mobility of the protein on SDS-
gels. 
 
The efficient catalysis of long, branched pADPr by PARP1 is stimulated by its 
interaction with DNA (D'Amours et al., 1999). Since PARP10 possesses potential RNA 
and/or DNA interaction motifs (Yu et al., 2005b), we tested whether nucleic acids could 
modify its catalytic activity. The addition of sheared salmon sperm DNA, linear or 
supercoiled plasmid DNA, or total cellular RNA neither stimulated the activity of full 
length PARP10 nor resulted in polymer formation (Fig. 15A and data not shown). 
Instead DNA led to a dose-dependent reduction of auto-modification. This was also 
true for GST-PARP10(818-1025), which contains the catalytic domain but not the N-
terminal potential RNA/DNA interaction motifs, indicating a direct effect of DNA onto 
the catalytic domain (Fig. 15B). Furthermore we addressed whether PARP10 is 
capable of catalyzing pADPr formation on heterologous substrates. As shown for a 
bacterially expressed catalytic fragment of PARP10 (Yu et al., 2005b), all four core 
histones were substrates of C-TAP-PARP10 and GST-PARP10(818-1025) but did not 
show any obvious shift in apparent molecular weight (Fig. 15C). 
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Figure 15. 
A. C-TAP-PARP10 and C-TAP-PARP10-G888W were auto-modified. The reactions contained 
the indicated amounts of sonicated salmon sperm DNA and total cellular RNA from HeLa cells. 
B. The experimental set-up was as in panel A. Here bacterially expressed GST-PARP10(818-
1025) was used that contains the catalytic domain. 
C. C-TAP-PARP10, C-TAP-PARP10-G888W and GST-PARP10(818-1025) were used to 
ADP-ribosylate core histones or BSA as indicated. 
 
To further compare the PARP1- and PARP10-catalyzed reactions, auto-modification 
products were analyzed directly, first by assaying for AMP and phosphoribosyl-AMP 
(PRAMP), and second by determining polymer length. PRAMP represents the 
phosphodiesterase reaction product of pADPr, while AMP is derived from mono-ADP-
ribosylated proteins and the terminal ADP-ribose of polymers. Auto-modified PARP1 
yielded a strong PRAMP signal, but PRAMP was not detectable in the PARP10-
catalyzed reaction (Fig. 16A), consistent with a lack of pADPr formation on auto-
modified PARP10. In contrast, AMP was released from auto-modified PARP10, 
confirming that it is mono-ADP-ribosylated. AMP was a minor product of auto-modified 
PARP1, consistent with long polymers. Indeed, PARP1 catalyzed the formation of 
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longer polymers with increasing NAD+ concentrations, while mainly monomeric ADP-
ribose and minute amounts of di- and trimers were associated with PARP10 auto-
modification (Fig. 16B). This difference in mono- vs. poly-ADP-ribose formation was 
reflected in the considerably lower Vmax of PARP10 as compared to PARP1 (2 vs 500 
pmol/min/?g, respectively) (Alvarez-Gonzalez, 1988). However, the KM values for 
NAD+, roughly 50 ?M for PARP10 (Fig. 16C), were comparable to the values 
determined for PARP1 (Mendoza-Alvarez and Alvarez-Gonzalez, 1993). 
 
 
Figure 16. 
A. PARP1 and C-TAP-PARP10 were auto-modified under standard reaction conditions using 
5?Ci of 32P-NAD+. ADP-ribosylation reaction products were subjected to phosphodiesterase 
treatment. Digestion products were analyzed by 2D-TLC and detected by autoradiography. 
B. PARP1 and PARP10 were auto-modified as described in panel A. Reaction products were 
removed from the proteins by base treatment and analyzed on a sequencing gel. Arrowheads 
indicate the length of ADP-ribose chains as determined by comigration of bromophenol blue (8-
mer) and xylene cyanol (20-mer) (Alvarez-Gonzalez and Jacobson, 1987; Tanaka et al., 1978). 
Autoradiograms are displayed. 
C. PARP10 auto-modification reactions were performed with a fixed amount of 
32
P-NAD
+
 and 
increasing concentrations of NAD
+
. The incorporated label was determined by TCA 
precipitation and Cerenkov counting and the data analyzed by Lineweaver-Burk. The displayed 
kinetic resulted from the mean values of three independent experiments. 
 
In summary, the lack of detectable mobility shifts of auto-modified PARP10 and of 
ADP-ribosylated core histones, the poor reactivity with two antibodies commonly used 
to detect pADPr, the lack of PRAMP upon phosphodiesterase treatment, and the lack 
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of detectable polymer formation, suggest strongly that PARP10 possesses mono-ADP-
ribosyltransferase but not polymerase activity. 
 
2.1.2 Molecular base for the transferase activity of PARP10 
A model for the PARP10 catalytic domain was generated using the recently determined 
crystal structure of PARP12 (PDB-ID 2PA9; Structural Genomics Consortium, 
unpublished), with which PARP10 shares 33% sequence identity. A structure-based 
alignment of PARP1, PARP3, PARP12, and the PARP10 model is shown in Figure 17. 
 
 
Figure 17 (in collaboration with B.H. Shilton). 
A structure-based sequence alignment of the catalytic domains of PARPs 1, 3, 10, and 12 is 
shown. Yellow shadings indicate structurally conserved regions. Asterisks indicate the residues 
of the conserved “HYE” triad (see text for details). 
 
PARP1 has pADPr polymerase activity, while PARP10 catalyzes only mono-ADP-
ribosylation. To identify the origins of this difference we compared the PARP10 model 
with that of PARP1. Core secondary structure elements are retained (Fig. 18A), as are 
the histidine (H887) and tyrosine (Y919) residues involved in NAD+ binding, and which 
constitute the first two amino acids of the highly conserved “HYE” triad found 
throughout the ADPr transferase superfamily (Figure 18B). However, it is clear that in 
PARP10 an isoleucine (I987) has replaced the catalytic glutamate found in PARP1 
(E988) (Fig. 18B). Therefore, even though a catalytic glutamate is present in all other 
related ADP-ribosyltransferases (Domenighini et al., 1994; Domenighini and Rappuoli, 
1996; Okazaki and Moss, 1994), the structure of PARP12 and the PARP10 model 
confirm the surprising observation that the catalytic glutamate is not present in these 
enzymes. Perhaps more surprising is that a close inspection of the PARP10 and 
PARP12 structures indicates there is no other residue in the active site that could 
substitute for the catalytic glutamate. 
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Figure 18 (in collaboration with B.H. Shilton). 
A. Superposition of PARP1 (magenta) and the PARP10 model (blue); only the backbone CA (C 
alpha) atoms are shown. The expected position of bound NAD
+
 is indicated based on the 
structure of diphtheria toxin in complex with NAD
+
 (Bell et al., 1996). Secondary structure 
elements are labeled and correspond to the structurally conserved regions indicated in Figure 17. 
In addition, the side chain of I987 in PARP10 is shown; this residue is at the beginning of ?-5, 
in the position occupied by the catalytic glutamate in PARP1. A stereoview is displayed. 
B. Detailed view of the nicotinamide-ribose binding site in PARP1 (magenta) and PARP10 
(blue). The side chains of the “HYE” motif in PARP1 (residues H862, Y896, and E988) are 
shown, along with the corresponding residues in PARP10. A stereoview is displayed. 
 
In addition to the absence of the catalytic glutamate in PARP10, there is a striking 
difference in the sequence that connects ß-4 and ß-5. In PARP1, this connecting loop 
is 37 residues long, whereas it is only 6 residues long in PARP10 (Fig. 17). In PARP1 
the catalytic glutamate (E988) is positioned at the N-terminus of ß-5, and the length 
and structure of the ß-4/ß-5 loop makes the region around E988 relatively crowded and 
constricted. In contrast, the short loop in PARP10 adopts a conformation that 
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effectively removes it from the active site region, making it much more open and 
accessible when compared with PARP1 (Fig. 18A).  
 
The lack of a glutamate in the catalytic site of PARP10, as well as the structure of the 
ß-4/ß-5 loop, which has been previously implicated in substrate recognition (Han and 
Tainer, 2002; Ruf et al., 1998b; Sun et al., 2004), appear to be the two features of 
PARP10 that correlate with its lack of pADPr polymerase activity. A comprehensive 
sequence alignment (Otto et al., 2005), indicates that PARPs 6 through 16 also lack a 
catalytic glutamate, and, in common with PARP10, most of these enzymes have a 6-
residue ß-4/ß-5 loop with a proline two residues N-terminal to the position where the 
catalytic glutamate is normally found. We have defined three PARP subfamilies based 
on the HYE triad at the catalytic core (Fig. 17, asterisks) and the length of the ß-4/ß-5 
loop (Table 1). The first is characterized by an HYE triad and a long ß-4/ß-5 loop. This 
subfamily consists of PARPs 1-5, with PARPs 1, 2, 5a and 5b having been 
demonstrated to synthesize polymers. In the second group (PARPs 6-8, 10-12, and 14-
16) the HYE motif is replaced by HYI/L/Y and the loop is considerably shorter. The first 
member of this group that has been analyzed in detail is PARP10, reported here. 
Accordingly we suggest that the members of this group function only as mono-ADP-
ribosyltransferases rather than polymerases. PARPs 9 and 13 of the third group 
possess QYT or YYV triads, respectively. These two PARP family members lack the 
catalytically important glutamate and the histidine, which binds the ß-NAD+ cofactor 
(Ruf et al., 1996; Ruf et al., 1998b). Since PARP9 has been reported to be catalytically 
inactive (Aguiar et al., 2005), we suggest that PARP13 will most likely also be inactive. 
 
To evaluate these hypotheses we tested the activities of different catalytic domains. 
The catalytic domain of PARP1, PARP1cat, although poorly active in comparison to the 
full-length protein, was able to catalyze the formation of long pADPr polymers, as 
indicated by a massive shift of the ADP-ribosylated protein to higher molecular weight 
and strong staining with mAb 10H (Fig. 19A and data not shown). The catalytic domain 
of PARP13, with YYV in the catalytic center and thus lacking both the glutamate and 
the histidine, did not reveal any auto-ADP-ribosylating activity (Fig. 19A). PARP14 was 
capable of ADP-ribosylation, but did not reveal any mobility shift, did not react with 
mAb 10H, and upon phosphodiesterase treatment only AMP but no PRAMP was 
released (Figs. 19A, B and data not shown). Thus PARP14 functions as a mono-ADP-
ribosyltransferase and not a polymerase. It is important to note that the lack of 
observed auto-ADP-ribosylation by PARP13 cannot only be explained by a lack of 
catalytic activity but also by the absence of potential auto-modification sites in the 
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analyzed GST fusion protein. Therefore an accurate analysis of the enzymatic 
properties of full-length PARP13 is necessary to draw a clear conclusion about its 
catalytic capacity. 
 
 
Figure 19. 
A. The catalytic domains of human PARP13 and murine PARP14 were amplified and expressed 
as GST-fusion proteins. Auto-modification activities of these two proteins and of the baculo-
expressed catalytic domain of PARP1 (aa656-1014) were analyzed by incorporation of 
32
P-
ADP-ribose with increasing NAD+ concentrations. 
B. GST-mPARP14 was auto-modified under standard reaction conditions using 5?Ci of 32P-
NAD
+
 and 50 ?M NAD+ at 30°C for 30 min. ADP-ribosylation reaction products were detached 
from TCA-precipitated proteins by alkaline treatment, extracted with phenol/chloroform and 
subjected to phosphodiesterase treatment. Digestion products were analyzed by 2D-TLC and 
detected by autoradiography. 
The displayed experiments were performed twice with similar results. 
 
The above findings support the structure- and sequence-based division of the PARP 
family into three functionally distinct subgroups, one with pADPr polymerase activity, 
one with mono-ADP-ribosyltransferase activity and one that is catalytically inactive (for 
summary see Table 1). Further studies analyzing the enzymatic properties of members 
of these subgroups will show if the proposed classifications can endure or if they will 
have to be re-adapted. 
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Table 1. 
Comparison of catalytic core motifs and loop length (between ß-sheets 4 and 5) and 
described/suggested enzymatic activities of PARP family members. 
 
PARP Protein 
name 
Gene 
symbol 
Catalytic 
core 
motif
1
 
Loop 
length 
(between 
ß-sheets 4 
and 5)
2
 
Postulated 
ADP-
ribosylation 
activity 
(mono (M) 
vs poly (P)) 
Demonstrated 
auto-ADP-
ribosylation 
Demonstrated 
polymerase 
activity 
Demonstrated 
mono-ADP-
ribose 
transferase 
activity 
1 PARP1 
(PARP) 
PARP1 HYE +++ (37) P + + - 
2 PARP2 PARP2 HYE +++ (40) P + + - 
3 PARP3 PARP3 HYE +++ (42) P + ? - 
4 VPARP PARP4 HYE ++ (14) P + + (short 
polymers) 
- 
5a TANK1 TNKS HYE ++ (10) P + + (no 
branching) 
- 
5b TANK2 TNKS2 HYE ++ (10) P + + (no 
branching) 
- 
6 PARP6 PARP6 HYI + (2) M ? ? ? 
7 TiPARP TIPARP HYI + (6) M + ? ? 
8 PARP8 PARP8 HYI + (2) M ? ? ? 
9 BAL1 PARP9 QYT + (6) inactive - - - 
10 PARP10 PARP10 HYI + (6) M + - (this study) + (this study) 
11 PARP11 PARP11 HYI + (6) M ? ? ? 
12 PARP12 ZC3HDC1 HYI + (6) M ? ? ? 
13 PARP13 ZC3HAV1 YYV + (6) inactive - (this study) - - 
14 BAL2 PARP14 HYL + (6) M + - (this study) + (this study) 
15 BAL3 PARP15 HYL + (6) M + ? ? 
16 PARP16 PARP16 HYY ++ (13) M ? ? ? 
 
1
Three amino acids relevant for catalytic activities of PARP enzymes. Histidine and tyrosine are 
within the catalytic center and important for function. The third amino acid, glutamate, has been 
demonstrated to be important for polymerase activity of PARP1 (Marsischky et al., 1995; Rolli 
et al., 1997). The three postulated subfamilies, i.e. the pADPr polymerases (yellow), the mono-
ADP-ribosyltransferases (green), and the catalytically inactive PARP members (grey), are 
indicated.  
2 
+++, ++, and + indicate long, intermediate and short loops, respectively. 
 
 
2.1.3 Characterization of the catalytic activity of PARP10: 
 ADP-ribosylation of acidic residues 
To understand the transferase function of PARP10 in more detail, we analyzed its 
catalytic properties. The auto-modification of PARP10 proceeded with second order 
kinetics, indicative of an intermolecular reaction (Fig. 20A). In addition the inactive C-
TAP-PARP10-G888W was a substrate of GST-PARP10(818-1025), which contains the 
catalytic domain, supporting the notion that the reactions occur intermolecularly (Fig. 
20B). This is in accordance with the results obtained for PARP1 (Kameshita et al., 
1986; Mendoza-Alvarez and Alvarez-Gonzalez, 1993). In order to define the region in 
PARP10 that is ADP-ribosylated, we prepared overlapping GST fusion proteins 
covering PARP10. When incubated in the presence of C-TAP-PARP10, the only 
modified fragment was GST-PARP10(818-1025) (Fig. 20B). Thus, this fragment is not 
only catalytically active but it also contains the auto-modification site(s). 
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Figure 20. 
A. C-TAP-PARP10 was titrated as indicated and the reaction products analyzed by SDS-PAGE 
(left panel). The labeled bands were cut out from the dried gel and counted. The mean values 
and standard deviation of three experiments are summarized in the right panel. 
B. The indicated PARP10 fragments were expressed as GST-fusion proteins and subjected to an 
enzymatic PARP assay with C-TAP-PARP10 or C-TAP-PARP10-G888W. Arrowheads indicate 
GST and the different GST-PARP10 fusion proteins. The labeled proteins, i.e. PARP10 full 
length and GST-PARP10(818-1025) are indicated by arrows. The experiment was performed 
twice with similar outcome. 
 
In order to analyze which parts of the catalytic domain are essential for the trans-ADP-
ribosylation by full-length TAP-PARP10, we prepared C-terminal deletion mutants of 
GST-PARP10(818-1025)-G888W. Deletion of the most C-terminal 30 aa of PARP10 
completely abrogated the use of this mutant as substrate for the full-length enzyme 
(Fig. 21). Since this deletion mutant lacks the conserved ß-sheet 6 participating in the 
catalytic core domain (Fig. 17), it can be concluded that an intact catalytic core is 
essential for the trans-ADP-ribosylation by the full-length enzyme. This can be 
explained in two ways: either the binding of NAD+ by the “substrate” catalytic domain is 
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necessary to get ADP-ribosylated, because it might induce a conformational change, or 
the disintegration of the three-dimensional structure of the catalytic domain causes the 
loss of protein-protein interactions between the intact enzyme and the potential 
“substrate” catalytic domain. Both explanations underline the importance of structural 
integrity for the catalytic core motif. As expected, all analyzed C-terminal deletion 
mutants of the catalytically active GST-PARP10(818-1025) resulted in an abrogation of 
auto-ADP-ribosylation as well as trans-ADP-ribosylation of TAP-PARP10-G888W (Fig. 
21). Regarding the importance of the deleted regions in the catalytic core, this is most 
likely due to the loss of its NAD+ binding capacity resulting in a dead enzyme. 
 
Figure 21. 
The indicated PARP10 fragments were expressed as GST-fusion proteins and subjected to an 
enzymatic PARP assay with C-TAP-PARP10 or C-TAP-PARP10-G888W. Arrowheads indicate 
the different GST-PARP10 fusion proteins. A second experiment confirmed the results obtained 
from the displayed experiment. 
 
ADP-ribosylation occurs on a number of distinct amino acids, including acidic residues, 
arginines, and cysteines, with distinct sensitivities of the respective chemical bond 
(Hassa et al., 2006). Auto-modified PARP10 was highly sensitive to hydroxylamine 
treatment, indicating an ester bond between ADP-ribose and acidic residues (Fig. 22A). 
However, auto-modified PARP10 was insensitive to HgCl2 (Fig. 22B), which cleaves 
Cys-ADP-ribose linkages (McDonald and Moss, 1994). meta-Iodobenzylguanidine 
(MIBG), an inhibitor of arginine-specific mARTs (Smets et al., 1990), did not inhibit the 
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enzymatic activity of PARP10 (Fig. 22C). Thus cysteines or arginines were not 
modified by PARP10. mARTs can be inhibited specifically by Vitamin K1 (Banasik et 
al., 1992). 
 
 
Figure 22. 
A. Immobilized GST-PARP10(818-1025) was auto-modified and then subjected to treatment 
with 1 M neutral NH2OH. Residual radioactivity was determined by autoradiography. 
B. Immobilized GST-PARP10(818-1025) was automodified with 
32
P-NAD
+
 and 50 ?M NAD+ 
at 30°C for 30 min. The modified proteins were then subjected to treatment with 1 mM neutral 
HgCl2. 
C. C-TAP-PARP10 was subjected to a PARP assay with the indicated concentrations of meta-
Iodobenzylguanidine (MIBG), an inhibitor of arginine-specific mARTs. 
D. C-TAP-PARP10 was subjected to PARP assays with the indicated concentrations of different 
PARP inhibitors. Control experiments (0 ?M) were performed with the highest concentrations 
of solvent used for the inhibitors. IC50 values for PARP1 are indicated as derived from the 
literature (Banasik et al., 1992; Jagtap et al., 2005; Southan and Szabo, 2003; Woon and 
Threadgill, 2005). 
All experiments were at least performed twice with similar outcomes. 
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In agreement with the conclusion drawn above that PARP10 is a non-classical mono-
ADP-ribosyltransferase, Vitamin K1 did not interfere with PARP10 function (Fig. 22D). 
In addition the differential sensitivity to known PARP1 inhibitors distinguishes PARP10 
from PARP1, despite the strong structural similarity (Fig. 22D). Regarding the small, 
but obvious differences in the catalytic center of bona fide PARPs like PARP1 and the 
novel PARPs functioning as mARTs, it is not surprising that especially many of the 
novel PARP inhibitors designed for PARP1 inhibition are inefficient in targeting 
PARP10 and presumably other novel PARPs. This also indicates that it should be 
possible to design potent inhibitors that are selective for the mARTs among the PARP 
family members. Such inhibitors might be useful tools to dissect the roles of mono-
ADP-ribosylation and poly-ADP-ribosylation in cells. 
 
One characteristic of the poly-ADP-ribosylation of PARP1 is its sensitivity to poly-ADP-
ribose glycohydrolase (PARG) and ADP-ribose hydrolase 3 (ARH3), while ARH1 and 
ARH2 are inactive towards pADPr (Oka et al., 2006). ARH1 has been described to 
remove ADP-ribose from proteins modified on arginines (Takada et al., 1993). So far 
no enzymatic activity has been reported for ARH2. Therefore we tested whether PARG 
was capable of de-ADP-ribosylating C-TAP-PARP10. Indeed, we observed a more 
than 2-fold reduction of auto-modified PARP10 after PARG treatment (Fig. 23A). This 
suggested that PARG can remove the ADP-ribose from an acidic residue, in addition to 
hydrolyzing the glycosidic bond between ADP-ribose units. To test this further we used 
PARP1-E988K, a PARP1 mutant with low catalytic activity restricted to mono-ADP-
ribosylation (Rolli et al., 1997). Importantly, this modification was reversed by PARG, 
supporting the notion that PARG has a mono-ADP-ribosyl-protein lyase activity; this 
activity has previously been ascribed to an enzyme distinct from PARG (Oka et al., 
1984). It is important to note that previous studies obtained similar results, suggesting 
that PARG is able to remove mono-ADP-ribose from acidic residues (Desnoyers et al., 
1995). To expand on this observation, auto-modified GST-PARP10(818-1025) was 
treated with PARG and ARH1-3. Both PARG and ARH3, but not ARH1 and 2, were 
able to de-ADP-ribosylate GST-PARP10(818-1025) (Fig. 23B). 
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Figure 23. 
A. C-TAP-PARP10 and PARP1-E988K were immobilized on Protein A-Sepharose using 
specific antibodies, auto-modified and subsequently subjected to PARG treatment. Residual 
radioactivity was determined by autoradiography. 
B. Immobilized GST-PARP10(818-1025) was auto-modified and afterwards subjected to 
PARG/ARH assay using the indicated GST proteins. 
The displayed data are representative for at least two performed experiments. 
 
Thus, in addition to their described pADPr glycohydrolase activity, PARG as well as 
ARH3 are likely able to remove the last ADP-ribose moiety from proteins ADP-
ribosylated on acidic residues. Together these findings strengthen our conclusion that 
PARP10 mono-ADP-ribosylates acidic residues. Whether PARG and ARH3 indeed 
serve as de-ADP-ribosylating enzymes for PARP10-modified proteins in vivo has to be 
addressed in the future. This will require to develop reagents that are suitable for the 
analysis of proteins mono-ADP-ribosylated on acidic residues (see discussion below). 
 
2.1.4 Identification of Glu882 as auto-ADP-ribosylation site 
It appears that PARPs modify acidic residues, but there is limited information on the 
identity of PARP-modified ADP-ribosylation sites; for example, the site(s) of auto-
modification have not been mapped in PARP1, despite considerable effort (Hassa et 
al., 2006). To identify potential auto-modification sites in PARP10, we evaluated the 
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positions of acidic residues in PARP10 using our structural model. Mutation of four 
potentially accessible acidic residues at the extreme C-terminus, either alone or in 
combination, reduced the auto-modification only slightly (Fig. 24A), suggesting that the 
C-terminus is not efficiently ADP-ribosylated. We then turned to four surface exposed 
glutamates, E866, E870, E877, and E882, and mutated these residues individually to 
alanine. Of these mutants GST-PARP10(818-1025)-E882A was significantly less auto-
ADP-ribosylated, while the other mutants showed no or less significant reduction (Fig. 
24B). Similarly the GST-PARP10(818-1025)-E882Q was poorly auto-modified (data not 
shown). No reduction in enzymatic activity per se was observed for GST-PARP10(818-
1025)-E882A as determined by its ability to trans-ADP-ribosylate C-TAP-PARP10-
G888W (Fig. 24C). Furthermore, the trans-ADP-ribosylation of the catalytically inactive 
GST-PARP10(818-1025)-G888W-E882A by the full-length C-TAP-PARP10 was also 
reduced (Fig. 24D). Thus these findings suggest that E882 is a major, but apparently 
not the only, acceptor site for PARP10 auto-ADP-ribosylation. 
 
Although our in vitro data clearly show that E882A is a site targeted by the PARP10 
auto-modification reaction, its importance in vivo and the functional relevance for the 
auto-modification remain elusive. Since antibodies recognizing mono-ADP-ribosylated 
acidic residues are commercially not available and mass spectrometric identification of 
ADP-ribosylation is technically not feasible due to the lability of the ester bond, it would 
be necessary to develop appropriate reagents to analyze the auto-modification of 
PARP10 and, even more important, the ADP-ribosylation of PARP10 substrates in 
vivo. The generation of antibodies targeting the PARP10 auto-modification site could 
be achieved by the enzymatic ADP-ribosylation of substrate peptides and the 
subsequent injection into rabbits. Polyclonal serum of the immunized animals should 
then be purified with the ADP-ribosylated peptides to get rid of the antibodies 
recognizing the unmodified peptide. Since ADP-ribose can be cleaved by 
pyrophosphatases, it will most likely be necessary to use a pyrophosphatase-resistant 
NAD+ analogue as described by Hilz and colleagues (Meyer and Hilz, 1986; Meyer et 
al., 1984). 
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Figure 24. 
A. The indicated PARP10 fragments were expressed as GST-fusion proteins in the 
background of a catalytically inactive mutant (GST-PARP10(818-1025)-G888W) and incubated 
in the presence of C-TAP-PARP10 with 
32
P-NAD
+
 and 50 ?M NAD+ at 30°C for 30 min. The 
reaction products were analyzed by SDS-PAGE.  
B. The indicated GST-fusion proteins were subjected to a standard PARP assay. Incorporated 
radioactivity was detected and quantified on a phosphoimager. Relative ADP-ribosylation was 
calculated using mean values derived from four separate experiments. Depicted is a 
representative experiment.  
C and D. The indicated PARP10 fragments were expressed as GST-fusion proteins, auto-
modified in the presence of C-TAP-PARP10-G888W (C) or C-TAP-PARP10 (D) and analyzed 
by autoradiography. 
All experiments were at least performed twice and showed results similar to the ones displayed. 
 
To investigate the feasibility that E882 of PARP10 could serve as the auto-modification 
site, a model of the PARP10 auto-modification complex was constructed (Fig. 25A). In 
this model, a “substrate” PARP10 (S-PARP10) was complexed with an “enzymatic” 
PARP10-NAD+ complex (NAD-PARP10). The NAD+ was positioned based on a 
complex between diphtheria toxin and NAD+ (PDB ID 1TOX; (Bell and Eisenberg, 
1996)). With relatively minor adjustments to loop regions, we were able to position the 
carboxylate of E882 in S-PARP10 very close to I987 of NAD-PARP10, such that the 
carboxylate of E882 occupies a position roughly equivalent to the position occupied by 
the carboxylate of the catalytic glutamate in PARP1 (Fig. 25A-C). Thus the pocket 
between the ribose-nicotinamide of NAD+ and I987 is sufficiently large to accommodate 
the glutamate of the substrate. 
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Figure 25 (in collaboration with B.H. Shilton). 
A. Two views of the auto-modification complex consisting of a PARP10 molecule with bound 
NAD
+
 (surface representation, along with NAD
+ 
as sticks with yellow carbon atoms) and a 
PARP10 substrate molecule (blue), including the side chain of E882, a site of ADP-ribosylation. 
B. Detail of the residues surrounding the E882 site of modification; residues from the substrate 
are illustrated with carbon atoms colored cyan with the sequence RPVEQV. 
C. The carboxylate of E882 (cyan carbons) occupies a position very close to that of the catalytic 
glutamate (E988) in PARP1 (magenta carbons) and can therefore act to stabilize the 
oxacarbenium ion transition state. 
 
2.1.5 Substrate-assisted catalysis by PARP10 
The ADP-ribosylation reaction has been well-studied, and a mechanism incorporating 
the most important features is illustrated in Figure 26A. NAD+ is bound by the enzyme, 
with the nicotinamide moiety positioned in a deep pocket and isolated from solvent; the 
lack of support for the positive charge on the nicotinamide promotes formation of the 
transition state (Berti et al., 1997). For the toxins, measurement of kinetic isotope 
effects indicate that the transition state bond orders are very small for both the leaving 
nicotinamide group and the incoming nucleophile and that the transition state has a 
high degree of oxocarbenium ion character (Berti et al., 1997; Parikh and Schramm, 
2004; Rising and Schramm, 1997; Scheuring et al., 1998; Scheuring and Schramm, 
1997). In other words, when the nucleophile has begun to form a bond with C1’, the 
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bond to the leaving group has almost been broken. Thus, for diphtheria toxin the 
mechanism has been termed a “dissociative” Sn2 reaction (Berti et al., 1997). 
 
The catalytic glutamate does not appear to be important for binding of NAD+ since its 
mutation in PARP1 (Marsischky et al., 1995) as well as the bacterial toxins (Bohmer et 
al., 1996; Douglas and Collier, 1990) does not affect the dissociation constant for 
NAD+. Instead, the catalytic glutamate functions to stabilize the oxocarbenium ion 
transition state that develops during the reaction. On this basis, the carboxyl group of 
the catalytic glutamate must be very close to the C1’-N bond, and therefore well-
positioned to stabilize the oxocarbenium ion transition state through a charge 
interaction. 
 
Given this well-characterized and essential function of the catalytic glutamate, its 
replacement with isoleucine in PARP10 raises the question of how this enzyme can 
efficiently catalyze ADP-ribosylation. Both PARP1 and PARP10 catalyze ADP-
ribosylation on substrate glutamate residues. PARP1 also has a polymerase activity 
and catalyzes elongation and branching reactions by adding ADP-ribosyl moieties to 
the initial glutamate-linked ADP-ribose and then to the growing pADPr chain. The 
nucleophile for the initial reaction is the carboxylate of the substrate glutamate, while 
the nucleophiles for the polymerization reactions are ribose hydroxyls. For PARP1, 
mutagenesis of the catalytic glutamate shows that these two reactions - chain initiation 
and polymerization - have different catalytic requirements. For example, mutation of the 
catalytic glutamate to alanine (E988A) abrogates polymerization, but the enzyme can 
still catalyze chain initiation, although at low rates compared to wild-type. Mutation of 
E988 to glutamine still results in loss of polymerization activity, but the mutant enzyme 
has only a slightly decreased ability to catalyze chain initiation. Finally, an E988D 
mutant catalyzes both chain initiation and elongation, but at reduced rates compared to 
wild-type (Marsischky et al., 1995; Ruf et al., 1998b). Thus, for PARP1 the degree of 
oxocarbenium ion stabilization by the residue at position 988 determines the catalytic 
properties of the enzyme. On this basis, the presence of isoleucine at the position of 
the catalytic glutamate in PARP10 could explain its lack of polymerase activity, and we 
reasoned that replacement of I987 with glutamate might restore a polymerase activity 
and improve its ability to catalyze chain initiation. 
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Figure 26 (in collaboration with B.H. Shilton). 
A. The dissociative Sn2-type mechanism. In this mechanism, the transition state is stabilized by 
the catalytic glutamate and has a high degree of oxocarbenium ion character. 
B. The indicated GST-PARP10 fragments were incubated in the presence of C-TAP-PARP10-
G888W with 
32
P-NAD
+
 and 50 ?M NAD+. The reaction products were analyzed by 
autoradiography. This experiment was performed twice with the same results. 
C. A fully dissociative substrate-assisted catalytic mechanism. The glutamate is attached to the 
substrate and is inserted into a position where it can promote the oxocarbenium ion transition 
state and react with it once it has formed. 
 
To address whether replacing I987 by glutamate in PARP10 might be sufficient to 
obtain a polymerase, GST-PARP10(818-1025)-I987E was tested for catalytic activity. 
Unexpectedly, the I987E mutation made the protein almost completely inactive as a 
mono-ADP-ribosyltransferase (Fig. 26B). In other words, mutation of I987E not only 
failed to improve the activity of PARP10, but actually abrogated its auto-modification 
activity. In contrast, mutation of T999, which was suggested to correspond to the 
catalytic E988 of PARP1 (Ame et al., 2004), to glutamate had no effect on catalytic 
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activity (Fig. 26B). This is consistent with its location on the surface of our PARP10 
model, away from the active site (data not shown). The loss of activity in the I987E 
mutant is difficult to explain given the conserved and virtually essential role for a 
catalytic glutamate in related ADP-ribosyltransferases, and also in light of the structural 
conservation of the enzyme, particularly in the active site region. Mutations at this 
position have been accommodated in many of the other related ADP-
ribosyltransferases, and from the PARP10 structure there is no obvious reason why a 
glutamic acid could not be accommodated at position 987. On this basis, we concluded 
that PARP10 must use a different catalytic mechanism than the other ADP-
ribosyltransferases, namely one that involves substrate-assisted catalysis. 
 
For substrate-assisted catalysis to be operational in PARP10, the site of modification 
also fulfills the function of the catalytic glutamate, and must therefore occupy a position 
close to where the catalytic glutamate would normally reside. This is supported by our 
structural model that is described above (Fig. 25A-C). A substrate-assisted catalytic 
mechanism could work as follows. First, given the similarity in the structure of PARP10 
with other ADP-ribosyltransferases, along with the identity of the NAD+ substrate, it is 
likely that the reaction proceeds through a similar oxocarbenium ion transition state. 
However, since PARP10 lacks a catalytic glutamate at position 987, the transition state 
is stabilized by a substrate glutamate and the reaction would proceed by a fully 
dissociative Sn1-type of mechanism (Fig. 26C). Insertion of the substrate glutamate 
into the region next to the nicotinamide ribose would promote formation of the 
oxocarbenium ion and cleavage of the ribose-nicotinamide bond, followed by 
nucleophilic attack on the oxocarbenium ion. A mechanism incorporating substrate-
assisted catalysis explains the surprising loss of activity of the I987E mutant of 
PARP10: insertion of an acidic group in exactly the same region that the substrate 
glutamate must bind would prevent modification of the substrate. 
 
Further experiments will be necessary to obtain additional data supporting the model of 
substrate-assisted catalysis by PARP10. These experiments can include the 
measurement of NAD+ glycohydrolase activity of GST-PARP10(818-1025) and the 
mutant GST-PARP10(818-1025)-I987E. Because the glycohydrolase activity is 
necessarily dependent on the catalytic glutamate (Bellocchi et al., 2006), it should be 
absent in PARP10-WT lacking the glutamate, but it should be restored in the PARP10-
I987E mutant. Additional evidence for the proposed mechanism might be obtained by 
the determination of crystal structures of the catalytic PARP10 domain bound to the 
non-hydrolysable carba-NAD+ and by co-crystallisation with a potential substrate. 
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These structures will allow us to refine the structure of the active center at atomic 
resolution, to define the structural changes occurring through NAD+ binding and to 
identify the structural requirements for insertion of a substrate into the active center. 
 
2.1.6 Functional relevance of the conserved loop region between ß-sheets 4/5 
In addition to the amino acids in the catalytic center, the loop region differs between the 
three proposed PARP subfamilies (Fig. 17 and Table 1). The protein model suggests 
that for the substrate to have access to this region, the structure of the loop connecting 
ß-strands 4 and 5 is critical (Fig. 27A). In this regard, PARPs 6-8, 10-12, and 14-16 
share a highly conserved feature: the loop for these proteins is very short. With the 
exception of PARPs 6 and 8, there is a conserved proline two residues N-terminal to 
the position normally occupied by the catalytic glutamate. Because of the limited 
rotation around the Phi bond, this proline residue places structural constraints on the 
polypeptide chain, and therefore the structure of the loop in the PARP12 structure is 
likely conserved in the other PARPs of this subfamily, including PARP10. Note that 
PARPs 6 and 8, which have an isoleucine in place of the catalytic glutamic acid, 
possess a short two residue turn between beta4 and beta5. Thus, the PARP enzymes 
of this subfamily most likely have a ß4-ß5 loop structure that allows insertion of a 
substrate-linked glutamate residue in place of the catalytic glutamate, which is missing 
from these enzymes. This structural arrangement is supported by our PARP10 dimeric 
model (Fig. 25A). 
 
To address the relevance of the loop in PARP10 we generated several mutants in this 
region, including changing P985 to alanine. All these mutants had little or no catalytic 
activity (Fig. 27B). This was obvious for the activity towards the mutated protein itself 
as well as the catalytically inactive PARP10-G888W, which has an unaltered E882 and 
surrounding amino acids. These findings strongly indicate that indeed the loop is critical 
for positioning the catalytic/acceptor glutamate of the substrate in the catalytic center. 
The functional relevance of the ß4-ß5 loop that is suggested by the mutagenesis 
studies (Fig. 27B) could be supported by domain switch experiments in which the loop 
residues in PARP10 are replaced by loop residues from another mono-ADP-
ribosyltranferase of the PARP family, e.g. PARP14. If the hypothesis that the loop plays 
an important role in substrate recognition as shown for the bacterial toxins (Han and 
Tainer, 2002; Sun et al., 2004) is correct, the resulting chimeric protein should loose its 
ability to modify full-length PARP10, but gain the ability to modify full-length PARP14. 
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Figure 27 (in collaboration with B.H. Shilton). 
A. The PARP10 loop (gray) in comparison to the PARP1 loop (magenta) are shown relative to 
substrate PARP10 (cyan) with the indicated acceptor site E882.  
B. The indicated GST-PARP10 fragments with mutations in the loop region were subjected to a 
PARP assay with C-TAP-PARP10-G888W. The obtained results were confirmed by one further 
experiment with similar findings. 
 
Employing substrate-assisted catalysis together with the loop structure would make 
PARP10 and related enzymes more specific for their substrates since the geometrical 
constraints required for modification are greater than they would be for the more 
conventional type of reaction seen for PARP1. Indeed PARP1 has a large number of 
substrates (Hassa et al., 2006). In contrast PARP10 is highly selective and several 
PARP1 substrates tested are not modified by PARP10 (Yu et al., 2005b). It might be 
possible to identify a potential consensus sequence for the PARP10 substrates by 
peptide scanning starting from a peptide that serves as PARP10 substrate, e.g. a 
peptide covering the region around the auto-modification site. The replacement of the 
surrounding amino acids might give indications which structural requirements and 
which charge of the amino acid side chains have to be given for efficient ADP-
ribosylation by PARP10. Another approach to gain insights into the PARP10-mediated 
ADP-ribosylation and into its biological role would be a generic approach to identify 
PARP10 substrates. This might be achieved by using a proteome array that works 
analogous to a conventional DNA microarray. It contains several thousands of GST-
fusion proteins spotted onto a nitrocellulose-coated glass carrier. The use of 
radioactively labeled NAD+ would allow us to identify the PARP10 substrates among 
the spotted proteins, and via positional mapping the labeled spots could be assigned to 
the corresponding proteins. This approach that is planned for the near future in our lab 
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will offer the possibility to screen for PARP10 substrates in a nearly proteome-wide 
fashion. 
 
If the ß4-ß5 loop is really responsible for substrate recognition, one might expect a high 
grade of sequence variations in this region among the PARP family members. Indeed, 
a comparison of the loop sequences revealed no obviously conserved residues, but 
instead showed a great diversity (Otto et al., 2005). An inspection of the PARP10 loop 
sequence (CICQPS) showed the unique presence of two cysteine residues that are 
absent in the other novel PARPs 7 to 16. Since cysteine residues can serve as redox 
sensors (D'Autreaux and Toledano, 2007), we tested whether the addition of DTT or 
iodocetamide would influence the catalytic properties of PARP10 (Fig. 28). While DTT 
as reducing agent is able to reverse disulphide bonds resulting in free thiol groups, 
iodoacetamide reacts with free thiol groups leading to the formation of S-
carboxyamidomethylcysteine, an irreversibly alkylated cysteine derivative. While DTT 
increased the catalytic activity of GST-PARP10(818-1025), no effect was observed for 
TAP-PARP10. In contrast, the addition of iodoacetamide to the reaction efficiently 
decreased the enzymatic activity of GST-PARP10(818-1025) as well as TAP-PARP10 
in a concentration-dependent manner (Fig. 28). Thus, the effect of DTT might be 
restricted to the GST-fusion proteins and therefore DTT might act on the level of the 
GST tag, while the blockage of thiol groups by iodoacetamide is relevant for the 
catalytic activity of both the GST fusion protein as well as TAP-PARP10.  
 
 
Figure 28. 
GST-PARP10(818-1025) and TAP-PARP10 were subjected to standard PARP assays with the 
indicated concentrations of DTT or iodoacetamide. The reaction mixture was separated by SDS-
PAGE. The gel was stained with Coomassie blue, dryed and incorporated label was analyzed by 
autoradiography. Depicted are preliminary data from a single experiment. 
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Since potentially all cysteines in PARP10 are subject to alkylkation by iodoacetamide, it 
cannot be excluded that cysteines apart from the two residues in the PARP10 loop are 
responsible for the observed decrease in catalytic activity. Therefore, we analyzed 
GST-PARP10(818-1025)-C981S/C893S, in which both cysteines were replaced by 
serine residues. We observed in our PARP10 model of the catalytic domain that the 
loop cysteines would be able to form hydrogen bonds with residues in the active center 
and therefore might be relevant for catalysis (data not shown). This property should be 
conserved in the Cys/Ser mutants because the hydroxyl group should be able to form 
the same hydrogen bonds as the thiol group, but in contrast to the thiol group the 
hydroxyl group cannot be blocked by iodoacetamide. This led us to the prediction that 
GST-PARP10(818-1025)-WT and GST-PARP10(818-1025)-C981S/C893S should 
behave in the same way regarding their normal enzymatic activity, but iodoacetamide 
treatment would abrogate the activity in the wild-type but not in the mutant enzyme.  
 
 
Figure 29. 
A. GST-PARP10(818-1025)-WT and –C981S/C983S were subjected to standard PARP assays 
with a constant amount of 
32
P-NAD
+
 and the indicated concentrations of ß-NAD
+
. The amount 
of incorporated label was determined by autoradiography of the electrophoretically separated 
reaction components. 
B, C. GST-PARP10(818-1025)-WT and –C981S/C983S were subjected to standard PARP 
assays with the indicated concentrations of DTT or iodoacetamide. The reaction mixture was 
separated by SDS-PAGE. The gel was stained with Coomassie blue, dryed and incorporated 
label was analyzed by autoradiography. 
Depicted are preliminary data from a single experiment. 
 
As expected, no difference in the basal activity of GST-PARP10(818-1025)-WT and 
GST-PARP10(818-1025)-C981S/C893S was observed (Fig. 29A). Interestingly, their 
susceptibility to treatment with DTT and iodoacetamide was also comparable (Fig. 29B, 
C). Thus, it is likely that DTT indeed acts on the level of the GST tag and has no 
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specific effects on the two cysteine residues present in the ß4-ß5 loop of PARP10. 
Regarding the action of iodoacetamide, it might be possible that iodoacetamide lowers 
the pH in the enzymatic reaction thereby inhibiting the ADP-ribosyltransferase activity 
of PARP10. This suggestion is supported by the observation that addition of sample 
buffer to the iodoacetamide-treated reactions resulted in a switch from blue to yellow 
coloring indicating acidification of the sample. To obtain information about the 
iodoacetamide action on the cysteines in the ß4-ß5 loop of PARP10, it will be 
necessary in future experiments to exclude the unspecific pH decrease by 
iodoacetamide. This might be achieved by pre-incubation of the enzyme with 
iodoacetamide resulting in irreversible cysteine alkylation and subsequent removal of 
iodoacetamide prior to the enzymatic assay. In summary, the so far performed 
experiments allow no clear conclusion about the potential regulation of enzymatic 
PARP10 activity by the redox state of the cysteine residues in the ß4-ß5 loop. 
 
2.1.7 Post-translational regulation of the catalytic PARP10 activity 
Our mass-spectrometric analysis of TAP-PARP10 revealed three phosphorylation sites 
in PARP10 targeted in vivo by so far unidentified kinases (data not shown). In order to 
investigate if these or other phosphorylation events contribute to the regulation of 
PARP10’s catalytic activity, we treated HA-PARP10 overexpressed in HeLa cells and 
immunoprecipitated by means of the HA tag with phosphatase and subjected it to a 
PARP assay. The effectiveness of the phosphatase treatment was controlled by the 
de-phosphorylation of the highly phosphorylated Rb protein in a parallel reaction (Fig. 
30). The de-phosphorylation of TAP-PARP10 resulted in a loss of catalytic activity of 
approximately 50% suggesting a positive influence of the phosphorylations on catalytic 
PARP10 activity.  
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Figure 30. 
HA-PARP10 was overexpressed in HeLa cells, immunoprecipitated with a mAb targeted 
against the HA tag (3F10) and subjected first to a phosphatase assay and afterwards to a 
standard PARP assay. The phosphatase reaction was controlled on immunoprecipitated 
endogenous Rb protein which phosphorylation state was analyzed by a mixture of three 
different antibodies recognizing prominently phosphorylated residues in Rb. 
This result was confirmed by a second experiment with similar outcome. 
 
 
A previous report analyzed the phosphorylation of PARP10 by Cyclin E/CDK2 and 
suggested that Cyclin E/CDK2 phosphorylates PARP10 on a single site, Thr-101 (Chou 
et al., 2006). The authors also observed a dependency of the catalytic activity on the 
presence of phosphorylated Thr-101 (Chou et al., 2006). This is contrary to the results 
obtained by our experiments showing that the catalytic domain per se, which does not 
contain Thr-101, is capable of auto- and trans-ADP-ribosylation. In addition, although 
phosphatase treatment resulted in reduced catalytic PARP10 activity, a robust basal 
activity was still present indicating that phosphorylations are not necessary for PARP10 
to act as mono-ADP-ribosyltransferase, but rather have stimulatory effects. Since the 
kinase activity of Cyclin E/CDK2 is important for the transition from G1 to S phase 
(Harper and Adams, 2001) and the PARP10 interaction partner c-MYC is also involved 
in this transition, we decided to analyze if PARP10 serves as substrate for Cyclin 
E/CDK2 and which parts of PARP10 might contain the phosphorylation sites. In vitro 
kinase assays revealed a robust phosphorylation of TAP-PARP10 with recombinant, 
highly purified Cyclin E/CDK2 (Luscher-Firzlaff et al., 2006; Pandithage et al., 2008) 
(Fig. 31). GST-PARP10(1-255) served as a good substrate in our kinase assay, which 
is consistent with the finding that Thr-101 is a Cyclin E/CDK2 substrate and with Thr-
101 lying in a CDK consensus sequence (S/T-P-x-K/R). But obviously PARP10 
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contains more than one Cyclin E/CDK2 phosphorylation site, because GST-
PARP10(408-649) as well as GST-PARP10(600-868) were even better substrates than 
GST-PARP10(1-255) (Fig. 31). It is interesting to note that the catalytic domain was a 
poor substrate for Cyclin E/CDK2 suggesting that Cyclin E/CDK2 phosphorylation 
might either have no influence on the catalytic activity or that it might induce a 
conformational change in the full-length PARP10 with allosteric effects on the catalytic 
activity. Further experiments will be necessary to dissect the potential functions of the 
Cyclin E/CDK2-mediated phosphorylation of PARP10 and to identify the modification 
sites. Considering the fact that Cyclin E/CDK2 and c-MYC participate in the same 
regulatory cell cycle events, the functional importance of this post-translational 
modification of PARP10 should not be underestimated. It might be possible that this 
phosphorylation occurring in vivo most likely at the G1-S phase transition regulates the 
action of PARP10 on its interaction partner c-MYC. If the biological role of PARP10 in 
connection to c-MYC is unraveled, the possible regulatory function of Cyclin E/CDK2 
should therefore be kept in mind. 
 
 
Figure 31. 
TAP-PARP10-G888W and the GST fusion proteins of PARP10 indicated by arrowheads were 
subjected to a kinase assay with Cyclin E/CDK2. The reaction products were separated by SDS-
PAGE and the incorporation of label was analyzed by autoradiography. Full-length PARP10 
and the auto-modified GST-Cyclin E/CDK2 are marked by arrows. 
The results of a single in vitro kinase assay are displayed. 
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2.1.8 Biological significance of the PARP10-mediated ADP-ribosylation reaction 
Despite our extensive analysis of PARP10’s enzymatic in vitro properties, very little is 
known about the relevance of its activity in vivo. It was shown before that PARP10 is 
able to interfere with the transformation of REFs, but this ability was not dependent on 
catalytic activity (Yu et al., 2005b). Therefore, we decided to analyze a potential role of 
PARP10’s ADP-ribosyltransferase activity in the proliferation of cells by performing a 
colony formation assay in HeLa cells. This assay allows for assessing the proliferative 
capacity of transfected cells after selection with puromycin. The overexpression of 
PARP10 resulted in a clear reduction of methylene blue-stained cells suggesting an 
anti-proliferative effect of PARP10 in this setting (Fig. 32A). Importantly, an opposite 
effect was observed for the catalytically inactive PARP10-G888W suggesting a 
dependency on PARP10’s catalytic activity. The overexpression of p27 led to a very 
strong reduction in the number of stained cells correlating well with its role as inhibitor 
of the G1-S phase transition (Fig. 32B). In addition to the G888W mutant of PARP10, 
another catalytically inactive mutant, PARP10-H887E, also exhibited no anti-
proliferative effect underlining the importance of an intact ADP-ribosyltransferase 
activity for the anti-proliferative phenotype observed for PARP10-WT (Fig. 32B).  
 
 
 
 
Figure 32. 
A. HA-PARP10-WT-, HA-PARP10-GW-expressing plasmids and the corresponding backbone 
vector as control were transfected into HeLa cells along with the pBabePuro plasmid mediating 
puromycin resistance. After transfection, it was selected for transfected cells using puromycin. 
After several days of growth, colonies were stained with methylene blue. 
B. The experiment from A was repeated using an additional enzymatically inactive PARP10 
mutant, PARP10-H887E, and p27, a known inhibitor of cell proliferation, as positive control. 
 
Although the observed phenotype of PARP10 in the colony formation assay indicates 
an inhibitory role of PARP10 with respect to proliferation, it will be necessary to define 
the precise function of the PARP10-mediated ADP-ribosylation in vivo. The results 
Results and discussion  70 
obtained from the above assay might result from an anti-proliferative or from a pro-
apoptotic effect, both leading to the observed reduction in cell number. Thus, an 
examination of the cell cycle distribution of PARP10-overexpressing cells, e.g. by 
FACS analysis, might give a hint if PARP10 interferes with cell cycle progression. A 
more direct analysis of proliferation could be accomplished by a BrdU assay that 
measures the percentage of cells undergoing DNA synthesis during S-phase. Since 
cells have to overcome an important cell cycle check point before entering mitosis, a 
potential interference of PARP10 with mitotic entry could be analyzed by FACS 
analysis using an antibody recognizing the phosphorylation of histone H3 at Ser-10, a 
hallmark of mitotic cells (Prigent and Dimitrov, 2003). A reduced percentage of mitotic 
cells would suggest a role for the PARP10-mediated ADP-ribosylation in mitosis 
resulting in delayed cell cycle progression. Such a delay would cause a reduced cell 
number in the colony formation assay. If PARP10 would act as pro-apoptotic protein 
instead of interfering with cell cycle progression, the analysis of caspase activation, a 
staining of Annexin-V at the cell surface, the release of cytochrome-c from the 
mitochondria or the nuclear translocation of AIF would reveal an increase in the 
induction of apoptosis. 
 
The phenotype of PARP10 in the colony formation assay is abrogated with the mutants 
PARP10-G888W and PARP10-H887E (Fig. 32). Since the two mutated residues 
participate directly in the NAD+ binding site, it is likely that the catalytic inactivity of 
these mutants is due to their inability to bind NAD+. Co-factor binding often triggers a 
conformational change in the catalytic center of enzymes potentially uncovering binding 
sites for interaction partners/substrates or modification sites. To exclude secondary 
effects due to the loss of NAD+ binding, the analysis of PARP10-I987E in the colony 
formation assay is desirable. This mutant most likely retains the ability to bind NAD+ but 
is unable to execute ADP-ribosylation due to interference of the active site glutamate 
with the inserted substrate glutamate (discussed above). From the in vitro results 
obtained with this mutant, it can be expected that I987E would behave like PARP10-
G888W with respect to the proliferation of HeLa cells. In order to examine the so far 
unknown role of the auto-modification reaction, PARP10-E882A should be also used in 
the colony formation assay. 
 
Since Chou et al. observed an accumulation of cells in G1-phase concomitant with a 
loss of cell viability after siRNA-mediated knockdown of PARP10 in HeLa cells (Chou 
et al., 2006), we generated pSuper-based shRNA vectors targeting different regions of 
the PARP10 mRNA within the ORF. We tested these constructs by co-expression 
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along with the PARP10-expressing plasmid pEVRF0-HA-PARP10 in HEK293 cells. 
The siRNAs siPARP10_1 and siPARP10_6 proved highly efficient in the knockdown of 
PARP10 protein, while a control siRNA targeting firefly luciferase exhibited no effect 
(Fig. 33A). Thus, we chose these siRNA constructs to examine the knockdown of 
PARP10 in the HeLa colony formation assay. Although the results from Chou et al. 
(Chou et al., 2006) suggested a growth-inhibitory effect, the siRNAs targeting PARP10 
were indistinguishable from the control siRNA targeting luciferase (Fig. 33B). Based on 
our observations we conclude that PARP10 is dispensable for the proper growth of 
HeLa cells, but the level of the PARP10-mediated ADP-ribosylation has to be tightly 
controlled. 
 
 
 
Figure 33. 
A. The efficiency of shRNA vectors targeting PARP10 was analyzed in HEK 293 cells. 5 ?g of 
pEVRF0-HA-PARP10 were co-transfected along with 15 ?g of the indicated shRNA vectors 
targeting Luciferase (siLuc_2) or PARP10 (siPARP10_1-6) into HEK293 cells. Three days after 
transfection, the cells were lysed in TAP lysis buffer and the levels of HA-PARP10 and Actin 
were analyzed by immunoblotting. The HA-PARP10 signal was corrected by the actin signal 
and normalized to the mock-transfected control. 
B. The effect of siRNA-mediated PARP10 knockdown on the proliferation of HeLa cells was 
assessed by colony formation assays as described in Fig. 32. 
The shown results were reproduced at least once in an independent experiment. 
 
Although the PARP10-targeting siRNAs were tested on overexpressed protein, it will 
be necessary to demonstrate their efficiency at the endogenous level. Since the 
endogenous PARP10 is not detectable by a straight immunoblot of HeLa cell lysates, 
this might be achieved either by an IP-Western approach or by a quantitative RT-PCR 
analyzing the level of PARP10 mRNA. If the endogenous RNA is equally efficiently 
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targeted as the overexpressed mRNA, we would expect efficient knockdown of the low 
abundant endogenous protein. Thus the above drawn conclusion should hold true that 
PARP10 is not necessary for HeLa cell proliferation. 
 
2.2  PARP10’s subcellular localization and nucleocytoplasmic shuttling  
 
2.2.1 PARP10 fragments display a heterogeneous subcellular localization 
As shown previously, the mainly cytoplasmic PARP10 is subject to nucleocytoplasmic 
shuttling and accumulates in the nucleus after treatment with Leptomycin B (LMB), a 
potent inhibitor of the Crm1-mediated nuclear export (Yu et al., 2005b). This is due to 
the presence of a functional NES in the C-terminal half of the protein whose mutation 
resembles the effect of LMB treatment (Yu et al., 2005b). While the nuclear export 
seems to be mainly dependent on this NES, it is unclear how PARP10 enters the 
nucleus. Bioinformatical searches for a classical nuclear localization signal were not 
successful suggesting that PARP10 might be imported into the nucleus via an 
alternative mechanism. In order to analyze which regions in PARP10 determine its 
subcellular localization we created CFP/YFP-tagged fusion proteins of overlapping 
PARP10 fragments (Fig. 34). All fusion proteins were expressed to an equal extent and 
comparable to the CFP/YFP tag alone (Fig. 34). Only minor breakdown products, if 
any, were observed after overexpression in COS-7 cells, and cleavage of the fusion 
proteins resulting in a free CFP/YFP tag was observed only in a low percentage (Fig. 
34). 
 
The CFP/YFP tag alone possesses a molecular weight of about 60 kDa (Fig. 34). 
Although its size is at the upper limit for passive diffusion through the nuclear pores 
(Allen et al., 2000; Terry et al., 2007), it is still able to cross the nuclear envelope 
passively resulting in a more or less equal distribution between nucleus and cytoplasm 
(Fig. 36). An additional increase in size by fusion to a heterologous protein should most 
likely abrogate the passive diffusion rendering the transport of the CFP/YFP fusion 
proteins across the nuclear envelope dependent on localization signals allowing 
facilitated diffusion with the help of karyopherins. Since all analyzed CFP/YFP fusion 
proteins possess apparent molecular weights of more than 90 kDa, it is very unlikely 
that these chimeric proteins are subject to passive diffusion across the nuclear 
membrane. Thus an accumulation of these fusion proteins in the nucleus should be 
indicative for ongoing nuclear import mechanisms. 
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Figure 34. 
The upper panel shows the overlapping fragments covering the whole protein chosen for 
expression as fusion proteins. The overexpression of the CFP/YFP-tagged fusion proteins and 
the expression of the tag alone was determined by an immunoblot of COS-7 lysates using an 
anti-GFP antibody. 
 
 
The analysis of the subcellular localization of the created CFP/YFP fusion proteins 
revealed a heterogeneous pattern with some fusion proteins present exclusively in the 
cytoplasm and others present in the cytoplasm and the nucleus (Fig. 35). As expected, 
the localization of PARP10(408-649) harboring the NES was restricted to the 
cytoplasm (Fig. 35). PARP10(1-255) and PARP10(600-868) also showed a mainly 
cytoplasmic localization, although a minor nuclear fraction was clearly detectable (Fig. 
35). Regarding aa 600-868 it is worth to consider that most of the NES covering aa 
598-607 is still present in this fragment and might be sufficient to mediate Crm1-
dependent export of this fragment, although the export might be impaired compared 
with PARP10(408-649). PARP10(206-459) covering the Glycine-rich region in PARP10 
was equally distributed between cytoplasm and nucleus indicating that the aa 206-459 
of PARP10 harbor sequences that enable the CFP/YFP fusion protein to enter the 
nucleus (Fig. 35). The uniform distribution suggests that neither an efficient NES 
mediates nuclear export nor a classical NLS forces the chimeric protein into the 
nucleus. PARP10(818-1025) representing the catalytic domain exhibited a slight 
accumulation in the nucleus suggesting that an active mechanism drives the nuclear 
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import of this fragment (Fig. 35). Interestingly, the catalytically inactive PARP10(818-
1025)-GW showed a more pronounced nuclear accumulation (Fig. 35). Since the 
absence of catalytic activity favored the nuclear localization of PARP10(818-1025), the 
auto-ADP-ribosylation or the ADP-ribosylation of substrates might have an impact on 
the nuclear import or the retention in the nucleus. Conceivable scenarios would be that 
the ADP-ribosylation interferes with the nuclear import by modifying proteins essential 
for the import process or that ADP-ribosylation results in the release from nuclear 
proteins holding up PARP10(818-1025) in the nucleus.  
 
Figure 35. 
For explanations, see top of next page. 
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The indicated CFP/YFP-fusion proteins were overexpressed in COS-7 cells and their subcellular 
distribution analyzed in PFA-fixed cells after Hoechst staining of nuclear DNA. Shown are 
merged pictures of CFP/YFP and Hoechst (left panel) and the corresponding brightfield images 
(middle panel) at 200x magnification. In addition, a representative confocal image with a red 
DRAQ5 DNA counterstain is displayed, while fusion proteins appear in blue (right panel). 
The displayed pictures are representative of several independent experiments showing very 
similar subcellular distributions. 
 
 
In summary, the localization of the analyzed PARP10 fragments suggests that at least 
one functional NES in PARP10 drives its nuclear export and that at least two regions in 
PARP10 might contribute to the entry of the full-length protein into the nucleus, with 
PARP10(818-1025) being the best candidate for possessing sequences that mediate 
nuclear uptake. 
 
Because the above experiments were all performed in the presence of ongoing nuclear 
export processes, one might miss an existing NLS if its effect is masked by a stronger 
NES. Thus we decided to analyze the steady-state localization of the CFP/YFP-
PARP10 fusion proteins in the presence of LMB. As expected, the LMB treatment had 
no effect on the CFP/YFP tag alone but inhibited the nuclear export of PARP10(408-
649) disrupting the function of the characterized NES and resulting in a more or less 
equal distribution between nucleus and cytoplasm (Fig. 36). LMB did not interfere with 
the subcellular localization of PARP10(206-459), (818-1025) and (818-1025)-GW 
indicating that these regions of PARP10 do not contain a classical NES which 
correlates with their significant nuclear fraction observed in the steady-state localization 
analysis (Fig. 36). The cytoplasmic localization of PARP10(1-255) was also not altered 
by the LMB-induced blockage of the Crm1-dependent export suggesting that this 
fragment might be exported from the nucleus via an alternative export mechanism or 
that it might be not able to enter the nucleus (Fig. 36). Interestingly, the cytoplasmic 
localization of PARP10(600-868) showed no susceptibility to LMB indicating that the 
absence of a significant nuclear fraction of this fusion protein is not due to the presence 
of the only partially deleted NES but due to the lack of nuclear import (Fig. 36). 
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Figure 36. 
The indicated CFP/YFP-fusion proteins were overexpressed in COS-7 cells and treated for 3.5h 
with 20 nM Leptomycin B (LMB) or a methanol solvent control prior to fixation with PFA. 
Their subcellular distribution was analyzed after Hoechst staining of nuclear DNA. Shown are 
merged pictures of CFP/YFP and Hoechst at 200x magnification. 
The displayed pictures are representative of several independent experiments showing very 
similar subcellular distributions. 
 
 
In order to confirm the function of the previously described NES in the context of the 
CFP/YFP fusion proteins, we mutated the functional NES in PARP10(408-649). In 
addition, we mutated the partially deleted NES in PARP10(600-868) to rule out any 
effect on the subcellular localization of the fusion protein. As expected, mutation of the 
NES resulted in nuclear accumulation of PARP10(408-649) confirming the results 
obtained with LMB (Fig. 37). Additional treatment of CFP/YFP-PARP10(408-649)-
dNES with LMB did not lead to a more pronounced localization in the nucleus 
indicating that no further Crm1-dependent export mechanisms mediate the nuclear 
export of this fragment. CFP/YFP-PARP10(600-868)-dNES showed a cytoplasmic 
localization comparable to the one observed for the corresponding wild-type fusion 
protein (Fig. 37). This result supports our hypothesis that the cytoplasmic localization of 
this chimeric protein is not dependent on the partially present NES but is most likely 
due to the lack of nuclear import. Consistent with our previous observations with the 
wild-type protein, the NES-mutated version was not sensitive to treatment with 
Leptomycin B ruling out the presence of a classical NES (Fig. 37). 
 
Figure 37. 
The indicated CFP/YFP-fusion proteins were processed as explained in Fig. 36. 
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In summary, the steady-state analysis of the CFP/YFP-PARP10 fusion proteins in the 
absence or presence of Crm1-dependent nuclear export revealed that the previously 
identified NES from aa 598-607 is the only functional NES in PARP10. In addition, our 
studies show that no classical NLS exists because one of the typical features of an 
NLS, the efficient targeting of chimeric proteins to the nucleus resulting in an almost 
completely nuclear localization (Lange et al., 2007), was observed for none of the 
analyzed fusion proteins. Since it is possible that an NLS is not encoded in the primary 
sequence but in the tertiary structure of a protein (Sessler and Noy, 2005) and thus 
might be missed in our analysis of PARP10 fragments, it is important to analyze the 
full-length protein in a similar setting (described below). Although no classical NLS was 
found by our studies, we provide some evidence that sequences within aa 206-649 and 
aa 818-1025 of PARP10 participate in the nuclear import of PARP10. Since 
PARP10(206-459) and PARP10(408-649) share identical amino acid sequences in 
their overlapping region, it is tempting to speculate that a potential import-mediating 
region is localized within aa 408-459. 
 
The nuclear import of PARP10 might be via a piggyback mechanism along with so far 
unidentified, NLS-containing interaction partners or it might be mediated by the direct 
interaction with importins. Further work is necessary to distinguish these two scenarios, 
which might be achieved e.g. by analyzing the potential interaction of the imported 
PARP10 fragments with known importins. To confirm that the observed nuclear import 
of the analyzed fusion proteins is indeed dependent on actively driven import 
mechanisms, it would be important to analyze their nuclear import in the absence of 
facilitated diffusion. A simple experiment would be to cool down the cells to 4°C, which 
would inhibit the active import mechanism but not significantly impair passive diffusion 
(Plafker and Macara, 2000). It is important to note here that the C-terminal part of 
PARP10 interacts with the oncoprotein c-MYC, a nuclear protein possessing a strong 
NLS (Henriksson and Luscher, 1996; Luscher and Eisenman, 1990). Since c-MYC 
would be a potential candidate for targeting PARP10(818-1025) to the nucleus, it would 
be interesting to analyze the localization of the corresponding CFP/YFP fusion protein 
in the absence of c-MYC. 
 
2.2.2 The nucleocytoplasmic shuttling of PARP10 fragments 
Since the analysis of the steady-state localization of the PARP10 fragments provides 
only static information about the subcellular localization, we chose the iFLAP approach 
to measure the dynamics of nucleocytoplasmic shuttling processes. iFLAP (inverted 
Fluorescence Localization After Photobleaching) makes use of the selective YFP 
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bleaching of CFP/YFP fusion proteins to follow up the movement of the bleached 
molecules within the cell. Because the CFP and YFP are inseparably coupled to the 
analyzed protein, CFP can serve as an internal control and the ratio of CFP and YFP 
fluorescence provides information about where the bleached molecules have moved. A 
cell adjacent to the bleached cell serves as control for potential artifacts caused by 
photobleaching during the image acquisition. Since we were interested in 
nucleocytoplasmic shuttling, we chose an experimental setting with bleaching in the 
cytoplasm. If the CFP/YFP ratio in the nucleus changes in this setting, this will be due 
to an exchange of molecules between the cytoplasm and the nuclear compartment 
resulting in the uptake of bleached molecules from the cytoplasm. It is important to note 
here that due to intrinsic technical limitations, namely the barely detectable 
fluorescence in the nucleus, it is difficult to analyze almost exclusively cytoplasmic 
proteins with this approach and care has to be taken with the interpretation of the 
obtained results. Therefore we carefully analyzed the raw data from the displayed 
experiments to exclude any artificial results. We came to the conclusion that these 
experiments, although difficult, especially the ones with PARP10(408-649), were 
technically sound and therefore interpretable without major limitations. 
 
We observed a high mobility of all analyzed CFP/YFP fusion proteins within the 
cytoplasm indicated by the rapid distribution of the bleached molecules from the bleach 
ROI to the other cytoplasmic areas (Fig. 38). An inspection of their nucleocytoplasmic 
shuttling behavior revealed a striking difference between PARP10(408-649) and all 
other PARP10 fragments (Fig. 38). While most fragments showed little exchange of 
bleached molecules between the cytoplasm and the nucleus visualized by the blue- or 
greenish-colored nucleoplasm, the CFP/YFP-PARP10(408-649) molecules were 
rapidly exchanged between both compartments indicated by the observation that the 
nuclear envelope seemed to present only a negligible barrier for the movement of 
these molecules and that the nucleoplasm was rapidly filled with cytoplasmically 
bleached molecules visualized by the red coloring (Fig. 38). Importantly, disruption of 
the NES in PARP10(408-649) led to a significant decrease in the nucleocytoplasmic 
shuttling resulting in levels slightly higher than for PARP10(206-459) (Fig. 38).  This is 
most likely due to the abrogation of nuclear export reducing the rate of molecular 
exchange between cytoplasmic and nuclear fusion proteins. The iFLAP analysis of 
PARP10(818-1025)-WT and -GW revealed a complete absence of any exchange 
between nucleus and cytoplasm within the time frame of the experiment (Fig 38). At the 
first glance this appears to be contradictory to its steady-state localization because the 
nuclear fraction of this PARP10 fragment has to enter the nucleus from the cytoplasm.  
Results and discussion  80 
 
Figure 38. 
The indicated CFP/YFP fusion proteins were expressed in COS-7 cells and subjected to an 
iFLAP approach using a confocal LSM510 microscope (Zeiss, Germany) as described in the 
experimental procedures. A pre-bleach confocal image is displayed for every experiment (left 
panel). Pseudo-colored images of different time points illustrate the movement of bleached 
molecules. Blue represents an equal ratio of CFP and YFP fluorescence intensity and red 
indicates the detection of only CFP fluorescence resulting from bleaching of the YFP 
molecules. The bleach ROI is marked by white boxes. 
The depicted experiments are representative of at least four independent experiments per 
analyzed PARP10 fragment. 
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A possible explanation might be that the nuclear import occurs very slowly and thus 
cannot be visualized during the 10 minutes of the experiment. A slow import would be 
in accordance with the high levels of cytoplasmic PARP10(818-1025) in the steady-
state localization indicating a potential oversaturation of the import mechanism. The 
same might be true for PARP10(206-459) that also showed a low level of 
nucleocytoplasmic transport (Fig. 38). In summary, our iFLAP experiments revealed 
that only PARP10(408-649) exhibits a rapid nucleocytoplasmic shuttling that is 
dependent on its functional NES while none of the other regions in PARP10 tend to 
shuttle across the nuclear envelope in a similar rapid fashion. This is to a large degree 
in accordance with our steady-state localization analysis demonstrating that 
PARP10(408-649) is able to enter the nucleus and that it is actively exported by means 
of its NES (Figs. 36 and 37). Thus the central part of PARP10 might mainly contribute 
to its subcellular localization. In order to clarify the role of this region in context of the 
full-length protein, it might be interesting to analyze a CFP/YFP-PARP10 fusion protein 
in which the aa 408-649 were removed. 
 
2.2.3 The nucleocytoplasmic shuttling of full-length PARP10 
So far we restricted our analysis to overlapping fragments of PARP10. In order to 
analyze the subcellular localization and the nucleocytoplasmic shuttling of the full-
length protein, we expressed CFP/YFP-PARP10 in COS-7 cells. Immunoblot analysis 
showed that the chimeric protein was expressed as a single band with an appararent 
molecular weight of more than 200 kDa (Fig. 39A). Surprisingly, an inspection of its 
subcellular localization revealed a remarkable cytoplasmic staining with several bright 
foci, which will be discussed and followed up in detail below (Fig. 39B). As expected, 
CFP/YFP-PARP10 was localized exclusively in the cytoplasm due to the presence of 
its NES as seen previously (Yu et al., 2005b). 
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Figure 39. 
A. CFP/YFP-PARP10 overexpression in COS-7 cells was determined by an immunoblot of 
COS-7 lysates using an anti-GFP antibody. 
B. Its subcellular distribution was analyzed in PFA-fixed cells after Hoechst staining of nuclear 
DNA. Shown are merged pictures of CFP/YFP and Hoechst (left panel) and the corresponding 
brightfield images (middle panel) at 200x magnification. In addition, a representative confocal 
image with a DRAQ5 DNA counterstain is displayed (right panel). 
 
In order to characterize the NES function in the context of the full-length protein, we 
analyzed the subcellular localization of CFP/YFP-PARP10-WT and -PARP10-dNES in 
the absence or presence of LMB. In contrast to the results obtained by Yu et al. (Yu et 
al., 2005b) with the HA-tagged protein, we did not observe a considerable 
accumulation of PARP10 in the nucleus after LMB treatment. Instead the inhibition of 
Crm1-dependent nuclear export resulted in a minor nuclear accumulation of CFP/YFP-
PARP10 in only some cells, with most cells still showing an almost exclusive 
cytoplasmic localization (Fig. 40). The same is true for CFP/YFP-PARP10-dNES that 
was also not sensitive to LMB treatment (Fig. 40).  
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Figure 40. 
The indicated CFP/YFP-fusion proteins were overexpressed in COS-7 cells and treated for 3.5h 
with 20 nM Leptomycin B (LMB) or a methanol solvent control prior to fixation with PFA. 
Their subcellular distribution was analyzed after Hoechst staining of nuclear DNA. Shown are 
merged pictures of CFP/YFP and Hoechst at 200x magnification. 
 
The obvious contrast between the previous results (Yu et al., 2005b) and the ones from 
the present study cannot be explained by cell type specific differences because we 
obtained similar results in U2OS cells used by Yu et al. and in HeLa cells (data not 
shown). It cannot be excluded that the kind of the tag makes the difference in the two 
experimental settings. While the results with HA-PARP10 suggest an efficient nuclear 
import of the fusion protein (Yu et al., 2005b), the present results with CFP/YFP-
PARP10 indicate that the fusion protein is not efficiently targeted to the nucleus but 
instead hardly enters the nucleus and only in a low percentage of cells (Fig. 40). If the 
used CFP/YFP tag potentially interferes with nuclear import e.g. by masking import-
mediating sequences, has to be clarified in future experiments using HA-PARP10 or 
other tagged PARP10 versions. A further explanation might be that the localization of 
HA-PARP10 was determined by indirect immunocytochemistry after fixation and 
permeabilization of cells (Yu et al., 2005b), which might lead to artifacts. The 
localization of CFP/YFP-PARP10-WT and -dNES was analyzed in living as well as in 
fixed cells without any changes due to fixation (own observations). Thus we can 
exclude an artifactual localization of the fusion proteins in the present study. It has to 
be further mentioned that the conclusions drawn from Yu et al. (Yu et al., 2005b) are 
based on the analysis of a very limited number of cells providing no information about 
the appearance of the whole cell population. In contrast, the overview images of 
CFP/YFP-PARP10 (Fig. 40) allow the assessment of the subcellular localization of a 
representative population of transfected cells. Although our data provide some 
evidence that full-length PARP10 enters the nucleus inefficiently, it is important to note 
that nuclear fractions of PARP10 exist at least in some cells (Fig. 40). If the 
appearance of nuclear PARP10 is somehow regulated e.g. in a cell cycle dependent 
fashion has to be clarified by further experiments. Importantly, experiments using 
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bimolecular fluorescence complementation (Hu et al., 2002) clearly demonstrate an 
interaction of PARP10 and its interaction partner c-MYC in the nucleus (unpublished 
results from J. Lüscher-Firzlaff) supporting the existence of a nuclear PARP10 fraction, 
which might be physiologically relevant in terms of regulating c-MYC function. 
 
In order to obtain more information about the nucleocytoplasmic shuttling of full-length 
PARP10, we subjected CFP/YFP-PARP10-WT and -dNES to the iFLAP approach. 
Both fusion proteins diffused freely in the cytoplasm as seen for the PARP10 fragments 
(Fig. 41). In accordance with our steady-state analysis of full-length PARP10 we were 
not able to measure significant nucleocytoplasmic shuttling of PARP10-WT or 
PARP10-dNES within the experimental time frame (Fig. 41). Although the mutation of 
the NES resulted in the appearance of a nuclear PARP10 fraction (Figs. 40 and 41B), 
the iFLAP analysis revealed only low levels of shuttling across the nuclear envelope 
(Fig. 41B). This result is comparable with the ones for PARP10(206-459) and 
PARP10(818-1025) indicating that the nuclear import occurs very slowly. 
 
 
Figure 41. 
The indicated CFP/YFP fusion proteins were expressed in COS-7 cells and subjected to an 
iFLAP approach using a confocal LSM510 microscope (Zeiss, Germany) as described in the 
experimental procedures. A pre-bleach confocal image is displayed for every experiment (left 
panel). Pseudo-colored images of different time points illustrate the movement of bleached 
molecules. Blue represents an equal ratio of CFP and YFP fluorescence intensity and red 
indicates the detection of only CFP fluorescence resulting from bleaching of the YFP 
molecules. The bleach ROI is marked by white boxes. 
 
The analysis of CFP/YFP-PARP10 with the iFLAP approach was technically 
complicated due to the hardly detectable nuclear fluorescence rendering the analysis 
prone to misinterpretations. It has to be mentioned that the result displayed in Fig. 41A 
is by far the best result obtained for CFP/YFP-PARP10 within a set of six experiments 
and that most of the other measurements were not analyzable due to signal artifacts 
created by the calculation procedure. Thus care has to be taken by the interpretation of 
these data. 
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The iFLAP result for CFP/YFP-PARP10-WT suggests that no nucleocytoplasmic 
shuttling is detectable within 10 minutes (Fig. 41A). This is somehow surprising 
considering the rapid shuttling of PARP10(408-649) (Fig. 38C) because the full-length 
protein should in theory possess all the features of the analyzed fragments, namely the 
functional NES around aa 600 and the two potential import-mediating regions from aa 
206-649 and aa 818-1025. Speculating about the reasons for this discrepancy, it might 
be due to the large difference in the molecular weight of CFP/YFP-PARP10 and 
CFP/YFP-PARP10(408-649) because the import of larger cargoes occurs significantly 
slower than that of smaller ones (Ribbeck and Gorlich, 2002). Since the crystal 
structure of PARP10 has not been resolved yet, it also cannot be excluded that the 
regions mediating nuclear import in PARP10(408-649) are not surface-exposed in full-
length PARP10 and therefore not accessible for interaction with potential NLS-
containing binding partners and/or importins. A less likely possibility could be that an 
additional NES is present in the full-length protein that is reconstituted from amino 
acids of separated regions of the protein. Since LMB treatment did not cause strong 
nuclear accumulation of CFP/YFP-PARP10 this potential NES had to act independent 
of Crm1. As outlined above the iFLAP analysis of CFP/YFP-PARP10 proved very 
difficult, and a strong interpretation is impossible with the data obtained so far. This is 
underlined by the observation that CFP/YFP-PARP10-dNES underwent a more rapid 
shuttling than PARP10-WT (Fig. 41B). Since a functional NES significantly contributes 
to the exchange of molecules between the cytoplasm and the nucleus, one would 
expect a decrease in nucleocytoplasmic shuttling if it is mutated, as seen for 
PARP10(408-649) (Fig. 38). Thus a conclusive answer to the emerged questions can 
only be given through further experiments including the resolution of the PARP10 
crystal structure, the screening for potential NLS-containing binding partners or 
interacting karyopherins and careful analysis of the endogenous protein. Unfortunately, 
the levels of endogenous PARP10 are very low in most adherent cell lines well-suited 
for microscopic analysis, while PARP10 is considerably higher expressed in 
suspension cell lines originating from the hematopoietic system. Thus the analysis of 
endogenous PARP10 in e.g. U937 cells requires the use of a cytospin apparatus in 
order to place the cells onto a cover slip and the establishment of a staining procedure 
with appropriate controls to verify that indeed endogenous PARP10 is stained. 
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2.2.4 PARP10 enriches in dynamic cytoplasmic foci 
As indicated above, for full-length PARP10 we unexpectedly observed a prominent 
enrichment in cytoplasmic foci (Figs. 39 and 40). Since we suspected that the 
CFP/YFP-tag might target PARP10 for aggregation, we repeated the analysis with HA-
PARP10 and PARP10-DsRed resulting again in the formation of prominent foci (data 
not shown). Although at present we cannot exclude the possibility that these foci are 
aggregation-driven artifacts, we made several observations that argue against simple 
aggregation. First, while a classical aggresome is a single perinuclear irregular shaped 
structure (Spector, 2006), the observed PARP10 foci are small round structures and 
are present in numbers from 0-30 (Figs. 39, 40, 42, and data not shown). Second, 
titrations of the plasmid encoding CFP/YFP-PARP10 did neither influence the amount 
nor the size of PARP10 foci, which would be expected if these structures would 
develop upon over-expression (data not shown). Third, preliminary experiments 
showed that co-expression of the chaperone Hsp70, which reduces the formation of 
aggregates (Gilks et al., 2004), had no effect on the formation of PARP10 foci (data not 
shown). To gain further insights into the formation and behavior of these cytoplasmic 
foci in a physiological setting, we decided to perform time-lapse microcopy in living 
cells. Analysis of COS-7 cells transfected with CFP/YFP-PARP10 by confocal 
microscopy revealed that the PARP10 foci are highly dynamic (Fig. 42). While at the 
beginning of the experiment several foci per cell were visible, these foci moved within 
the cytoplasm and tend to fuse during the time course of the experiment ending up with 
fewer and larger foci after about 4 hours of observation (Fig. 42, compare time points 0 
and 220 min). Interestingly, one of the observed cells most likely entered mitosis 
indicated by breakdown of the nuclear envelope and rounding of the cell accompanied 
by the loss of the PARP10 foci (Fig. 42, time point 160 min). Since the time-lapse 
microscopy was performed on a confocal microscope, it cannot be doubtlessly 
concluded that the foci indeed have disintegrated. Instead it might be possible that due 
to the rounding of the cell the PARP10 foci have moved out of focus and thus were not 
visible any longer. 
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Figure 42. 
The movement of CFP/YFP-PARP10 was followed up by confocal live-cell imaging using a 
LSM510 microscope (Zeiss, Germany). The displayed images were selected from the indicated 
time points. Note that the foci tend to fuse and that only very few foci occur de novo. The cell in 
the center of the group enters mitosis by 160 min. 
 
In order to resolve the question if PARP10 foci vanish during mitosis, we switched to a 
conventional fluorescence microscope for the time-lapse microscopy and extended the 
observation time up to more than 20 hours. In addition, we decided to analyze the 
PARP10 foci in a cell line of human origin and transfected HeLa cells with CFP/YFP-
PARP10. We observed again the movement of PARP10 foci in the cytoplasm and their 
tendency to fuse (Fig. 43). Importantly, in one cell we were able to follow up the 
disintegration of two larger foci and the subsequent formation of several smaller foci 
(Fig. 43, white box). This observation clearly indicates that PARP10 foci are dynamic, 
can disintegrate and can form de novo arguing against aggregation artifacts driven by 
over-expression. The vanishing of the two large foci was temporally associated with a 
rounding of the cell (Fig. 43, time point 900 min). Although this might be indicative for a 
beginning of mitosis, it is important to note that the cell neither underwent mitotic 
division nor re-settled within the next six hours of observation. In contrast, two non-
transfected cells clearly passed through mitosis within a normal time frame as 
observed in the brightfield images (Fig. 43, parental cells and sister cells marked by 
yellow asterisks). An additional cell expressing CFP/YFP-PARP10 also rounded up 
early in the experiment and did not re-settle within the observation period (Fig. 43, 
marked by yellow hash mark), and none of the other transfected cells underwent 
normal mitosis, although the doubling time of HeLa cells is within the range of the time 
frame of the time-lapse microscopy. 
Results and discussion  88 
 
Figure 43 (in collaboration with A.S. Sechi). 
CFP/YFP-PARP10 expressing HeLa cells were analyzed by epifluorescent live-cell imaging for 
more than 20h. Fluorescence and brightfield images from the indicated time points are 
displayed. Please note that the cells expressing CFP/YFP-PARP10 do not undergo cell division 
during the time period, while some non-transfected cells do (marked by yellow asterisks). A 
CFP/YFP-PARP10 expressing cell rounded up during the imaging and did not re-settle even 
after several hours (marked by yellow hash mark). The fusion of PARP10 foci and subsequent 
de novo formation of several smaller foci can be followed up in the cell marked by the white 
box. 
 
Based on these preliminary data one might speculate that the CFP/YFP-PARP10-
expressing cells might exhibit a disturbed cell cycle progression, potentially caused by 
a reduced ability to enter mitosis and/or a delay in mitotic progression. Such cell cycle 
malfunction would be a possible explanation for the growth-inhibitory effect observed in 
the HeLa cell colony formation assays (Fig. 32). Further time-lapse microscopy 
analyses will be necessary to get a better idea about the behavior of PARP10 foci 
throughout the cell cycle. An especially useful tool for this kind of experiments would be 
the use of genetically engineered cells whose cell cycle stages can be visualized in 
vivo by fluorescence techniques (Sakaue-Sawano et al., 2008). 
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2.2.5 The N-terminal domains in PARP10 participate in foci formation 
Since the formation of cytoplasmic PARP10 foci was only observed in the full-length 
protein but not in the CFP/YFP-PARP10 fragments (Figs. 35 and 39), we decided to 
generate N-terminal deletions of CFP/YFP-PARP10 lacking the potential RNA/DNA 
recognition motifs to evaluate their potential implication in foci formation. In addition, 
the appearance of PARP10 foci resembles the one of RNA-processing particles, P 
bodies and stress granules (Spector, 2006), indicating a potential role of PARP10’s 
RNA recognition motif and its Glycine-rich region. Indeed, the deletion of its N-terminal 
regions severely compromised the formation of cytoplasmic PARP10 foci (Fig. 44, 
upper panels). Although the N-terminal parts of PARP10 were important for the 
development of the PARP10-enriched cytoplasmic bodies, they were not essential as 
indicated by the observation that most of the cells transfected with CFP/YFP-
PARP10(257-1025) and -PARP10(552-1025) still displayed foci although at a lower 
frequency (Fig. 44). Accordingly, the analysis of COS-7 cells transfected with 
CFP/YFP-PARP10(1-459) revealed that the aa 1-459 are not sufficient for the 
formation of the foci, which is also true for the central part of PARP10 from aa 408-868 
(Fig. 44, lower panels). Thus the development of PARP10 foci seems to be dependent 
on its C-terminal catalytic domain, although the catalytic domain itself is not sufficient 
(Figs. 35 and 44). The inspection of the subcellular localization of PARP10(1-459) also 
supported our suggestion that sequences within aa 208-459 mediate nuclear import. 
While CFP/YFP-PARP10(1-255) was localized mainly in the cytoplasm due to the lack 
of nuclear import (Figs. 35 and 36), the addition of further C-terminal regions up to aa 
459 rendered the fusion protein able to enter the nucleus as indicated by the equal 
distribution between cytoplasm and nucleus (Fig. 44). 
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Figure 44. 
The indicated CFP/YFP fusion proteins were overexpressed in COS-7 cells and their subcellular 
distribution was analyzed in PFA-fixed cells after Hoechst staining of nuclear DNA. Shown are 
merged pictures of CFP/YFP and Hoechst (left panel) and the corresponding brightfield images 
(middle panel) at 200x magnification. In addition, a representative confocal image with a red 
DRAQ5 DNA counterstain and the fusion proteins in blue is displayed (right panel). 
 
In order to estimate the influence of the N-terminal regions on the PARP10 foci 
formation, we counted the number of foci per cell in the populations of transfected cells 
expressing CFP/YFP-PARP10-WT, -PARP10(257-1025) and -PARP10(552-1025). 
This quantitative approach revealed striking differences between the cells expressing 
full-length PARP10 or the N-terminally deleted versions (Fig. 45A). Regarding their 
capacity to develop PARP10 foci, the deletion of the RRM dramatically increased the 
percentage of cells without foci compared to PARP10-WT. Further deletion of the 
Glycine-rich region did not result in major changes (Fig. 45B). The differences between 
the populations of cells expressing PARP10-WT or PARP10-dN mutants were 
statistically highly significant as proved by a ?2 test (Fig. 45B). The N-terminal deletions 
also significantly affected the number of foci observed per cell, with only very few cells 
with more than 5 foci being detected (Fig. 45C). Again no significant differences 
between the PARP10-dN1 (aa-257-1025) and the PARP10-dN2 (aa 552-1025) 
population were observed (Fig. 45C). Thus the N-terminal RRM contributes to the 
formation of PARP10-enriched cytoplasmic foci by increasing the percentage of cells 
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possessing foci in general and by increasing the percentage of cells containing 
numerous foci in particular. 
 
 
 
 
Figure 45. 
The foci formation by CFP/YFP-PARP10-WT, -dN1 (aa257-1025) and -dN2 (aa552-1025) was 
analyzed after overexpression in COS-7 cells. 
A. The populations of WT-expressing (n=63), dN1-expressing (n=48) and dN2-expressing cells 
(n=39) were subdivided into cells with no foci, with 1-5 foci or with more than 5 foci and 
displayed as pie diagram with the percentage of each sub-population indicated. 
B. The populations were sub-divided into cells with or without foci and displayed as column 
diagram. A statistical ?2 test was performed to verify that the PARP10-dN1 and -dN2 
populations are different from the PARP10-WT population in terms of foci formation. The test 
showed a high significance with  p<0.005. 
C. The foci-forming cells of each population were subdivided into cells with 1-5 foci or more 
than 5 foci. Note that abrogation of the N-terminal protein domains nearly abolishes the 
occurrence of cells with more than 5 foci. 
 
Although we have not yet analyzed if the RRM in PARP10 is indeed functional in terms 
of RNA binding, we consider it highly likely from its implications on the development of 
PARP10 foci. Since RNA recognition motifs are often found in proteins mediating RNA 
transport or processing (Farina and Singer, 2002; Lunde et al., 2007; Maris et al., 
2005) and PARP10 foci resemble the appearance of RNA-processing particles, a 
contribution of PARP10’s RRM in the foci formation would make sense. Future 
experiments have to clarify if the formation of PARP10 foci could be influenced e.g. by 
modulating the levels of cytoplasmic RNA or stalling the translation of mRNAs. 
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2.2.6 PARP10 foci seem to represent novel cytoplasmic bodies 
At first glance, the cytoplasmic PARP10 foci resemble the appearance of RNA-
processing particles, but also a vesicular or endosomal origin cannot be excluded. 
Therefore we analyzed the co-localization of PARP10 with different markers of 
cytoplasmic sub-structures. As a control for the occurrence of PARP10 in the foci of 
CFP/YFP-PARP10-transfected cells, we stained PARP10 with a specific antibody. The 
complete overlap of both stainings confirmed the presence of PARP10 in the 
cytoplasmic foci (Fig. 46A). Co-localization experiments with PARP10 and the 
endosomal markers EEA1 and Rab5 revealed no significant overlap between both sub-
structures indicating that PARP10 foci do not represent endosomal structures (Figs. 
46B and C). PARP10 foci did also not co-localize with the Golgi compartment (Fig. 
46D). Since we could demonstrate that the RRM is involved in the formation of 
PARP10 foci (Figs. 44 and 45) and the foci are similar to P bodies and stress granules 
(Anderson and Kedersha, 2008; Eulalio et al., 2007; Parker and Sheth, 2007; Spector, 
2006), we analyzed if PARP10 might be a component of P bodies or stress granules. 
Therefore we co-expressed CFP/YFP-PARP10 and RFP-tagged versions of the stress 
granule component TIA-1 and the P body component Dcp1a. Although especially the 
TIA-1-induced cytoplasmic foci exhibited a similar appearance like the PARP10 foci, 
we observed no co-localization of PARP10 and TIA-1 or Dcp1a (Figs. 46E and F). 
From these experiments we concluded that the cytoplasmic PARP10 foci are neither 
related to endosomes nor show co-localization with RNA-processing particles, at least 
in a setting where markers for RNA-processing particles were over-expressed along 
with CFP/YFP-PARP10. 
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Figure 46. 
The co-localization of PARP10 foci with markers of different cytoplasmic structures was 
analyzed in PFA-fixed COS-7 cells by immunocytochemistry. 
A. The presence of CFP/YFP-PARP10 in the observed foci was verified with an anti-PARP10 
antibody (5H11) and a secondary anti-rat-Cy3 antibody. 
B. Endosomes were stained by an anti-EEA1 antibody and a secondary Cy3-coupled antibody. 
C. Rab5 was co-expressed and analyzed with an anti-Rab5 antibody and a secondary Alexa555-
coupled antibody. 
D. The co-localization of DsRed-PARP10 and the Golgi apparatus was analyzed by an anti-
GM310 antibody and a secondary Cy2-coupled antibody. 
E. CFP/YFP-PARP10 and RFP-TIA1 were co-expressed and their localization analyzed in 
PFA-fixed COS-7 cells. 
F. CFP/YFP-PARP10 and RFP-Dcp1a were co-expressed and their localization analyzed in 
PFA-fixed COS-7 cells. 
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2.2.7 PARP10 foci might be related to RNA-processing particles 
Despite the obvious lack of co-localization between PARP10 foci and the over-
expressed components of RNA-processing particles, we extended our co-localization 
studies of PARP10 and P bodies or stress granules. In collaboration with Georg 
Stöcklin, a well-known expert in the field of RNA-processing particles (Gilks et al., 
2004; Kedersha et al., 2005; Stoecklin and Anderson, 2007; Yamasaki et al., 2007), we 
were able to analyze a potential connection between PARP10 and these sites of RNA 
decay and storage in more detail. The staining of endogenous P bodies through their 
core component Hedls (Fenger-Gron et al., 2005; Yu et al., 2005a) confirmed our 
previous result that PARP10 foci and P bodies are distinct cytoplasmic substructures 
(Fig. 47A). The same is true for PARP10 foci and stress granules that were induced by 
arsenite or FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) treatment and 
stained by their component HuR (Gallouzi et al., 2000). Thus the cytoplasmic PARP10-
enriched bodies can be clearly separated from RNA-processing particles based on 
their localization. 
 
 
 
Figure 47. 
The co-localization of CFP/YFP-PARP10 and RNA-processing particles was analyzed in COS-
7 cells (in collaboration with G. Stöcklin, DKFZ Heidelberg). 
For explanations, see top of next page. 
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A. CFP/YFP-PARP10 was overexpressed in COS-7 cells and endogenous Hedls present in P-
bodies (PBs) was stained with an anti-S7K antibody and a red-fluorescent secondary antibody. 
A merge picture with an additional DAPI stain of the nuclear DNA is shown to assess a 
potential co-localization. 
B. CFP/YFP-PARP10 was overexpressed in COS-7 cells and endogenous HuR present in stress 
granules (SGs) was stained with an anti-HuR antibody and a red-fluorescent secondary 
antibody. The formation of stress granules was stimulated by treatment with arsenite or FCCP 
(carbonyl cyanide p-trifluoromethoxyphenylhydrazone). A merge picture with an additional 
DAPI stain of the nuclear DNA is shown to assess a potential co-localization. 
 
 
Since stress granules are not present in unstressed cells but form under stress 
conditions where translation of mRNAs is stalled (Anderson and Kedersha, 2008), we 
decided to analyze if the induction of stress granule promoting stress would have an 
influence on the localization of PARP10 foci with respect to components of RNA-
processing particles. Therefore we co-expressed CFP/YFP-PARP10 and the P body 
components RFP-Dcp1a or RFP-Lsm1 and analyzed their localization in the absence 
or presence of stress (Fig. 48). In support of our previous analysis, we observed no co-
localization of PARP10 foci and Dcp1a in untreated cells (Fig. 48A). Surprisingly, 
treatment of the cells with arsenite or FCCP resulted in an at least partial, sometimes 
complete co-localization of PARP10 and Dcp1a in cytoplasmic foci (Figs. 48B and C). 
Analysis of the co-localization between PARP10 and Lsm1 revealed a significant 
overlap even in untreated cells, which was significantly enhanced by stress treatment 
(Figs. 48D-F). 
 
Based on these observations we concluded that although PARP10 foci and P bodies 
are distinct from each other in unstressed cells, the induction of stress that inhibits 
translation of mRNAs and causes the formation of stress granules results in a 
significant co-localization between P body components and PARP10 in the cytoplasmic 
PARP10 foci. Interestingly, overexpressed RFP-Dcp1a co-localizes well with 
endogenous P bodies, while RFP-Lsm1 does not (G. Stöcklin, personal 
communication). This implies that under stress conditions PARP10 foci might not only 
co-localize with Dcp1a but also with other P body components. The overlap between 
CFP/YFP-PARP10 and RFP-Lsm1 in unstressed cells suggest that Lsm1 might be a 
component of P bodies but might also be recruited to PARP10 foci.   
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Figure 48. 
The co-localization of CFP/YFP-PARP10 and components of RNA-processing particles was 
analyzed in COS-7 cells (in collaboration with G. Stöcklin, DKFZ Heidelberg). 
A. CFP/YFP-PARP10 and RFP-Dcp1a was co-expressed in COS-7 cells and their distribution 
analyzed in fixed cells. A merge picture with an additional DAPI stain of the nuclear DNA is 
shown to assess a potential co-localization. 
B,C. The co-localization of PARP10 and Dcp1a was analyzed after treatment with arsenite or 
FCCP. 
D. CFP/YFP-PARP10 and RFP-Lsm1 was co-expressed in COS-7 cells and their distribution 
analyzed in fixed cells. A merge picture with an additional DAPI stain of the nuclear DNA is 
shown to assess a potential co-localization. 
E, F. The co-localization of PARP10 and Lsm1 was analyzed after treatment with arsenite or 
FCCP. 
 
The functional connection between PARP10 and P body components has to be 
analyzed in further detail e.g. by performing interaction assays between PARP10 and 
these proteins. Since Dcp1a as well as Lsm1 are proteins involved in the decapping of 
RNA (Parker and Sheth, 2007), it will be interesting to test if PARP10 also plays a role 
in the processing of RNA which might be among others decapping, deadenylation or 
degradation of RNA. Little is known about the regulatory processes which occur within 
P bodies and stress granules and which determine the assembly or disintegration of 
these structures. Obviously, these functional processes have to be tightly regulated 
due to the general implications on the cellular translation. Since PARP10 possesses 
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mono-ADP-ribosyltransferase activity thereby mediating a reversible and potentially 
highly dynamic post-translational modification, it would be important to analyze if 
potential substrates for PARP10 exist in RNA-processing particles and if the 
modification of these substrates plays a regulatory role for P body function.  
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3. Conclusions 
 
Here we report that one of the novel PARP family members, PARP10, lacks 
polymerase activity while showing robust ADP-ribosyltransferase activity. PARP10 also 
lacks a catalytic glutamate that has a critical function in all of the previously 
characterized ADP-ribosyltransferases. We show that PARP10 like PARP1 modifies 
acidic residues and that the auto-ADP-ribosylation reaction occurs in trans. Molecular 
modeling revealed that the catalytic glutamate is replaced by an isoleucine in PARP10 
and that no residue in the active center can functionally substitute for it. Strikingly, a 
PARP10-I987E mutant, in which the catalytic glutamate is restored, is completely 
devoid of activity. On this basis, we propose that PARP10 employs a mechanism of 
substrate-assisted catalysis (SAC) (Dall'Acqua and Carter, 2000; Kosloff and Selinger, 
2001), where the glutamate that is modified fulfills the function of the catalytic 
glutamate. Such a mechanism explains why PARP10 does not function as a 
polymerase. 
 
Since PARP14, an additional novel PARP enzyme that lacks the catalytic glutamate, 
possesses enzymatic activity comparable to PARP10, i.e. ADP-ribosyltransferase 
activity but no detectable polymer formation, our findings suggest that PARP10 is the 
prototypical enzyme of a subclass of the PARP family. Thus while PARPs 1-5 function 
as polymerases, the novel PARPs 6-16 are mono-ADP-ribosyltransferases. These lack 
the conserved catalytic glutamate and we suggest that they all may use substrate-
assisted catalysis for ADP-ribosylating substrate. There are two exceptions within this 
PARP subfamily, PARPs 9 and 13, which lack the conserved histidine in the catalytic 
center in addition to the glutamate. The histidine is required for NAD+-binding. Indeed 
these two PARPs do not possess auto-ADP-ribosylation capacity. In summary we 
propose to subdivide the PARP family into three subfamilies, the first with bona fide 
pADPr polymerase activity (PARPs 1-5), the second with mono-ADP-ribosyltransferase 
activity (PARPs 6-8, 10-12, 14-16), and the third without catalytic activity (PARPs 9 and 
13).  
 
Intracellular mono-ADP-ribosylation has been postulated as a mechanism to regulate 
many different aspect of cell physiology. However the only enzymes described to 
mono-ADP-ribosylate substrates in cells are different bacterial toxins, while the 
mammalian mono-ADP-ribosyltransferases (ecto-enzymes) appear to be localized 
strictly extracellularly (Aktories and Barbieri, 2005; Corda and Di Girolamo, 2003; 
Hassa et al., 2006; Holbourn et al., 2006). Intracellular mono-ADP-ribosylation may 
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result from the action of PARG on substrates carrying pADPr or by inefficient catalysis 
of polymerases. However there is no evidence to support either model. Finally Sirtuins 
have been suggested to function as mono-ADP-ribosyltransferases, in particular SIRT4 
and SIRT6 (Haigis et al., 2006; Liszt et al., 2005). Since the NAD+ binding motif and the 
mode of catalysis is distinct between Sirtuins and PARP enzymes (Otto et al., 2005; 
Ruf et al., 1998b; Sauve et al., 2006), it is unlikely that ADP-ribosyltransferases of the 
Sirtuin family target acidic residues and employ substrate-assisted catalysis. Therefore 
our discovery of a mono-ADP-ribosylating class of PARP enzymes represents the first 
account of intracellular enzymes mono-ADP-ribosylating acidic residues. Importantly, 
the overexpression of PARP10 impairs the growth of HeLa cells dependent on mono-
ADP-ribosyltransferase activity suggesting an important role for the PARP10-mediated 
ADP-ribosylation reaction in physiological processes. The mechanism of substrate-
assisted catalysis proposed here, which uses a substrate glutamate and possibly an 
aspartate for catalysis, together with eight additional PARP family members potentially 
able to mono-ADP-ribosylate, suggests that mono-ADP-ribosylation of acidic residues 
might be a wide spread post-translational mechanism to control protein function. In 
addition mono-ADP-ribosylation might serve as acceptor sites for poly-ADP-ribose 
polymerases, possibly expanding the functional range of PARPs 1-5 considerably. It 
will now be important to identify the substrates that are mono-ADP-ribosylated by 
PARP10 and other PARP-like mono-ADP-ribosyltransferases to elucidate the 
physiological role of this modification. 
 
As described previously, PARP10 shuttles between the nucleus and the cytoplasm (Yu 
et al., 2005b). Here we present data confirming that PARP10 is able to enter the 
nucleus upon inhibition of Crm1-mediated nuclear export. PARP10 contains a single 
functional NES mediating its export and being responsible for its mainly cytoplasmic 
localization. Despite careful analysis we were not able to define a classical NLS in 
PARP10, but we propose that three regions within PARP10 exhibit NLS-like features 
enabling nuclear entry. Future experiments will have to clarify if all of these regions 
contribute to the nucleocytoplasmic shuttling of PARP10 and if nuclear uptake is 
mediated by direct interaction with importins or via a piggyback mechanism through 
interaction with an NLS-containing protein. 
 
Interestingly, PARP10 enriches in prominent cytoplasmic foci. These are dynamic, tend 
to fuse and can form de novo as confirmed by time-lapse microscopy.  PARP foci likely 
do not represent previously described cytoplasmic substructures. Importantly, the 
deletion of the RNA recognition motif in PARP10 significantly reduces the formation of 
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these foci indicating an important role for RNA in the subcellular localization of 
PARP10. Although the capacity of the RRM to bind RNA has not been analyzed yet, 
the influence on the development of PARP10 foci suggests that the RRM exerts a 
physiological role. We demonstrate that PARP10 foci are distinct from RNA-processing 
particles, i.e. P bodies and stress granules, but that some core components involved in 
RNA decay are shared between both cytoplasmic substructures, which is significantly 
enhanced under stress conditions that stall translation of mRNAs. Thus PARP10 might 
play a role in the processing of RNA and in cellular stress responses. 
 
Future work will be directed towards understanding the SAC-based ADP-ribosylation 
reaction in more detail and towards the identification and analysis of PARP10 
substrates and interaction partners to gain insights into its biological function. In 
addition, it will be necessary to develop novel tools for the analysis of mono-ADP-
ribosylated proteins. The analysis of the subcellular localization of endogenous 
PARP10 will help to elucidate the relevance of the observed PARP10 foci, and further 
experiments have to be performed in order to understand the physiological role of 
PARP10 in these foci, which might be linked to RNA processes. 
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4. Experimental Procedures 
 
4.1  Consumables and Reagents 
Consumables 
Consumables were purchased from: 
Amersham Biosciences, Ansell, Becton Dickinson, Beranek, Biometra, Bio-Rad, Brand, 
Braun, Corning, Costar, Eppendorf, Falcon, Fisher Scientific, Fuji, Greiner, Hartenstein, 
Integra Biosciences, Kimberley-Clark, Merck, Millipore, Nalgene, Nerbe Plus, Nunc, 
Roth, Sarstedt, Sartorius, Schleicher&Schuell, Stratagene, Terumo, TPP, VWR, WillCo 
Wells. 
 
Reagents 
Reagents met at least the criteria for the purity standard p.a. and were purchased from: 
Amersham Biosciences, AppliChem, Baker, Bayer, BD Biosciences, Biozym, 
Calbiochem, Clontech, Delta, Difco, Fluka, GE Healthcare, Gibco, Invitrogen, 
Invivogen, KMF, Fermentas, Merck, MP Biomedicals, New England Biolabs, Perkin 
Elmer, Qiagen Riedel-de-Haën, Roche, Rockland, Roth, Sigma, Stratagene, USB, 
Zymo Research. 
 
4.2  Oligonucleotides 
The following oligonucleotides were purchased from MWG Biotech, Germany: 
 
Oligo name sequence 5’ ? 3’ 
siPARP10#1_1 GAT CCC CGG GTA GAG GGA TTA TGA CAT TCA AGA 
GAT GTC ATA ATC CCT CTA CCC TTT TTG GAA A 
siPARP10#1_2 AGC TTT TCC AAA AAG GGT AGA GGG ATT ATG ACA TCT 
CTT GAA TGT CAT AAT CCC TCT ACC CGG G 
siPARP10#2_1 GAT CCC CGT GCA GGG ACT GTG ACA ATT TCA AGA 
GAA TTG TCA CAG TCC CTG CAC TTT TTG GAA A 
siPARP10#2_2 AGC TTT TCC AAA AAG TGC AGG GAC TGT GAC AAT TCT 
CTT GAA ATT GTC ACA GTC CCT GCA CGG G 
siPARP10#3_1 GAT CCC CCT TGA AGG ACC GGA TAT GAT TCA AGA 
GAT CAT ATC CGG TCC TTC AAG TTT TTG GAA A 
siPARP10#3_2 AGC TTT TCC AAA AAC TTG AAG GAC CGG ATA TGA TCT 
CTT GAA TCA TAT CCG GTC CTT CAA GGG G 
siP10#4for GAT CCC CTG GGT CCC ATG GAG ATC ACT TCA AGA 
GAG TGA TCT CCA TGG GAC CCA TTT TTG GAA A 
siP10#4rev AGC TTT TCC AAA AAT GGG TCC CAT GGA GAT CAC TCT 
CTT GAA GTG ATC TCC ATG GGA CCC AGG G 
siP10#5for GAT CCC CAG TGG CAG AAC GAG TGT TGT TCA AGA 
GAC AAC ACT CGT TCT GCC ACT TTT TTG GAA A 
siP10#5rev AGC TTT TCC AAA AAA GTG GCA GAA CGA GTG TTG TCT 
CTT GAA CAA CAC TCG TTC TGC CAC TGG G 
siP10#6for GAT CCC CAG GCC TTG AAG AGG TGG ACT TCA AGA 
GAG TCC ACC TCT TCA AGG CCT TTT TTG GAA A 
siP10#6rev AGC TTT TCC AAA AAA GGC CTT GAA GAG GTG GAC TCT 
CTT GAA GTC CAC CTC TTC AAG GCC TGG G 
Experimental Procedures  102 
attB1-PARP10-5 GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC CAA 
CAA CCT GGA GCG TCT GGC 
attB2-PARP10 GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TTA 
AGT GTC TGG GGA GCG GC 
PARP10delC1rev GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TTA 
CTG GGT GTC GTG GAA GAT GAC G 
PARP10delC2rev GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TTA 
GTA GCG CAG GAG CAC GTG GCC AGG AC 
PARP10delC3rev GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TTA 
GTA GCG GTC CTG CAC CGA CAG GGA G 
PARP10delC4rev GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TTA 
TGC CGT CGT GCC GTG GTA CAG CAC C 
attB1-PARP10C30 GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC CGC 
GCT GCC CAC CCA CCT CAT CAC 
attB1-PARP10C50 GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC CGA 
CAG CGC CGT GGA CTG CAT C 
attB1-PARP7 GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC CAT 
CCA AGT CCC TGT TTC TGC AG 
attB1-P7aa332 GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC CTC 
CAC ACC ACC CTC TAG CAA TG 
attB2-PARP7 GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TTA AAT 
GGA AAC AGT GTT ACT GAC TTC 
attB1-PARP9 GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC CGA 
GGT CCT TAT GGC TGC CTT TC 
attB2-PARP9 GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TTA 
ATC AAC AGG GCT GCC ACT TGC G 
attB1-PARP12cat GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC CAT 
GCA GAA GCA GAA TGG AGG GAA GG 
attB1-P12aa283 GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC CAG 
CTT TCA AGA TAA GTG CCA TAG AGT TC 
attB2-PARP12 GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TTA 
CTG TCG GCT GCT GAA CAG GGA G 
attB1-PARP13 GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC CCA 
GGA GGA CTT TTG CTT CCT ATC 
attB1-P13aa604 GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TTA 
CTG CCT AAA TGT GAT AAG ATA CTC AG 
attB2-PARP13 GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TTA 
ACT AAT CAC GCA GGC TTT GTC TTC 
attB1-mPARP14 GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC CGA 
TTT CAC GGT GGA CTT GAG C 
attB2-mPARP14 GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TTA 
CTG CCT AAA TGT GAT AAG ATA CTC AG 
PARP10G888Wfor GCC GGT GCC GTC GTC CAG TGG TAC AGC ACC TGC 
PARP10G888Wrev GCA GGT GCT GTA CCA CTG GAC GAC GGC ACC GGC 
PARP10E1005A_for CCA CCT CAT CAC CTG CGC GCA CGT GCC CCG CGC 
TTC CC 
PARP10E1005A_rev GGG AAG CGC GGG GCA CGT GCG CGC AGG TGA TGA 
GGT GG 
D1013D1014A_for CGC TTC CCC CGC CGC CCC CTC TGG GC 
D1024A_for GGC CGC TCC CCA GCC ACT TAA GAC CCA G 
I987E_for GCA TCT GCC AGC CCA GCG AGT TCG TCA TCT TCC 
ACG A 
I987E_rev TCG TGG AAG ATG ACG AAC TCG CTG GGC TGG CAG 
ATG C 
P10T182E_for ACC CAG GCG CTG CCC GAG CAC CTC ATC ACC TGC 
P10T182E_rev GCA GGT GAT GAG GTG CTC GGG CAG CGC CTG GGT 
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P10R192K_for GCG AGC ACG TGC CCA AGG CTT CCC CCG ACG A 
P10R204K_for CTC TGG GCT CCC GGG CAA GTC CCC AGA CAC TTA AG 
E866Afor GCA GCA GCA GTA TGC GCT GTA CCG GGA GC 
E866Arev GCT CCC GGT ACA GCG CAT ACT GCT GCT GC 
E870Afor GCT GTA CCG GGC GCG CCT GCT GC 
E870Arev GCA GCA GGC GCG CCC GGT ACA GC 
E877Afor GCA GCG ATG CGC GCG GCG CCC GG 
E877Arev CCG GGC GCC GCG CGC ATC GCT GC 
E882Afor GCG CCC GGT GGC GCA GGT GCT GT 
E882Arev ACA GCA CCT GCG CCA CCG GGC GC 
E882Qfor GGC GCC CGG TGC AGC AGG TGC TG 
E882Qrev CAG CAC CTG CTG CAC CGG GCG CC 
del981-984neu_for CTA CGA CAG CGC CGT GGA CCC CAG CAT CTT CGT 
CAT CT 
del981-984neu_rev AGA TGA CGA AGA TGC TGG GGT CCA CGG CGC TGT 
CGT AG 
del983neu_for CCG TGG ACT GCA TCC AGC CCA GCA TCT TC 
del983neu_rev GAA GAT GCT GGG CTG GAT GCA GTC CAC GG 
P985Afor ACT GCA TCT GCC AGG CCA GCA TCT TCG TC 
P985Arev GAC GAA GAT GCT GGC CTG GCA GAT GCA GT 
D980AI982Sfor CAG CGC CGT GGC CTG CAG CTG CCA GCC CA 
D980AI982Srev TGG GCT GGC AGC TGC AGG CCA CGG CGC TG 
D980AI982SP985Afor  GCG CCG TGG CCT GCA GCT GCC AGG CCA GCA TCT 
D908AI982SP985Arev  AGA TGC TGG CCT GGC AGC TGC AGG CCA CGG CGC 
P10C981SC983Sfor GCG CCG TGG ACA GCA TCA GCC AGC CCA GC 
P10C981SC983Srev GCT GGG CTG GCT GAT GCT GTC CAC GGC GC 
 
 
4.3 Plasmids 
Eukaryotic expression plasmids 
pBabe Puro This is a retroviral mammalian expression vector driving the 
expression of a puromycin resistance gene under the control of 
a SV40 early promoter (J.P. Morgenstern, and H. Land (1990) 
Nucleic Acids Research 18(12): 3587-96). 
pCMV-Rab5 This vector drives the expression of human Rab5 under control 
of a CMV promoter (A. Krüttgen). 
pCS2+-p27 A cDNA encoding human p27 was cloned into the EcoRI site of 
pCS2+ to drive expression of p27 under control of a CMV 
promoter (J. Vervoorts). 
pEQ176P2 This vector was routinely used for control transfections for 
CMV-containing vectors if the respective backbone vector for 
the transfected plasmid was not available.  It is derived from 
pEQ176 which drives expression of ß-galactosidase under 
control of a CMV promoter. Most of the cDNA encoding ß-
galactosidase was cut out by a PvuII restriction digest (J. 
Lüscher-Firzlaff). 
pEVRF0-HA 
 
This vectors allows for the expression of N-terminally HA-
tagged proteins in eukaryotic cells under control of a strong 
CMV promoter (Matthias et al., 1989). The vector contains 
pSP65 plasmid sequences, a human CMV promoter/enhancer, 
the translation initiation region from the HSV thymidine kinase, 
the splicing and polyadenylation signals from the rabbit ß-globin 
gene and the SV40 origin of replication. 
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pEVRF0-HA-
PARP10  
The full-length cDNA encoding the 1025 aa PARP10 protein 
was ligated into pEVRF0-HA from pSport-p150 T+B using the 
KpnI and XbaI restriction sites (S. Schreek). 
pEVRF0-HA-
PARP10-G888W 
This vector was obtained from pEVRF0-HA-PARP10 by site-
directed mutagenesis using the oligos PARP10G888Wfor and 
PARP10G888Wrev (E. Poreba). 
pEVRF0-HA-
PARP10-H987E 
This vector was obtained from pEVRF0-HA-PARP10 by site-
directed mutagenesis using appropriate oligos (E. Poreba, J. 
Lüscher-Firzlaff). 
pEVRF0-HA-
PARP10-dNES 
The SphI/BssHII fragment from pBS-PARP10-dNES was 
subcloned into the plasmid pEVRF0-HA-PARP10 using the 
same restriction sites (M. Yu). 
pECYFP This vector drives the expression of a eCFP/YFP-double tag 
under control of a CMV promoter. A Kanamycin/Neomycin 
resistance gene is included for selection in bacteria and 
mammalian cells, respectively (B. Giese, AG Müller-Newen). 
pECYFP-PARP10 PARP10 cDNA was cut out of GW-pD-PARP10 with Bsp1407I 
and filled with Klenow enzyme and ligated into pECYFP cut with 
Asp718I and filled with Klenow enzyme (K. Montzka). The 
reading frame was corrected by digesting the plasmid DNA with 
HindIII, filling up with Klenow enzyme and re-ligation (H. 
Schuchlautz). 
pECYFP-PARP10-
dNES 
PARP10-dNES cDNA was cut out of GW-pD-PARP10-dNES 
with Bsp1407I and filled with Klenow enzyme and ligated into 
pECYFP cut with Asp718I and filled with Klenow enzyme (K. 
Montzka). The reading frame was corrected by digesting the 
plasmid DNA with HindIII, filling up with Klenow enzyme and re-
ligation (H. Schuchlautz). 
pDsRed-Monomer-
N1 
This vector allows for the expression of a monomeric mutant 
from the tetrameric Discosoma sp. red fluorescent protein. The 
expression is driven by a CMV promoter. Genes cloned into the 
MCS are expressed as fusions to the N-terminus of DsRed-
Monomer (Clontech). 
pDsRed-Monomer-
N1-PARP10 
This vector allows for the expression of a C-terminally DsRed-
tagged PARP10. cDNA encoding PARP10 was obtained from 
pcDNA5/FRT/TO/C-TAP-PARP10 by restriction digest with 
BamHI, subsequent mung bean nuclease treatment and HindIII 
digestion of plasmid DNA. pDsRed-Monomer-N1 was prepared 
in the same way. After gelextraction vector DNA and insert DNA 
were ligated (H. Schuchlautz). 
pDsRed-Monomer-
N1-PARP10-G888W 
This vector allows for the expression of a C-terminally DsRed-
tagged PARP10. cDNA encoding PARP10 was obtained from 
pcDNA5/FRT/TO/C-TAP-PARP10-G888W by restriction digest 
with BamHI, subsequent mung bean nuclease treatment and 
HindIII digestion of plasmid DNA. pDsRed-Monomer-N1 was 
prepared in the same way. After gelextraction vector DNA and 
insert DNA were ligated (H. Schuchlautz). 
GW-pHA This vector is derived from pEVRF0-HA which was made 
compatible with the Gateway system by insertion of the 
Gateway cassette Reading frame C1 (RfC1) into the SmaI site 
(R. Lilischkis). 
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GW-pECYFP The vector pECYFP was made compatible with the Gateway 
system by insertion of the Gateway cassette Reading frame C1 
(RfC1) into the SmaI site. It allows for the expression of N-
terminally CFP/YFP-tagged proteins (K. Montzka). 
GW-pECYFP-
PARP10 (1-255), 
(206-459), (408-
649), (600-868),  
(818-1025), (818-
1025) GW 
These vectors were created by a LR reaction with GW-pECYFP 
and the corresponding pDONR/Zeo entry vectors (H. 
Schuchlautz). 
GW-pECYFP-
PARP10 (257-1025), 
(552-1025), (1-459), 
(408-868) 
These vectors were created by a LR reaction with GW-pECYFP 
and the corresponding pDONR/Zeo entry vectors (L. Milke). 
pRFP-Dcp1a This vector drives the expression of RFP-tagged human Dcp1a 
(G. Stöcklin). 
pRFP-Lsm1 This vector drives the expression of RFP-tagged human Lsm1 
(G. Stöcklin). 
pRFP-TIA-1 This vector drives the expression of RFP-tagged human TIA-1 
(G. Stöcklin). 
pSuper-siLuc#2 This vector drives the expression of a functional shRNA 
targeted against the luciferase mRNA from the histone H1 PolIII 
promoter (C. Cornelissen). 
pSuper-
siPARP10#1, 2, 3, 4, 
5, 6 
These vectors were derived from pSuper by insertion of the 
hybridized oligos siPARP10#1, 2, 3, 4, 5, 6 between the BglII 
and HindIII sites. They drive the expression of shRNAs 
designed for targeting the PARP10 mRNA (C. Cornelissen, H. 
Schuchlautz). 
 
Prokaryotic expression plasmids 
GW-pGST This vector is derived from pGEX-4T-2 (GE Healthcare) which 
was made compatible with the Gateway system by insertion of 
the Gateway cassette Reading frame A (RfA) into the MCS. It 
allows for the IPTG-inducible expression of a N-terminally GST-
tagged protein under control of a tac promoter and the lac 
operator (R. Lilischkis). 
GW-pGST-PARP10 (1-
255), (206-459), (408-
649), (600-868),  (818-
1025), (818-1025) GW 
These vectors were created by a LR reaction with GW-pGST 
and the corresponding pDONR/Zeo entry vectors (K. Montzka). 
GW-pGST-PARP10 
(818-995), (818-975), 
(818-932), (818-891) 
These vectors were created by a LR reaction with GW-pGST 
and the corresponding pDONR/Zeo entry vectors (H. 
Schuchlautz). 
GW-pGST-PARP10-C30 
(996-1025), 
-C50 (976-1025) 
These vectors were created by a LR reaction with GW-pGST 
and the corresponding pDONR/Zeo entry vectors (H. 
Schuchlautz). 
GW-pGST-PARP10 
(818-1025) I987E, 
T999E, E1005A 
These vectors were created by a LR reaction with GW-pGST 
and the corresponding pDONR/Zeo entry vectors (H. 
Schuchlautz). 
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GW-pGST-PARP10 
(818-1025)GW E1005A, 
D1013/1014/1024A, 
E1005A/D1013/ 
1014/1024A, 
R1009/1021K 
These vectors were created by a LR reaction with GW-pGST 
and the corresponding pDONR/Zeo entry vectors (H. 
Schuchlautz). 
GW-pGST-PARP10 
(818-1025) P985A, 
D980A/I982S, 
D980A/I982S/P985A, 
delC983, del981-984 
These vectors were created by a LR reaction with GW-pGST 
and the corresponding pDONR/Zeo entry vectors (H. 
Schuchlautz). 
GW-pGST-PARP10 
(818-1025) E866A, 
E870A,E877A,E882A 
These vectors were created by a LR reaction with GW-pGST 
and the corresponding pDONR/Zeo entry vectors (H. 
Schuchlautz). 
GW-pGST-PARP10 
(818-1025)GW 
E866A,E870A, E877A, 
E882A 
These vectors were created by a LR reaction with GW-pGST 
and the corresponding pDONR/Zeo entry vectors (H. 
Schuchlautz). 
GW-pGST-PARP10 
(818-1025) E866Q, 
E870Q,E877Q, E882Q 
These vectors were created by a LR reaction with GW-pGST 
and the corresponding pDONR/Zeo entry vectors (H. 
Schuchlautz). 
GW-pGST-PARP10 
(818-1025)GW 
E866Q,E870Q, E877Q, 
E882Q 
These vectors were created by a LR reaction with GW-pGST 
and the corresponding pDONR/Zeo entry vectors (H. 
Schuchlautz). 
GW-pGST-PARP10 
(818-1025)GW 
E866A/E870A, 
E870A/E877A, 
E877A/E882A, 
E866A/E870A/E877A, 
E866A/E870A/E882A, 
E870A/E877A/E882A 
These vectors were created by a LR reaction with GW-pGST 
and the corresponding pDONR/Zeo entry vectors (H. 
Schuchlautz). 
GW-GST-mPARP14cat 
(1591-1817), 
-PARP13cat (717-902), 
-PARP7cat (463-657), 
-PARP12cat (548-701) 
These vectors were created by a LR reaction with GW-pGST 
and the corresponding pDONR/Zeo entry vectors (H. 
Schuchlautz). 
pGEX-2T-ARH1 This vector allows for the expression of a N-terminally GST-
tagged ARH1 (Paul O. Hassa, EMBL Heidelberg). 
pGEX-2T-ARH2 This vector allows for the expression of a N-terminally GST-
tagged ARH2 (Paul O. Hassa, EMBL Heidelberg). 
pGEX-2T-ARH3 This vector allows for the expression of a N-terminally GST-
tagged ARH3 (Paul O. Hassa, EMBL Heidelberg). 
pGEX-2T-PARGcat This vector allows for the expression of the N-terminally GST-
tagged catalytic domain (aa380-977) of bovine PARG (Paul O. 
Hassa, EMBL Heidelberg). 
pET24b-TEV-H The cDNA encoding the TEV protease  was cloned into the 
MCS of pET24b (Novagen) (Brian H. Shilton, UWO London, 
Canada). 
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Cloning vectors / Gateway entry vectors 
pDONR/Zeo This vector allows for the recombination of attB-PCR products 
into its attP1 and attP2 sites replacing the Gateway cassette 
containing the negative selective ccdB gene. M13 priming sites 
allow sequencing of the cloned PCR product in both directions. 
The EM7 promoter drives expression of the Zeocin resistance 
genes used for selection in E. coli. rrnB T1 and T2 transcription 
terminators protect the cloned gene from expression by vector-
encoded promoters (Invitrogen). 
pDONR/Zeo-
PARP10 (1-255) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 1-255 of 
PARP10 (K. Montzka). 
pDONR/Zeo-
PARP10 (206-459) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 206-459 of 
PARP10 (K. Montzka). 
pDONR/Zeo-
PARP10 (408-649) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 408-649 of 
PARP10 (K. Montzka). 
pDONR/Zeo-
PARP10 (600-868) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 600-868 of 
PARP10 (K. Montzka). 
pDONR/Zeo-
PARP10 (818-1025) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 818-1025 of 
PARP10 (K. Montzka). 
pDONR/Zeo-
PARP10 (818-1025) 
GW 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 818-1025 of 
PARP10-G888W (K. Montzka). 
pDONR/Zeo-
PARP10 (1-459) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 1-459 of 
PARP10 (L. Milke). 
pDONR/Zeo-
PARP10 (408-868) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 408-868 of 
PARP10 (L. Milke). 
pDONR/Zeo-
PARP10 (257-1025) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 257-1025 of 
PARP10 (L. Milke). 
pDONR/Zeo-
PARP10 (552-1025) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 552-1025 of 
PARP10 (L. Milke). 
pDONR/Zeo-
PARP10-C30 (996-
1025) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 996-1025 of 
PARP10 (H. Schuchlautz). 
pDONR/Zeo-
PARP10-C50 (976-
1025) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 976-1025 of 
PARP10 (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-995) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 818-995 of 
PARP10 (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-975) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 818-975 of 
PARP10 (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-932) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 818-932 of 
PARP10 (H. Schuchlautz). 
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pDONR/Zeo-
PARP10 (818-891) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 818-891 of 
PARP10 (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
I987E 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) by site-directed mutagenesis using the primers 
I987E_for/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
T999E 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) by site-directed mutagenesis using the primers 
P10T182E_for/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
E1005A 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) by site-directed mutagenesis using the primers 
PARP10E1005A_for/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
GW E1005A 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) GW by site-directed mutagenesis using the primers 
PARP10E1005A_for/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
GW D1013/1014/ 
1024A 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) GW by site-directed mutagenesis using the primers 
D1013/D1014A_for and D1024A_for (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
GW R1009/1021K 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) GW by site-directed mutagenesis using the primers 
P10R192K_for and P10R204K_for (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
GW E1005A/ D1013/ 
1014/1024A 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) GW E1005A by site-directed mutagenesis using the 
primers P10R192K_for and P10R204K_for (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
P985A 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) by site-directed mutagenesis using the primers 
P985Afor/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
C981S/C983S 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) by site-directed mutagenesis using the primers 
P10C981SC983Sfor/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
D980A/I982S 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) by site-directed mutagenesis using the primers 
D980AI982Sfor/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
D980A/I982S/P985A 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) by site-directed mutagenesis using the primers 
D980AI982SP985Afor/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
delC983 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) by site-directed mutagenesis using the primers 
del983neu_for/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
del981-984 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) by site-directed mutagenesis using the primers del981-
984_for/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
E866A, E870A, 
E877A, E882A 
These vectors were obtained from pDONR/Zeo-PARP10 (818-
1025) by site-directed mutagenesis using the primers 
E886Afor/rev, E870Afor/rev, E877Afor/rev, E882Afor/rev (H. 
Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
GW E866A, E870A, 
E877A, E882A 
These vectors were obtained from pDONR/Zeo-PARP10 (818-
1025) GW by site-directed mutagenesis using the primers 
E886Afor/rev, E870Afor/rev, E877Afor/rev, E882Afor/rev (H. 
Schuchlautz). 
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pDONR/Zeo-
PARP10 (818-1025) 
E866Q, E870Q, 
E877Q, E882Q 
These vectors were obtained from pDONR/Zeo-PARP10 (818-
1025) by site-directed mutagenesis using the primers 
E886Qfor/rev, E870Qfor/rev, E877Qfor/rev, E882Qfor/rev (H. 
Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
GW E866Q, E870Q, 
E877Q, E882Q 
These vectors were obtained from pDONR/Zeo-PARP10 (818-
1025) GW by site-directed mutagenesis using the primers 
E886Qfor/rev, E870Qfor/rev, E877Qfor/rev, E882Qfor/rev (H. 
Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
GW E866A/E870A 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) GW E870A by site-directed mutagenesis using the 
primers E866Afor/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
GW E870A/E877A 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) GW E870A by site-directed mutagenesis using the 
primers E877Afor/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
GW E877A/E882A 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) GW E877A by site-directed mutagenesis using the 
primers E882Afor/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
GW 
E866A/E870A/E877A 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) GW E866A/E870A by site-directed mutagenesis using 
the primers E877Afor/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
GW 
E866A/E870A/E882A 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) GW E866A/E870A by site-directed mutagenesis using 
the primers E882Afor/rev (H. Schuchlautz). 
pDONR/Zeo-
PARP10 (818-1025) 
GW 
E870A/E877A/E882A 
This vector was obtained from pDONR/Zeo-PARP10 (818-
1025) GW E870A/E877A by site-directed mutagenesis using 
the primers E882Afor/rev (H. Schuchlautz). 
pDONR/Zeo-
mPARP14cat (1591-
1817) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 1591-1817 
of murine PARP14 (H. Schuchlautz). 
pDONR/Zeo-
PARP13cat (717-
902) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 707-902 of 
human PARP13 (H. Schuchlautz). 
pDONR/Zeo-
PARP7cat (463-657) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 463-657 of 
human PARP7 (H. Schuchlautz). 
pDONR/Zeo-
PARP12cat (548-
701) 
This entry vector was created by a Gateway BP reaction with 
pDONR/Zeo and an attB-PCR product covering aa 548-701 of 
human PARP12 (H. Schuchlautz). 
 
4.4 Antibodies 
?-Actin (C4) Monoclonal mouse IgG1 antibody recognizing an epitope that 
has been conserved in actins from human skeletal muscle to 
plants (MP Biomedicals). 
?-EEA1 (cl.14) Monoclonal mouse IgG1 antibody raised against rat EEA1 (BD 
Biosciences). 
?-GM130 (cl. 35) Monoclonal mouse IgG1 antibody raised against the C-terminus 
of rat GM130 (BD Biosciences). 
?-GFP (600-301-
215) 
Monoclonal mouse IgG2a antibody raised against full length 
GST-GFP (Rockland). 
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?-HA (3F10) 
 
Monoclonal rat IgG1 antibody that recognizes the HA peptide 
sequence (YPYDVPDYA) derived from the influenza 
hemagglutinin protein, even when the HA peptide is introduced 
into unrelated recombinant proteins by “epitope tagging”. 
(Roche). 
?-mouse IgG (H+L) 
Alexa 555-
conjugated (A21425) 
Conjugated secondary antibody from goat recognizing the heavy 
and light chains of murine IgG antibodies (Invitrogen). 
?-mouse IgG (H+L) 
Cy2-conjugated 
(115-225-003) 
Conjugated secondary antibody from goat recognizing the heavy 
and light chains of murine IgG antibodies (Jackson Immuno 
Research). 
?-mouse IgG (H+L) 
Cy3-conjugated 
(715-165-151) 
Conjugated secondary antibody from donkey recognizing the 
heavy and light chains of murine IgG antibodies (Jackson 
Immuno Research). 
?-mouse IgG + IgM 
(H+L) HRP-
conjugated (115-
036-068) 
Conjugated secondary antibody from goat recognizing the heavy 
and light chains of murine IgG and IgM antibodies (Jackson 
Immuno Research). 
?-PARP10 (5H11) Monoclonal rat antibody raised against GST-PARP10 (1-907) 
(Yu et.al., 2005). 
?-PARP10 (891-
6/890-6) 
Polyclonal serum from rabbits immunized against GST-PARP10 
(1-907) (Yu et.al., 2005). 
891-0/890-0 Control bleeds corresponding to 891-6/890-6.  
?-PARP1 (1835238) Polyclonal serum from rabbits immunized against full length 
recombinant PARP1 (Roche). 
?-PAR (10H) Monoclonal mouse IgG3 antibody raised against purified poly-
ADP-ribose (Calbiochem). 
?-PAR (96-10-04) Polyclonal rabbit antibody raised against poly-ADP-ribose with 
methylated BSA. It is described to recognize PAR of 6-100 
bases in size (Alexis Biochemicals). 
?-phospho-Rb 
(Ser780, 
Ser807/811) (9307, 
9308) 
Polyclonal rabbit antibodies raised against a synthetic KLH-
coupled phospopeptide corresponding to residues around 
Ser780 and Ser807/811 of human Rb (Cell Signaling). 
?-Rab5 (cl. 1) Monoclonal mouse IgG2? antibody raised against human Rab5 
(BD Biosciences). 
?-rabbit IgG + IgM 
(H+L) HRP-
conjugated (111-
035-144) 
Conjugated secondary antibody from goat recognizing the heavy 
and light chains of rabbit IgG and IgM antibodies (Jackson 
Immuno Research). 
?-rat IgG+IgM (H+L) 
Cy3-conjugated 
(112-166-068) 
Conjugated secondary antibody from goat recognizing the heavy 
and light chains of rat IgG and IgM antibodies (Jackson Immuno 
Research). 
?-rat IgG+IgM (H+L) 
FITC-conjugated 
(112-096-068) 
Conjugated secondary antibody from goat recognizing the heavy 
and light chains of rat IgG and IgM antibodies (Jackson Immuno 
Research). 
?-rat IgG + IgM 
(H+L) HRP-
conjugated (112-
035-068) 
Conjugated secondary antibody from goat recognizing the heavy 
and light chains of rat IgG and IgM antibodies (Jackson Immuno 
Research). 
?-Rb (C-15) Polyclonal rabbit antibody with an epitope mapping at the C-
terminus of human Rb (Santa Cruz). 
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4.5 Work with nucleic acids 
4.5.1 DNA preparation 
DNA was extracted from transformed bacteria following the manufacturer’s instructions 
using the Qiagen Plasmid Maxi Kit (Qiagen) for preparative purposes and the Zippy 
Plasmid Miniprep Kit (Zymo Research) for small-scale preparations. 
 
4.5.2 RNA preparation 
Total RNA was extracted from cultured cells using the RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s instructions. 
 
4.5.3 Enzymatic manipulation of plasmid DNA 
10x Magic Buffer: 200 mM Tris pH 7.5 
   700 mM NaCl 
   200 mM KCl 
   100 mM MgCl2 
   0.5 mM spermine 
   0.125 mM spermidine 
 
Calf Intestine Alkaline Phosphatase (Fermentas) 
 
T4 DNA Ligase (Fermentas) 
 
Plasmid DNA was digested in 20 ?l reaction volume using restriction enzymes 
(Fermentas) with the appropriate buffers for 1h to o/n at the appropriate temperature, 
usually 37°C. Double digests were routinely performed in magic buffer. De-
phosphorylation of terminal 5’-phosphates was achieved by incubation with calf 
intestine alkaline phosphatase (Fermentas) for 1h. DNA was ligated using T4 DNA 
ligase (Fermentas). Sticky-end ligations were carried out for 1-2h at ambient 
temperature. For blunt-end ligations, 5% PEG2000 was included in the reaction, and 
the reaction was incubated o/n at 16°C. 
 
4.5.4 Agarose gel electrophoresis 
TBE:   89 mM Tris-Base 
   89 mM boric acid 
   2 mM EDTA 
 
10x DNA Loading Buffer: 50 mM Tris pH 8.0 
   50 mM EDTA 
   50% (v/v) glycerol 
   0.25% (w/v) bromophenol blue 
   0.25% (w/v) xylene cyanol 
 
Agarose Low EEO (Sigma) 
NuSieve GTG Agarose (Biozym Scientific) 
 
Gel electrophoresis of DNA was performed as described (Sambrook et al., 1989) in 
0.8-2% agarose gels using low EEO agarose (Sigma) or in 3.5-4% agarose gels using 
NuSieve GTG Agarose (Biozym Scientific ) for short DNA fragments and hybridized 
oligonucleotides. 
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4.5.5 Gel extraction of DNA 
DNA was recovered from agarose gels after electrophoresis using the Zippy Gel DNA 
Recovery Kit (Zymo Research) according to the manufacturer’s instructions. 
 
4.5.6 Gateway cloning 
The Gateway technology (Invitrogen) is a universal cloning method based on the site-
specific recombination properties of bacteriophage lambda. It allows for the rapid and 
efficient movement of DNA sequences into multiple vector systems. First, the desired 
target DNA is amplified by PCR using primers possessing the recombination sites (att 
sites). Second, the PCR product flanked by att sites is recombined into a so-called 
entry vector. Finally, this entry vector can be used to recombine into the destination 
vector of interest depending on the intended use. 
Gateway cloning was performed according to the manufacturer’s instructions with slight 
modifications. For PCR amplification, either an equal mixture of recombinant Taq 
polymerase (Fermentas) and cloned Pfu polymerase (Fermentas) or 1-2 U of Phusion 
polymerase (Finnzymes) was used. The recombination reactions were carried out o/n 
with half the amount of reagents as recommended. 
 
4.5.7 Site-directed mutagenesis 
Primers for site-directed mutagenesis were designed using the online available 
QuikChange Primer Design Program (Stratagene). The mutagenesis of single or 
adjacent base pairs was carried out using the QuikChange Site-directed Mutagenesis 
Kit (Stratagene) following the manufacturer’s instructions. For the introduction of 
several mutations, the QuikChange Multi Site-directed Mutagenesis Kit (Stratagene) 
was used. All obtained plasmids were checked for correct amplification by sequencing 
of the whole insert DNA. 
 
4.5.8 Generation of pSuper-based siRNA constructs 
siRNA oligonucleotides targeting the desired sequence were designed using the online 
available program siDirect (genomics.jp/sidirect). After using the BLAST algorithm 
sequences being specific for both strands were selected. An oligonucleotide was 
designed according to the following scheme: 5’ GAT CCC C target sequence TTC AAG 
AGA complementary sequence TTT TTG GAA A 3’. Another oligonucleotide was 
designed according to the following scheme: 5’ AGC TTT TCC AAA AA target 
sequence TCT CTT GAA complementary sequence GGG 3’. The hybridized oligos 
were cloned into pSuper (Brummelkamp, 2002) digested with BglII and HindIII. 
 
4.6 Work with prokaryotic cells 
4.6.1 Bacteria strains 
E.coli XL10-Gold 
(Stratagene) 
Tetr D(mcrA)183 D(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-
1 recA1 gyrA96 relA1 lac Hte [F’ proAB lacIqZDM15 Tn10 (Tetr) 
Amy Camr] 
E.coli DH5? 
(Invitrogen) 
F- ?80dlacZ?M15?(lacZYA-argF) U169 recA1 endA1 hsdR17(rk- 
mk
+) phoA supE44 ?- thi-1 gyrA96 relA1 
E.coli DB3.1 
(Invitrogen) 
F- gyrA462 endA ?(sr1-recA) mcrB mrr hsdS20 (rB- mB-) supE44 
ara14 galK2 lacY1 proA2 rpsL20 (StrR) xyl5 ?- leu mtl1 
E.coli BL21(DE3) 
pLysS (Stratagene) 
B F- dcm ompT hsdS(rB
– mB
–) gal ?(DE3) [pLysS Camr] 
 
 
Experimental Procedures  113 
4.6.2 Materials for work with prokaryotic cells 
LB Medium: 1% (w/v) tryptone 
 0.5% (w/v) yeast extract 
 1% (w/v) NaCl 
 pH 7.0 
 
Low Salt LB Medium: 1% (w/v) tryptone 
 0.5% (w/v) yeast extract 
 0.5% (w/v) NaCl 
 pH 7.5 
 
TB Medium: 1.2% (w/v) Tryptone 
 2.4% (w/v) yeast extract 
 4% (v/v) glycerol 
 17 mM KH2PO4 
 74 mM K2HPO4 
 
Agar plates (Amp/Kan): LB Medium 
 1.5% (w/v) Bacto Agar (Difco) 
 100 ?g/ml ampicillin or 
 30 ?g/ml kanamycin 
 
Agar Plates (Zeo): Low Salt LB Medium 
 1.5% (w/v) Bacto Agar (Difco) 
 50 ?g/ml zeocin (Invitrogen) 
 
  
4.6.3 Protocols for work with prokaryotic cells 
4.6.3.1 Bacterial Transformation 
After thawing 100 μl chemically competent bacteria were transferred to a 14 ml round-
bottom tube (Falcon) and mixed with plasmid DNA, usually 100-500 ng. After up to 30 
minutes on ice bacteria were heat-shocked for 45 seconds at 42°C and immediately 
placed back on ice. Subsequently, 1 ml of LB medium was added and bacteria 
incubated for 1h at 37°C. Bacteria were pelleted by centrifugation, re-suspended in 100 
?l of LB medium and plated on LB agar plates containing the appropriate antibiotic. 
Plates were incubated o/n at 37°C until bacterial colonies got visible. 
 
4.6.3.2 Purification of GST fusion proteins 
TNE Buffer: 20 mM Tris pH 8.0 
 150 mM NaCl 
 1 mM EDTA 
 5 mM DTT 
 1 mM Pefabloc SC (Roche) 
 14 μg /ml aprotinin 
 
GST Wash Buffer: 100 mM Tris pH 8.0 
 120 mM NaCl 
 
GST Elution Buffer: 100 mM Tris pH 8.0 
 120 mM NaCl 
 20 mM glutathione 
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Two to three colonies of transformed bacteria were used to inoculate a starter culture 
of usually 50 ml LB medium supplemented with 0.4-1.0% (w/v) Glucose and the 
appropriate antibiotic which was grown o/n at 37°C. The main culture was started by 
dilution of the starter culture at least 1:30 in the same type of medium. The culture was 
grown at 37°C until an OD600 ? 0,5-0,7 was reached. Afterwards expression of the GST 
fusion protein was induced by addition of 0.5-1.0 mM IPTG. Expression was allowed 
for 2-3h at 37°C or for o/n at ambient temperature. Subsequently, bacteria were 
pelleted by centrifugation at 3,500 xg, re-suspended in ice-cold TNE buffer and lysed 
for 30 min on ice in the presence of 100 μg/ml lysozyme. Cells were solubilized by 
sonication and lysates cleared from cell debris by centrifugation at 10,000 xg for 30 
min. The supernatant was incubated with 500 ?l equilibrated Glutathione Sepharose 
4B beads (Amersham Biosciences) per 30 ml of lysate for 1h at 4°C. Beads were 
washed three times with PBS and transferred to a 0.8x4 cm chromatography column 
(Bio-Rad). After washing with 1 ml of GST wash buffer bound proteins were eluted in 
three fractions with 300 ?l of GST elution buffer per fraction. Aliquots of the eluted 
proteins were subjected to SDS-PAGE and subsequent Coomassie staining in order to 
estimate the concentration of the purified proteins in comparison to a BSA standard 
series. 
 
4.6.3.3 Purification of His-tagged TEV protease 
Buffer A: 20 mM HEPES pH 7.5 
 300 mM NaCl 
 10% (v/v) glycerol 
 0.1% (v/v) NP-40 
 5 mM imidazole 
 14 μg/ml aprotinin 
 
Buffer B: 20 mM HEPES pH 7.5 
 200 mM NaCl 
 10% (v/v) glycerol 
 0.1% (v/v) NP-40 
 10 mM EDTA 
 10 mM DTT 
 14 μg/ml aprotinin 
 
Buffer C: 50 mM Tris pH 8.0 
 1 M NaCl 
 10% (v/v) glycerol 
 0.5 mM DTT 
 1 mM EDTA 
 
E. coli BL21 (DE3) transformed with vector pET24b-TEV-H were used to inoculate a 
culture in TB medium. Expression was induced by addition of 0.4-1.0 mM IPTG. After 
incubation for 3-4h at 37°C cells were harvested and re-suspended in buffer A. After 
incubation with lysozyme the lysate was sonicated well and cleared by centrifugation. 
His-tagged TEV protease was pulled out with TALON™ Metal Affinity Resin (BD 
Biosciences), washed extensively with buffer A and eluted with buffer B. Eluted TEV 
protease was dialysed o/n against the high salt buffer C, aliquoted and stored at -80°C. 
All purification steps from lysis on were carried out on ice or at 4°C to prevent 
denaturation of the thermally instable TEV protease. The amount of TEV protease 
needed to provide efficient cleavage was determined empirically for every single 
charge. 
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4.7 Work with eukaryotic cells (cell culture) 
4.7.1 Eukaryotic cell lines 
HEK 293 
(ATCC CRL-1573) 
This is an adherent epithelial cell line derived from human 
embryonic kidney (HEK) cells transformed with Adenovirus 5 
DNA. The Ad5 insert is integrated into chrosome 19q13.2. It is 
a hypotriploid cell line with a modal chromosome number of 64, 
occurring in 30% of cells. 
HeLa 
(ATCC CCL-2) 
This is an adherent epithelial cell line derived from a cervical 
adenocarcinoma of a 31 year old black female. 100% 
aneuploidy is observed with a modal chromosome number of 
82. HeLa cells have been reported to contain HPV-18 
sequences. P53 expression was reported to be low, and 
normal levels of pRB were found. 
U-937 
(ATCC CRL-1593.2) 
This monocytic suspension cell line was derived from 
malignant cells obtained from the pleural effusion of a 37 year 
old male patient with histiocytic lymphoma. U-937 cells can be 
induced to terminal monocytic differentiation by phorbol esters, 
vitamin D3, ?-interferon, TNF, and retinoic acid. 
COS-7 
(ATCC CRL-1651) 
This is an African green monkey (Cercopithecus aethiops)  
kidney fibroblast-like cell line suitable for transfection by 
vectors requiring expression of SV40 T antigen. This line 
contains T antigen, retains complete permissiveness for lytic 
growth of SV40, supports the replication of ts A209 virus at 
40C, and supports the replication of pure populations of SV40 
mutants with deletions in the early region. The line was derived 
from the CV-1 cell line (ATCC CCL-70) by transformation with 
an origin defective mutant of SV40 which codes for wild type T 
antigen. 
U-2 OS 
(ATCC HTB-96) 
This is an adherent epithelial cell line derived from a 
moderately differentiated osteosarcoma of a 15 year old girl. It 
is chromosomally highly altered, with chromosome counts in 
the hypertriploid range. 
Flp-In? T-REx?-293 
(Invitrogen #R780-07) 
This cell line was derived from HEK293. It expresses the Tet 
repressor from pcDNA6/TR and contains a single integrated 
Flp Recombination Target (FRT) site from pFRT/lacZeo 
resulting in expression of a lacZ-Zeocin fusion gene. This cell 
line can be used to generate a tetracycline-inducible 
expression cell line by cotransfecting the pcDNA5/FRT/TO 
expression vector containing your gene of interest and the Flp 
recombinase expression plasmid, pOG44. 
Flp-In? T-REx?-293-
pcDNA5/FRT/ 
TO/C-TAP, 
C-TAP-PARP10, 
C-TAP-PARP10- 
G888W, N-TAP-
PARP10 
 
This stably transfected cell lines were generated by 
transfection of Flp-In? T-REx?-293 cells with pOG44 and 
pcDNA5/FRT/TO/C-TAP, C-TAP-PARP10, C-TAP-PARP10-
G888W, N-TAP-PARP10. Stable cell lines were obtained by 
selection with hygromycin B and Blasticidin S. 
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4.7.2 Materials for cell culture work 
DMEM (Gibco) with 4,5 g/l Glucose 
PBS: 140 mM NaCl 
 2.6 mM KCl 
 2 mM Na2HPO4 
 1.45 mM KH2PO4 
 
Blasticidin S (Invivogen) 10 mg/ml 
Doxycyclin (Sigma) 1 mg/ml 
Hygromycin B (Roche) 50 mg/ml 
Penicillin / Streptomycin (Seromed) 10.000 Units/ml / 10.000 ?g/ml 
Trypsin / EDTA (Seromed) 0.5 / 0.02% (w/v) in PBS 
FCS (Gibco) 
Tissue culture dishes (Sarstedt) ?6 cm, 10 cm, 15 cm 
Tissue culture plates (TPP) 6-Well 
1 ml cyrotubes (Nalgene) 
 
Culture conditions: 
All cell lines were cultured under humidified atmosphere of 5% CO2 at 37°C. 
HEK 293, HeLa, and COS-7 cells were cultured in DMEM supplemented with 10% (v/v) 
FCS and 1% (v/v) Penicillin/Streptomycin. U-937 cells were cultured in RPMI-1640 
supplemented with 10% (v/v) FCS and 1% (v/v) Penicillin/Streptomycin. U-2 OS cells 
were cultured in RPMI-1640 supplemented with 10% (v/v) FCS and 1% (v/v) 
Penicillin/Streptomycin. 
Stably transfected Flp-In? T-REx?-293 cell lines were maintained in regular DMEM 
supplemented with 15 μg/ml Blasticidin S and 50 μg/ml hygromycin B. 
 
4.7.3 Protocols for work with eukaryotic cells 
4.7.3.1 Cryo-conservation and thawing of cells 
For cryo-conservation, cells grown to log phase were usually re-suspended in 
cryotubes in 1 ml FCS with 10% (v/v) DMSO at a density of 5-8x106. After incubation 
on ice for 30 min, the cryo tubes were wrapped with several layers of tissue paper, put 
into an insulated box and slowly cooled down for 16-48h at -80°C. Afterwards, the 
cryotubes were transferred to -150°C for long-term storage. 
For thawing of frozen cells, cryotubes were thawed in a water bath at 37°C. 
Immediately after melting of the ice crystals, cells were suspended in 10 ml fresh 
medium, pelleted by centrifugation, re-suspended in 10 ml fresh medium and 
transferred to an appropriate culture dish or flask. 
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4.7.3.2 Transient transfection 
 
A) calcium phosphate method 
 
2x Hebs buffer: 274 mM NaCl 
 42 mM HEPES 
 9.6 mM KCl 
 1.5 mM Na2HPO4 
 pH 7.1 
 
HEPES buffer: 142 mM NaCl 
 10 mM HEPES 
 6.7 mM KCl 
 pH 7.3 
 
250 mM CaCl2 
 
The transient transfection of adherent cells was performed according to the calcium 
phosphate method (Bousset et al., 1994; Chen and Okayama, 1988). This method is 
based on the precipitate formation of calcium-phosphate-DNA complexes which are 
taken up by the cells through endocytosis. The calcium phosphate method was used to 
transfect HEK 293 cells. 
The day prior to the transfection, about 1x106 /4x105 cells were seeded on ?10 cm/?6 
cm tissue culture dishes. For transfection, 20 μg/4 μg of total DNA was diluted in 500 
?l/200 μl 250 mM CaCl2 and incubated for up to 30 min at ambient temperature. 
Subsequently, 500 μl/200 μl 2x Hebs buffer was added in drops, the solution mixed by 
agitation and afterwards pipetted onto the cell monolayer. The dishes were swayed and 
put back into the incubator. After up to 6h incubation time, the cells were freed from 
residual precipitate by washing with 10 ml/4 ml HEPES buffer. Subsequently, fresh 
medium was added. 
 
B) ExGen 500 transfection reagent (Fermentas) 
 
ExGen 500 is a 22 kDa linear polyethylenimine that interacts with DNA to form small, 
highly diffusible complexes which are readily endocytosed. ExGen 500 was used for 
the transfection of HeLa cells according to the manufacturer’s instructions with an 
ExGen 500/DNA ratio of 3.3. 
 
C) FuGENE 6 transfection reagent (Roche) 
 
FuGENE 6 is a lipid-based transfection reagent. Lipids and DNA form complexes due 
to ionic interactions and are taken up by the transfected cells. FuGENE 6 was used for 
the transfection of COS-7 cells according to the manufacturer’s instructions with an 
FuGENE 6/DNA ratio of 3. 
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4.7.3.3 Preparation of cell lysates 
Frackelton Buffer (F Buffer): 10 mM HEPES pH 7.5 
 50 mM NaCl 
 30 mM Na4P2O7 
 50 mM NaF 
 5 ?M ZnCl2 
 pH 7.05 
 0.2 % (v/v) Triton X-100 
 10% (v/v) glycerol 
 100 ?M Na3VO4 
 500 ?M Pefa Bloc (Roche) 
 0.025 U/ml ?2-macroglobulin (Roche) 
 2.5 ?g/ml pepstatin A 
 2.5 ?g/ml leupeptin  
 150 ?M benzamidin 
 14 ?g/ml aprotinin 
 10 mM sodium ß-glycerophosphate 
 
Cells were lysed in F buffer or TAP lysis buffer (see below) at a concentration of about 
5x107 cells per ml of buffer. Adherent cells were incubated on ice for 5 min, scraped off, 
transferred into an Eppendorf tube and incubated on ice for additional 10 min. 
Suspension cells were incubated in an Eppendorf tube on ice for 20 min. Cell debris 
was spun down at 16,000 xg for 20 min at 4°C. The supernatant was transferred to a 
new Eppendorf tube and either used immediately for further analysis or stored at -
20°C. 
 
4.7.3.4 Colony formation assay 
Methylene Blue Solution: 0.2 % (w/v) methylene blue in MeOH 
Puromycin 1 mg/ml 
 
The day before transfection, 2.5 x105 HeLa cells were seeded onto ?6 cm culture 
dishes. The cells were transfected using ExGen 500 with 5 ?g total plasmid DNA 
including 0.5 ?g pBabePuro for selection. 6 h after transfection the medium was 
replaced. After additional 3 h puromycin was added to a final concentration of 2 ?g/ml. 
Cells were selected for 16 h and supplied with fresh medium. Cells were let grown for 
additional 3-6 days until the cells transfected with a control plasmid reached a 
confluency of about 90%. Cells were washed once with PBS and the formed colonies 
were stained with methylene blue solution for up to 30 min. After two washes with 
ddH2O the plates were air-dried and the colony formation documented with a scanner. 
 
 
4.8 Work with proteins 
4.8.1 Denaturing Discontinuous Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
2x/4x Sample Buffer: 160 mM / 320 mM Tris pH 6.8 
 20% / 40% (v/v) glycerol 
 10% / 8% (w/v) SDS 
 0.25% / 0.5% (w/v) BPB 
 100 mM / 200 mM ß-ME 
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Running Buffer: 25 mM Tris base 
 250 mM glycine 
 0.1% (w/v) SDS 
 
Protein Ladder: PageRuler Prestained Protein Ladder, 11-170 
kDa (Fermentas) 
 PageRuler Protein Ladder, 10-200 kDa 
(Fermentas) 
 
The denaturing SDS-PAGE allows for the separation of complex protein mixtures 
according to the molecular size of the proteins. SDS binds quantitatively to the 
denatured proteins and generates a negative net charge of the proteins due to its 
anonic properties. Therefore, proteins can be separated solely by their molecular 
weight during their electrophoretically enforced movement towards the anode through a 
polyacrylamide gel matrix. 
The discontinuous SDS-PAGE was essentially performed according to Laemmli 
(Laemmli, 1970) with a 5% stacking gel and a 10-20% separating gel. 
 
4.8.2 Western Blot 
Semi-dry Transfer Buffer: 25 mM Tris base 
 192 mM glycine 
 20% (v/v) methanol 
 
Tank Blot Transfer Buffer: 25 mM Tris base 
 192 mM glycine 
 0.1% (w/v) SDS 
 
0.2% (w/v) Ponceau S in 3% (v/v) TCA 
 
Proteins separated by SDS-PAGE can afterwards be transferred electrophoretically 
onto nitrocellulose or PVDF membranes. During the transfer the SDS is mainly 
removed from the proteins resulting in at least partially renaturation of the proteins 
which allows for subsequent immunodetection (see below). 
The semi-dry transfer includes a “sandwich” of gel and membrane surrounded by thick 
Whatman papers soaked in semi-dry transfer buffer. This sandwich is placed in a 
blotting chamber between two electrode plates. 
The Western Blot was essentially performed according to Towbin (Towbin et al., 1979). 
For semi-dry transfer, proteins were transferred from the gel to the membrane for 1h at 
2 mA per cm2 of membrane size. 
In order to fix the proteins on the membrane and to control transfer efficiency, the 
membrane was routinely stained with Ponceau S for 1-2 min and afterwards washed 
twice with dH2O. 
 
4.8.3 Immunodetection of proteins 
PBS-T: PBS 
 0.05% (v/v) Tween-20 
 
Blocking Buffer: PBS-T 
 5% (w/v) skim milk powder 
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ECL solutions (Pierce) 
 
After blotting proteins onto a membrane, they can be detected by specific antibodies. 
This immunoblot procedure involves the blocking of unspecific binding sites on the 
membrane using skim milk or BSA, the specific binding of a primary antibody targeted 
against the protein of interest, the specific binding of a secondary antibody targeted 
against the invariable part of the primary antibody which is coupled to horseradish 
peroxidase (HRP), and finally the addition of a chemoluminescent substrate which is 
turned over by the HRP under emission of light. This emission can be detected by a 
highly sensitive camera system or by X-ray films. 
Routinely, blocking was achieved by incubation of the membrane in blocking buffer for 
at least 30 min. The primary antibody was incubated for 2h at ambient temperature or 
o/n at 4°C. After at least five washes in PBS-T with minimal 5 min per wash step, the 
secondary antibody was incubated for 45-60 min at ambient temperature. Prior to 
detection, at least three rounds of washing in PBS-T were performed. The detection 
was carried out with a computer-assisted camera (LAS-3000, Fuji). 
 
4.8.4 Rapid Coomassie Staining 
Fixing Solution: 25% (v/v) isopropanol 
 10% (v/v) acetic acid 
 
Staining Solution: 10% (v/v) acetic acid 
 0.006% (w/v) CBB G-250 (Bio-Rad) 
 
Destaining Solution: 10% acetic acid 
 
Coomassie stain stains proteins unspecifically through interaction with cationic and 
hydrophobic amino acid residues. 
After SDS-PAGE, the gel was fixed for 10-15 min and afterwards stained for 2-3h 
under slight agitation. In order to reduce background staining, the gel was destained 
either for 1-2h in destaining solution or o/n in dH2O. 
 
4.8.5 Mass-spectrometric analysis 
0.5 M Iodoacetamide 
Gel-Code Blue Stain Reagent (Pierce) 
 
In order to avoid possible keratin contaminations, all solutions were prepared with Milli-
Q water and sterilized by filtration through a 0.22 ?m filter (Millipore). As far as 
possible, all working steps were carried out under clean bench conditions. 
For preparing proteins samples for mass-spectrometric analysis, the samples were 
diluted in 2x sample buffer, boiled for 5 min at 95°C and cooled down to 55°C. After 
addition of iodoacetamide to a final concentration of 100 mM, the samples were 
incubated az 55°C for 10 min. Subsequently, the samples were subjected to SDS-
PAGE. After electrophoresis, the gel was stained with Gel-Code Blue following the 
manufacturer’s instructions. For further analysis, the gel was shrink-wrapped and 
shipped to David W. Litchfield (University of Ontario, London, Canada). 
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4.8.6 Tandem Affinity Purification 
TAP Lysis Buffer: 50 mM  Tris pH 7.5 
 150 mM NaCl  
 1 mM EDTA  
 10% (v/v) glycerol  
 1% (v/v) NP-40  
 1 mM DTT  
 100 μM sodium vanadate 
 14 ?g/ml aprotinin  
 4 μM leupeptin  
 0.5 mM PMSF 
 
TEV Buffer: 50 mM Tris pH 7.5 
 150 mM NaCl 
 0.5 mM EDTA 
 1 mM DTT 
 
Calmodulin Binding Buffer: 10 mM Tris pH 7.5 
 150 mM NaCl 
 0.2% (v/v) NP-40 
 1 mM magnesium acetate 
 2 mM calcium chloride 
 1 mM imidazole 
 10 mM ?-ME 
 
Calmodulin Wash Buffer : 50 mM ammonium bicarbonate pH 8.0 
 75 mM NaCl 
 1 mM magnesium acetate 
 1 mM imidazole 
 2 mM calcium chloride 
 
Calmodulin Elution Buffer : 50 mM ammonium bicarbonate pH8.0 
 25 mM EGTA 
 
IgG affinity matrix: IgG Sepharose 6 Fast Flow 
 (Amersham Biosciences) 
 
Calmodulin affinity matrix: Calmodulin Sepharose 4B 
 (Amersham Biosciences) 
 
 
Tandem affinity purification (TAP) allows for the highly selective purification of protein 
complexes under native conditions. This is reached by two successive purification 
steps: the first one involves the binding of Protein A to IgG Sepharose beads from 
which the purified proteins are eluted through cleavage of the Protein A-tag by TEV 
protease. The second step is the binding of the residual Calmodulin binding peptide to 
Calmodulin Sepharose beads. Finally, purified proteins are eluted using EGTA which 
disrupts the Ca2+-dependent binding to the Calmodulin column. 
Expression of TAP fusion proteins from stable cell lines was induced by 1 ?g/ml 
doxycycline for 10-14h. Cells were harvested by centrifugation at 200 xg, washed once 
with ice-cold PBS and pelleted again. All following steps were carried out at 4°C. Cells 
were re-suspended in 15 ml lysis buffer per 500 ml of suspension culture and lysed for 
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30 minutes under slight agitation. Lysate was cleared by centrifugation at 15,000 xg for 
20 minutes. The supernatant was incubated with 125 ?l equilibrated IgG Sepharose 6 
FF (Amersham Biosciences) per 15 ml lysate for 1h under rotation. Beads were 
pelleted at 200 xg for 2 minutes and washed three times with TEV buffer. Beads were 
re-suspended in five volumes of TEV buffer and approximately 200-500 ng of His-
tagged TEV protease per 10 ?l beads were added. Cleavage was performed for 2h 
under permanent agitation. After TEV cleavage, the beads were pelleted and the 
supernatant was transferred to a new tube containing equilibrated Calmodulin 
Sepharose 4B (Amersham Biosciences) (equal volume as for IgG sepharose). IgG 
Sepharose was washed once with three volumes of calmodulin binding buffer, pelleted 
and the supernatant combined with the supernatant of the TEV cleavage. After addition 
of 1/200 volume of 1 M CaCl2, the pooled supernatants were incubated with the 
Calmodulin Sepharose for 90 minutes. Subsequently the beads were pelleted and 
washed three times with calmodulin wash buffer. Beads were re-suspended in two 
volumes of elution buffer and incubated for 20 minutes under permanent agitation. 
Beads were pelleted and the supernatant containing the purified proteins was 
transferred to a new tube avoiding transfer of beads and stored at -80°C. To avoid 
negative effects of EGTA on enzymatic activity in subsequent assays 25 mM MgCl2 
was added prior to storage. 
 
4.9 Enzymatic assays 
4.9.1 PARP assay 
PARP Reaction Buffer: 50 mM Tris pH 8.0 
  0.2 mM DTT 
  4 mM MgCl2 
 
[32P]-NAD+ 370 MBq/ml (10 ?Ci/?l) (Amersham Biosciences) 
ß-NAD+ (Sigma) 
 
A PARP assay detects the incorporation of radioactively labeled [32P]-NAD+ into 
substrate proteins mediated by enzymes of the ADP-ribosyltransferase class. 
PARP assays were carried out routinely in 30 ?l reaction volume at 30°C for 30 
minutes in PARP reaction buffer using 50 ?M ß-NAD+ (Sigma) and 1 ?Ci 32P-NAD+ 
(Amersham Biosciences) if not indicated otherwise. 500 ng of enzyme and 1 ?g of 
substrates were used routinely. The reactions were stopped by addition of SDS sample 
buffer. For quantification of incorporated label either radioactive bands were cut out 
and activity measured by Cerenkov counting or reactions were stopped by addition of 
500 ?l BSA (100 ?g/ml) and 530 ?l ice-cold TCA, precipitated material was spotted 
onto GF/C filter (Whatman), washed several times with 5% TCA and subsequently with 
95% EtOH, air-dried and measured by Cerenkov counting. 
PARP1 used as positive control was baculo-derived. This protein was already 
associated with DNA resulting in full enzymatic activity and addition of DNA did not 
result in a further activation (our unpublished observation). 
 
4.9.2 Analysis of ADP-ribosylation reaction products 
Diethyl ether 
Phenol/Chloroform/IAA (49:49:2) 
Alkaline TE Buffer: 10 mM Tris 
  1 mM EDTA 
  pH 12.0 
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Urea Loading Buffer: 50% (w/v) urea 
  25 mM NaCl 
  4 mM EDTA 
  0.02% xylene cyanol 
  0.02% bromophenol blue 
 
Phosphodiesterase Buffer: 100 mM Tris pH 8.0 
  100 mM NaCl 
  15 mM MgCl2 
  1 mM sodium vanadate 
  100 nM okadaic acid 
 
Phosphodiesterase I (USB) 1 mg/ml in 100 mM Tris pH 8.0, 100 mM NaCl, 15 mM 
MgCl2 and 50% glycerol 
 
TLC plates PEI-F cellulose 20 cm x20 cm (Merck) 
 
Solvents A: isobutyric acid / 25% NH4OH / H20 
(50/1.1/28.9, by volume) 
 
Solvents B: 0.1 M sodium phosphate pH 6.8 / ammonium 
sulfate / n-propanol (100/60/2, v/w/v) 
 
PARP assays were carried out as decribed above using 5 ?Ci 32P-NAD+ and indicated 
amounts of ß-NAD+. Reactions were stopped by addition of 500 ?l BSA (100 ?g/ml) 
and 530 ?l ice-cold TCA. 
Analysis of polymer length by PAGE was carried out as described previously (Panzeter 
and Althaus, 1990). Briefly, TCA-precipitated proteins were washed twice with diethyl 
ether and re-suspended in alkaline TE buffer. ADP-ribose modifications of acidic amino 
acid residues were detached from the proteins during a 3h incubation at 60°C. 
Subsequently, samples were extracted with Phenol/Chloroform/IAA, and the aqueous 
phase dried in a Speed-Vac. Samples were dissolved in urea loading buffer and, after 
pre-electrophoresis for 1h at 55 W (constant power), loaded onto a 20% 
polyacrylamide gel (60 cm x20 cm x0.15 mm). Electrophoresis at 55 W was carried out 
until the bromophenol blue dye had migrated about three-fourths of the entire gel 
length. The gel was transferred to a thin Whatman paper and exposed to X-ray films at 
-80°C. 
Analysis of the ADP-ribosylation reaction products by 2D-TLC after hydrolysis with 
phosphodiesterase I (purchased from USB) was carried out as reported previously 
(Keith et al., 1990). Briefly, samples were treated as described above for analysis of 
polymer length. But after drying the samples in a Speed-Vac, they were dissolved in 30 
?l of phosphodiesterase buffer. After addition of 1 ?l of phosphodiesterase I, ADP-
ribosylation reaction products were hydrolyzed for 3.5h at 37°C. In order to separate 
the hydrolysis products, 3 ?l of the reaction were spotted onto a TCL plates. The 
development was performed in two dimension using solvents A in the first dimension 
and solvents B in the second dimension. Dried TLC plates were exposed to X-ray films 
at -80°C. 
 
4.9.3 PARG/ARH assay 
PARG/ARH Buffer: 50 mM potassium phosphate buffer pH 7.5 
  10 mM MgCl2 
  5 mM DTT 
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Proteins were immobilized on beads, either glutathione agarose or Protein A beads 
coupled with the appropriate antibody, and auto-modified in a standard PARP assay 
with 32P-NAD+ as described above. The auto-modified proteins were pelleted by 
centrifugation, the beads washed two times with PARG/ARH buffer and re-suspended 
in 40 ?l PARG/ARH buffer. After addition of 1 ?g GST or GST-PARGcat, -ARH1, -
ARH2 or -ARH3, the reaction was incubated for 2h at 37°C to allow for the de-ADP-
ribosylation of the auto-modified proteins. The reaction was stopped by addition of 15 
?l 4x sample buffer and subjected to SDS-PAGE. After drying the gel, residual 
radioactivity was determined via exposure to X-ray films at -80°C. 
 
4.9.4 Phosphatase assay 
Phosphatase Buffer: 50 mM Tris Ph 8.0 
 1 mM MgCl2 
 100 ?M sodium vanadate 
 50 mM NaF 
 10 mM sodium ß-glycerophosphate 
 50 nM okadaic acid 
 
Shrimp Alkaline Phosphatase 5U/?l (Roche) 
 
Potentially phosphorylated proteins were immunoprecipitated using Protein A or 
Protein G beads and the appropriate antibodies. The beads were washed two times 
with the used lysis buffer and two times with phosphatase buffer. Subsequently, the 
beads were re-suspended in 30 ?l phosphatase buffer and 5U of phosphatase were 
added or not added in a mock-treated sample, respectively. The reaction was 
incubated for 30 min at 30°C. Afterwards, the reaction was stopped by addition of 15 ?l 
4x sample buffer and the mixture subjected to SDS-PAGE. The phosphorylation state 
of the proteins was checked by phospho-specific antibodies, if possible. 
 
4.10 Microscopy techniques 
4.10.1 Immunocytochemistry 
Glass coverslips 
PBS 
Fixing Solution: 3.7% PFA in PBS 
Permeabilizing Solution: 0.1% Triton-X100 in PBS 
Blocking Solution: 1% BSA in Permeabilizing Solution 
Antibody Solution: 0.2% BSA in PBS 
Hoechst 33258 10 mg/ml 
Mowiol 4-88 
 
Cells grown on glass coverslips were washed twice with PBS and fixed for 15-30 min at 
ambient temperature depending on the cell line. The cells were washed with PBS and 
afterwards with permeabilizing solution. Blocking of unspecific binding sites was 
achieved by 30 min incubation with blocking solution at ambient temperature. The 
primary antibody directed against the protein to be visualized was diluted in antibody 
solution and incubated on the cells for 45-60 min in a humid dark box at 37°C. 
Unbound antibody was washed away by several rounds of washing with antibody 
solution. The secondary antibody conjugated to the desired fluorophore was diluted in 
antibody solution and incubated in the same way as the primary one. After washing 
with antibody solution, PBS and ddH20, Hoechst stain was diluted 1/5000 in ddH20 and 
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incubated for 1-2 min. After washing twice with ddH20, the coverslip was embedded in 
Mowiol 4-88. The next day stained cells were inspected by epifluorescence microscopy 
on an Olympus IX50 or by confocal microscopy on a Zeiss Axiovert LSM510. 
 
 
4.10.2 Time-lapse microscopy 
For live-cell imaging, cells were seeded onto glass coverslips or glass-bottom dishes 
(Willco Wells) and transfected using FuGene reagent (Roche). Time-lapse microscopy 
was performed on a confocal Zeiss Axiovert LSM510 or on an epifluorescent 
microscope Zeiss Axiovert 200 (in collboration with A. Sechi) both equipped with an 
incubation chamber set to 37°C and a CO2 gas supply providing constantly 5% CO2. 
 
4.10.3 iFLAP (inverted fluorescence localization after photobleaching) 
For iFLAP analysis, cells were seeded onto glass coverslips and transfected with 
plasmids expressing CFP/YFP fusion proteins using FuGene reagent (Roche). iFLAP 
was performed on a confocal Zeiss Axiovert LSM510 with a water-corrected C-
Apochromat 63x objective (NA 1.2). The pinhole size was set to 200 ?m. YFP was 
excited with a 514 nm laser and detected with a BP 530-600 nm filter set. CFP was 
excited with a 458 nm laser and detected with a BP 480/20 nm filter set. 
For the measurement of iFLAP, the YFP fluorescence was repetitively bleached about 
every six seconds at maximum 514 nm laser intensity with 20 pulses within a defined 
ROI in the cytoplasm. After each bleaching, an image of the size 512x512 pixels was 
taken in the CFP and the YFP channel. A total of 120 frames were taken within about 
12 minutes of measurement. An unbleached control cell situated next to the bleached 
cell was analyzed in parallel to control the potential unspecific effects caused by 
photobleaching. 
The pictures were filtered using the “median” and “lowpass 7x7” function and 
processed by the ratio function: Channel 1 (YFP) / Channel 2 (CFP) x (-4096) + 4096. 
The processed images were pseudo-colored with a rainbow palette. While blue color 
corresponds to an equal ratio of CFP and YFP fluorescence intensity (result of the 
above ratio function: 0), red color corresponds to a very low level of YFP fluorescence, 
while CFP fluorescence levels are still high (result of the above ratio function: 
approximately 4096). 
 
 
4.11 Molecular modeling 
In collaboration with Brian H. Shilton (University of Ontario, London, Canada) a 
structural analysis of the catalytic domain of PARP10 was performed. The following 
paragraph gives a short description of this analysis. 
PARP12 has approximately 33% sequence identity with PARP10, and therefore the 
recently determined crystal structure of PARP12 (PDB-ID 2PQF; Structural Genomics 
Consortium, unpublished) supplies a good template for modeling PARP10. To 
incorporate as much structural information as possible into the PARP10 model and to 
provide an idea about which regions of the protein can be most reliably modeled, we 
aligned the structures of human PARP1 (PDB-ID 1UK0 (Kinoshita et al., 2004)) and 
PARP3 (PDB-ID 2PA9; Structural Genomics Consortium, unpublished) with PARP12. 
Even though the sequence identity between either PARP1 or PARP3 and PARP12 was 
less than 20%, there was clear structural similarity: there were 148 CA atoms in 
PARP12 that were within 3.5 Å of the corresponding CA atoms in PARP1 or PARP3, 
and the overall RMS distance for these matched positions was 1.4 Å. This structure-
based alignment is shown in Figure 2A, where the yellow shading represents 
structurally conserved regions. Starting with the comprehensive alignment in Otto et al. 
(Otto et al., 2005), the PARP10 sequence was incorporated into the structure-based 
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alignment and submitted to the SwissModel server for threading and optimization 
(Schwede et al., 2003). There were no serious stereochemical problems with the model 
that was returned, indicating that the PARP10 sequence was wholly compatible with 
the template structures. 
To model the PARP10 binary complex, a “substrate” PARP10 (S-PARP10) was 
manually positioned onto an “enzymatic” PARP10-NAD+ complex (NAD-PARP10) such 
that the carboxylate of E882 from S-PARP10 was positioned close to I987 of the NAD-
PARP10. In this way, E882 was positioned to act as the catalytic glutamate and can 
also react with the nicotinamide ribose to form the ADP-ribosylated product. There was 
only one way to bring the two molecules together such that there were no steric 
clashes between conserved structural elements and E882 was positioned as 
described. The complex was energy minimized by manually adjusting two loop regions 
– namely residues 842-847 and 907-913 – in the NAD-PARP10 molecule, and then 
making a number of minor side chain and main chain adjustments in both S-PARP10 
and NAD-PARP10. This was followed by a round of energy minimization in CNS 
(Brunger et al., 1998). CA positions were harmonically restrained to maintain the 
structure of the complex, all other atoms including those of NAD+ were allowed to 
move. The final PARP10 binary structure had good stereochemistry as assessed by 
CNS indicators and Procheck (Laskowski et al., 1993) with 83% of residues falling in 
the most favoured regions of the Ramachandran plot, and no residues in the 
generously allowed or disallowed regions. 
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6. Appendix 
 
6.1 Abbreviations 
°C Degree Celsius 
A Ampere 
aa Amino acid 
Ab Antibody 
Ad5 Adenovirus 5 
A.dest. Destilled water 
ADP Adenosine diphosphate 
Amp Ampicillin 
AMP Adenosine monophosphate 
APS Ammonium persulfate 
ARC Ankyrin repeat cluster 
ARH ADP-Ribose hydrolase 
ART ADP-Ribosyltransferase 
ATCC American Type Culture Collection 
ATP Adenosine triphosphate 
ß-ME ß-Mercaptoethanol 
BAL B-Aggressive Lymphoma 
BER Base excision repair 
bHLH Basic helix-loop-helix 
bp base pair(s) 
BPB Bromophenole blue 
Bq Bequerel 
BSA Bovine serum albumin 
ca. circa 
CA C alpha 
CaM Calmodulin 
CBB Coomassie brilliant blue 
CFP Cyan fluorescent protein 
CDK Cyclin-dependent kinase 
ChIP Chromatin immunoprecipitation 
Ci Curie 
cm2 square centimeter 
CMV Cytomegalie virus 
Da Dalton 
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DBD DNA binding domain 
DLBCL Diffuse large B cell lymphoma 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxide 
DNA Desoxyribonucleic acid 
DRE Dioxin response elements 
DSB Double strand break 
DTT Dithiothreitol 
ECL Enhanced chemoluminescens 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
e.g. for example  
EGTA Ethyleneglycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid 
ES Cell Embryonic stem cell 
EST Expressed sequence tag 
et.al. et alii  
f.a.v. Final assay volume 
FCCP Carbonyl cyanide p-trifluoromethoxyphenylhydrazone 
FCS Fetal calf serum 
FISH Fluorescence In Situ Hybridisation 
g Gramm 
g gravitation constant ( g = 9,81 m / s?) 
GAP GTPase activating protein 
GDP Guanosine diphosphate 
GEF Guanine nucleotide exchange factor 
GSK Glycogen synthase kinase 
GTP Guanosine triphosphate 
h hour(s) 
Hebs Hepes buffered saline 
HEK Human embryo kidney 
HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HMG High mobility group 
HMT Histone methyltransferase 
HRP Horseradish peroxidase 
i.e. that is  
IgG Immunoglobulin G 
IP Immunoprecipitation 
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IPTG Isopropyl-ß-D-1-thiogalacopyranoside 
IRAP Insulin-responsive amino peptidase 
ITC Isothermal calorimetry 
k Kilo 
KLH Keyhole limpet hemocyanin 
? wave length of light 
l Litre 
LB Luria Broth 
LOH Loss of heterozygosity 
LPS Lipopolysaccharide 
? Micro 
m Meter 
m Milli 
M Mega 
M Molar (mol / l) 
mART Mono-ADP-Ribosyltransferase 
MCS Multiple cloning site 
MDCK Madin-Darby canine kidney 
MIBG meta-Iodobenzylguanidine 
min Minute(s) 
MNNG N-Methyl-N'-Nitro-N-Nitrosoguanidine 
mRNA messenger RNA 
MS Mass spectrometry 
n Nano 
NAD Nicotinamide adenindinucleotide 
NEB New England Biolabs 
NES Nuclear export signal 
NHEJ Non-homologous end joining 
NLS Nuclear localisation signal 
NP-40 Nonidet P-40 
NPC Nuclear pore complex 
NuMA Nuclear mitotic apparatus protein 
o- ortho- 
OAADPR O-Acetyl-ADP-ribose 
OD Optical density 
p.a. pro analysi 
PAGE Polyacrylamide gel electrophoresis 
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PAR Poly-ADP-ribose 
pADPr Poly-ADP-ribose 
PARG Poly-ADP-ribose glycohydrolase 
PARP Poly-ADP-ribose polymerase 
PBS Phospate buffered saline 
PBZ Poly-ADP-ribose-binding zinc finger 
PcG Polycomb group 
PKR Protein kinase R 
PMSF Phenylmethylsulphonyl fluoride 
PTM Post-translational modification 
PVDF Polyvinylidene fluoride 
QM/MM Quantum mechanical / Molecular mechanical 
RAR Retinoic acid receptor 
REF Rat embryo fibroblast 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute 
RRM RNA recognition motif 
rpm rounds per minute 
SAC Substrate-assisted catalysis 
SDS Sodium dodecyl sulfate 
shRNA short hairpin RNA 
SSB Single strand break 
TAP Tandem affinity purification  
TB Terrific Broth 
TCA Trichloroacetic acid 
TCDD 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
TE Tris-EDTA 
TEP Telomere-associated protein 
TEV Tobacco Etch virus 
U Unit 
UIM Ubiquitin-interacting motif 
v/v volume per volume  
Vol. Volume 
w/v weight per volume 
WB Western Blot 
WT Wild-type 
x times / -fold 
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XC Xylene cyanol 
YFP Yellow fluorescent protein 
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